# Appendix L:Excluded studies

## L.1 Review Question 1: Which pharmacological blood glucose lowering therapies should be used to control blood glucose levels in people with type 2 diabetes?

**Table 1: Excluded studies of full text papers**

| Number | Reference | Reason for exclusion |
|---|---|---|
| 1 | Aas,A.M., Hanssen,K.F., Berg,J.P., Thorsby,P.M. Insulin-stimulated increase in serum leptin levels precedes and correlates with weight gain during insulin therapy in type 2 diabetes. Journal of Clinical Endocrinology and Metabolism.94 (8) (pp 2900-2906 | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 2 | Aas,A.M., Ohrvik,J., Malmberg,K., Ryden,L., Birkeland,K.I. Insulin-induced weight gain and cardiovascular events in patients with type 2 diabetes. A report from the DIGAMI 2 study. Diabetes, Obesity & Metabolism 2009;11(4):323-29. | Drug comparison not of interest-insulin vs. insulin |
| 3 | Ahren,B., Foley,J.E., Ferrannini,E., Matthews,D.R., Zinman,B., Dejager,S. Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherap | outcomes not of interest |
| 4 | Ahren,B., Leguizamo,Dimas A., Miossec,P. Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M). Diabetes Care 2013;36(9):2543-50. | focus on timing of administration |
| 5 | Ahren,B., Schweizer,A., Dejager,S., Dunning,B.E., Nilsson,P.M., Persson,M. Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. Journal of Clinical Endocrinology & Metabolism 2009;94(4):1236-43. | <12 week treatment duration |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 6 | Al,Sifri S., Basiounny,A., Echtay,A., Al,Omari M., Harman-Boehm,I., Kaddaha,G., et al. The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial. Internationa | unclear if previous blood glucose lowering therapies were washed out/discontinued |
| 7 | Althouse,A.D., Abbott,J.D., Forker,A.D., Bertolet,M., Barinas-Mitchell,E., Thurston,R.C., Mulukutla,S. Risk factors for incident peripheral arterial disease in type 2 diabetes: Results from the bypass angioplasty revascularization investigatio | unclear treatment groups or intervention |
| 8 | Althouse,A.D., Abbott,J.D., Sutton-Tyrrell,K., Forker,A.D., Lombardero,M.S., Buitron,L.V., Pena-Sing,I. Favorable effects of insulin sensitizers pertinent to peripheral arterial disease in type 2 diabetes. Diabetes Care.36 (pp 3269-3275), 2013 | unclear treatment groups or intervention |
| 9 | Altuntas,Y., Ozen,B., Ozturk,B., Sengul,A., Ucak,S., Ersoy,O. Comparison of additional metformin or NPH insulin to mealtime insulin lispro therapy with mealtime human insulin therapy in secondary OAD failure. Diabetes, Obesity and Metabolism 2003;5(6 | unclear if previous blood glucose lowering therapies were washed out/discontinued |
| 10 | Alvarsson,M., Sundkvist,G., Lager,I., Berntorp,K., Fernqvist-Forbes,E., Steen,L., et al. Effects of insulin vs. glibenclamide in recently diagnosed patients with type 2 diabetes: a 4-year follow-up. Diabetes, Obesity & Metabolism 2008;10(5):421-29. | Drug comparison not of interest-insulin vs. 1 OAD |
| 11 | Alvarsson,Michael, Sundkvist,G.+, Lager,Ibe, Henricsson,Marianne, Berntorp,Kerstin, Fernqvist-Forbes,Eva, et al. Beneficial Effects of Insulin Versus Sulphonylurea on Insulin Secretion and Metabolic Control in Recently Diagnosed Type 2 Diabetic Patie | Drug comparison not of interest-insulin vs. 1 OAD |
| 12 | Amador-Licona,Norma, Gu-ÝÝ• zar-Mendoza,Juan Manuel, Vargas,Enrique, S+¡nchez-Camargo,Guillermo. The short-term effect of a switch from glybenclamide to metformin on blood pressure and microalbuminuria in patients with type 2 diabetes mellitus. Archives | unclear if previous blood glucose lowering therapies were washed out/discontinued |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 13 | Amori,R.E. & Lau,J. Efficacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysis. Journal of the American Medical Association.298 (2) (pp 194-206), 2007.Date of Publication: 11 Jul 2007. 2007;(2):194-206. | Systematic review/meta-analysis/pooled analysis/review |
| 14 | Anderson,J.H., Jr, Brunelle,R.L. MEaltime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Archives of Internal Medicine 1997;157(11):1249-55. | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 15 | Anderson,James H., Brunelle,Rocco L., Koivisto,Veikko A., Trautmann,Michael E., Vignati,Louis. Improved mealtime treatment of diabetes mellitus using an insulin analogue. | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 16 | Anon. A critical analysis of the clinical use of incretin-based therapies: The benefits by far outweigh the potential risks. Diabetes Care.36 (pp 2126-2132), 2013.Date of Publication: 2013. 2013;(7):2126-32. | Systematic review/meta-analysis/pooled analysis/review |
| 17 | Anon. Addition of linagliptin to metformin improves glycaemic control in type 2 diabetes. Australian Journal of Pharmacy.93 (1110) (pp 97), 2012.Date of Publication: November 2012. 2012;(1110):97. | abstract only/not full paper |
| 18 | Anon. Changes in bone biological markers after treatment of Iranian diabetic patients with pioglitazone: No relation to polymorphism of PPAR- (Pro12Ala). Journal of Research in Medical Sciences.18 (4) (pp 366-367), 2013.Date of Publication: 2013. 2013;(4) | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 19 | Anon. Characteristics associated with maintenance of mean A1C<6.5% in people with dysglycemia in the ORIGIN trial. Diabetes Care 2013;36(10):2915-22. | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 20 | Anon. Combining incretin-based therapies with insulin: realizing the potential in type 2 diabetes. [Review][Erratum appears in Diabetes Care. 2013 Dec;36(12):4172]. Diabetes Care 2013;36():Suppl-32. | Systematic review/meta-analysis/pooled analysis/review |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 21 | Anon. Corrections to Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: An open-label, non-inferiority randomised trial. [Lancet Diabetes Endocrinol, 2, (2014), 46-55]. Lancet Diabetes and Endocrinology.2 | duplicate or same study results |
| 22 | Anon. Corrigendum to A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: A 52-week, randomized study [Diabet. Med., 27 (2010) 318-3 | abstract only/not full paper |
| 23 | Anon. Erratum: Clinical practice considerations and review of the literature for the use of DPP-4 inhibitors in patients with type 2 diabetes and chronic kidney disease (Endocrine Practice 6 (1025-1034)). Endocrine Practice.20 (pp 379), 2014.Date of Publi | Systematic review/meta-analysis/pooled analysis/review |
| 24 | Anon. Erratum: Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: A 54-week randomized trial (American Journal of Kidney Diseases (2013) 61:4 (579-587)). American Journal of Kidney Diseases.62 (4) (pp 847), 20 | abstract only/not full paper |
| 25 | Anon. Errtum to Assessing the cardio-cerebrovascular safety of vildagliptin: Meta-analysis of adjudicated events from a large Phase III type 2 diabetes population. [Diabetes Obes Metab, 12, (2010), 485-494]. Diabetes, Obesity and Metabolism.12 (9) (pp 832 | Systematic review/meta-analysis/pooled analysis/review |
| 26 | Anon. GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other? International Journal of Clinical Practice 2014;68(5):557-67. | Systematic review/meta-analysis/pooled analysis/review |
| 27 | Anon. Glucose control: Non-insulin therapies. South African Family Practice.56 (pp S21-S31), 2014.Date of Publication: 2014. 2014;(1):S21-31. | Systematic review/meta-analysis/pooled analysis/review |
| 28 | Anon. Insulin aspart : an evidence-based medicine review. Clinical Drug Investigation 2004;24(12):695-717. | Systematic review/meta-analysis/pooled analysis/review |
| 29 | Anon. Insulin therapy and cancer. [Review]. Diabetes Care 2013;36():Suppl-4. | Systematic review/meta-analysis/pooled analysis/review |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 30 | Anon. LY2605541-A preferential hepato-specific insulin analogue. Diabetes.63 (pp 390-392), 2014.Date of Publication: February 2014. 2014;(2):390-92. | commentary/letter/editorial |
| 31 | Anon. Pathophysiological and pharmacological rationale for the use of exenatide once weekly in patients with type 2 diabetes. Advances in Therapy 2014;31(3):247-63. | Systematic review/meta-analysis/pooled analysis/review |
| 32 | Anon. The importance of incretin therapies for managing type 2 diabetes. Lancet Diabetes and Endocrinology.2 (pp 95-97), 2014.Date of Publication: February 2014. 2014;(2):95-97. | Systematic review/meta-analysis/pooled analysis/review |
| 33 | Anon. The safety of incretin based drugs. BMJ .348 , 2014.Article Number: g2779.Date of Publication: 25 Apr 2014. 2014;(Online):n. pag.. | Systematic review/meta-analysis/pooled analysis/review |
| 34 | Anon. Tolerability of saxagliptin in patients with inadequately controlled type 2 diabetes: Results from 6 phase III studies. Journal of Managed Care Pharmacy.20 (pp 120-129), 2014.Date of Publication: February 2014. 2014;(2):120-29. | Systematic review/meta-analysis/pooled analysis/review |
| 35 | Apovian,C.M., Bergenstal,R.M., Cuddihy,R.M., Qu,Y., Lenox,S., Lewis,M.S. Effects of Exenatide Combined with Lifestyle Modification in Patients with Type 2 Diabetes. American Journal of Medicine.123 (5) (pp 468.e9-468.e17), 2010.Date of Publication: M | across treatment strategy |
| 36 | Arakaki,R.F., Blevins,T.C., Wise,J.K., Liljenquist,D.R., Jiang,H.H., Jacobson,J.G. Comparison of insulin lispro protamine suspension versus insulin glargine once daily added to oral antihyperglycaemic medications and exenatide in type 2 diabetes | Drug comparison not of interest - insulin + 3 OADs vs insulin + 3 OADs |
| 37 | Araki,E., Kawamori,R., Inagaki,N., Watada,H., Hayashi,N., Horie,Y., et al. Long-term safety of linagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes, Obesity & Metabolism 2013;15(4):364-71. | dose comparison of same drug |
| 38 | Aravind,S.R., Ismail,S.B., Balamurugan,R., Gupta,J.B., Wadhwa,T., Loh,S.M., et al. Hypoglycemia in patients with type 2 diabetes from India and Malaysia treated with sitagliptin or a sulfonylurea during Ramadan: a randomized, pragmatic study. Current | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 39 | Armstrong,M.J., Barton,D., Gaunt,P., Hull,D., Guo,K., Stocken,D., et al. Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): Study protocol for a phase II multicentre, double-blinded, randomised, controlled trial. BMJ Open.3 (11) | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 40 | Aroda,V.R., Henry,R.R., Han,J., Huang,W., DeYoung,M.B., Darsow,T. Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic Review. Clinical Therapeutics.34 (6) (pp 1247-1258.e22), 2012.Date of Publication: June 2012. 201 | Systematic review/meta-analysis/pooled analysis/review |
| 41 | Asche,C.V., Bode,B., Busk,A.K. The economic and clinical benefits of adequate insulin initiation and intensification in people with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism.14 (1) (pp 47-57), 2012.Date of Publication: January 2012. 201 | Systematic review/meta-analysis/pooled analysis/review |
| 42 | Aschner,P., Chan,J., Owens,D.R., Picard,S., Wang,E., Dain,M.P., et al. Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial. Lancet 2 | Drug comparison not of interest-insulin + 1 OAD vs. 2 OADs |
| 43 | Asnani,S., Kunhiraman,B., Jawa,A., Akers,D. Pioglitazone restores endothelial function in patients with type 2 diabetes treated with insulin. Metabolic Syndrome & Related Disorders 2006;4(3):179-84. | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 44 | August,P., Hardison,R.M., Hage,F.G., Marroquin,O.C., McGill,J.B., Rosenberg,Y., Steffes,M. Change in albuminuria and eGFR following insulin sensitization therapy versus insulin provision therapy in the BARI 2D study. Clinical Journal of the Am | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 45 | Aulinger,B.A., Bedorf,A., Kutscherauer,G., De,Heer J., Holst,J.J. Defining the Role of GLP-1 in the Enteroinsulinar Axis in Type 2 Diabetes Using DPP-4 Inhibition and GLP-1 Receptor Blockade. Diabetes 2014;63(3):1079-92. | <12 week treatment duration |
| 46 | Bachmann,W., Petzinna,D., Raptis,S.A., Wascher,T. Long-term improvement of metabolic control by acarbose in type 2 diabetes patients poorly controlled with maximum sulfonylurea therapy. Clinical Drug Investigation 2003;23(10):679-86. | across treatment strategy |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 47 | Bader,G. Vildagliptin more effectively achieves a composite endpoint of HbA1c<7.0% without hypoglycaemia and weight gain compared with glimepiride after 2 years of treatment. Diabetes Research and Clinical Practice.100 (3) (pp e78-e81), 2013.Date of Publi | duplicate or same study results |
| 48 | Baldwin,D., Zander,J., Munoz,C., Raghu,P., DeLange-Hudec,S., Lee,H., et al. A randomized trial of two weight-based doses of insulin glargine and glulisine in hospitalized subjects with type 2 diabetes and renal insufficiency. Diabetes Care 2012;35(10 | <12 week treatment duration |
| 49 | Baradari,A.G., Zeydi,A.E., Aarabi,M. Metformin as an adjunct to insulin for glycemic control in patients with type 2 diabetes after CABG surgery: a randomized double blind clinical trial. Pakistan journal of biological sciences: PJBS 2011;14(23):1047-54 | <12 week treatment duration |
| 50 | Barbieri,M., Rizzo,M.R., Marfella,R., Boccardi,V., Esposito,A. Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors. Atherosclerosis 2013;227(2):349-54. | unclear if previous blood glucose lowering therapies were washed out/discontinued |
| 51 | Barnett,A. Dosing of insulin glargine in the treatment of type 2 diabetes. Clinical Therapeutics.29 (6) (pp 987-999), 2007.Date of Publication: June 2007. 2007;(6):987-99. | Systematic review/meta-analysis/pooled analysis/review |
| 52 | Barnett,A.H. Complementing insulin therapy to achieve glycemic control. [Review]. Advances in Therapy 2013;30(6):557-76. | Systematic review/meta-analysis/pooled analysis/review |
| 53 | Barnett,A.H., Burger,J., Johns,D., Brodows,R., Kendall,D.M., Roberts,A. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinatio | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 54 | Barnett,A.H., Charbonnel,B., Donovan,M., Fleming,D. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. Current Medical Research and Opinion.28 (4) (pp 513-523) | Drug comparison not of interest- insulin + 1 OAD vs. insulin + 2 OADs |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 55 | Barnett,A.H., Charbonnel,B., Li,J., Donovan,M. Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy. Clinical Drug Investigation 2013;33(10):707-17. | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 56 | Barnett,A.H., Huisman,H., Jones,R., von,Eynatten M. Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: A randomised, double-blind, placebo-controlled trial. The Lancet.382 ( | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 57 | Bazzano,L.A., Lee,L.J., Shi,L., Reynolds,K., Jackson,J.A. Safety and efficacy of glargine compared with NPH insulin for the treatment of Type 2 diabetes: A meta-analysis of randomized controlled trials. Diabetic Medicine.25 (8) (pp 924-932), 2008.Date | Systematic review/meta-analysis/pooled analysis/review |
| 58 | Bebakar,W.M., Chow,C.C., Kadir,K.A., Suwanwalaikorn,S., Vaz,J.A., Bech,O.M. Adding biphasic insulin aspart 30 once or twice daily is more efficacious than optimizing oral antidiabetic treatment in patients with type 2 diabetes. Diabetes, Obesity & Me | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 59 | Bech,Per & Moses,Robert. The effect of prandial glucose regulation with repaglinide on treatment satisfaction, wellbeing and health status in patients with pharmacotherapy-na+¯ve Type 2 diabetes: A placebo-controlled, multicentre study. Quality of Life R | outcomes not of interest |
| 60 | Beisswenger,P.J., Brown,W.V., Ceriello,A., Le,N.A., Goldberg,R.B., Cooke,J.P., et al. Meal-induced increases in C-reactive protein, interleukin-6 and tumour necrosis factor alpha are attenuated by prandial + basal insulin in patients with Type 2 diab | Focus on test meals in sub study |
| 61 | Bell,D.S., Dharmalingam,M., Kumar,S. Triple oral fixed-dose diabetes polypill versus insulin plus metformin efficacy demonstration study in the treatment of advanced type 2 diabetes (TrIED study-II). Diabetes, Obesity & Metabolism 2011;13(9):800-05. | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 62 | Belsey,J. Glycaemic control and adverse events in patients with type 2 diabetes treated with metformin + sulphonylurea: a meta-analysis. Diabetes, Obesity & Metabolism 2008;10():Suppl-7. | Systematic review/meta-analysis/pooled analysis/review |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 63 | Bengel,F.M., Abletshauser,C., Neverve,J., Schnell,O., Nekolla,S.G., Standl,E. Effects of nateglinide on myocardial microvascular reactivity in Type 2 diabetes mellitus--a randomized study using positron emission tomography. Diabetic Medicine 2005;22( | comparison with unlicensed drug or drug indication |
| 64 | Bennett,W.L., Maruthur,N.M., Singh,S., Segal,J.B., Wilson,L.M., Chatterjee,R., et al. Comparative effectiveness and safety of medications for type 2 diabetes: An update including new drugs and 2-drug combinations. Annals of Internal Medicine.154 (9) | Systematic review/meta-analysis/pooled analysis/review |
| 65 | Bergenstal,R.M., Li,Y., Porter,T.K. Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c < 7%, without weight gain or hypoglycaemia, over 52 weeks. Diabetes, Obesity & Metabolism 2013;15(3):264 | Systematic review/meta-analysis/pooled analysis/review |
| 66 | Bergenstal,R.M., Rosenstock,J., Arakaki,R.F., Prince,M.J., Qu,Y., Sinha,V.P. A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes. Di | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 67 | Berhanu,P. & Perez,A. Effect of pioglitazone in combination with insulin therapy on glycaemic control, insulin dose requirement and lipid profile in patients with type 2 diabetes previously poorly controlled with combination therapy. Diabetes, Obesity & | Drug comparison not of interest- insulin + 1 OAD vs. insulin + 2 OADs |
| 68 | Berlie,H. Glucagon-like peptide-1 receptor agonists as add-on therapy to basal insulin in patients with type 2 diabetes: a systematic review. Diabetes, Metabolic Syndrome and Obesity Targets and Therapy 2012;5():165-74. | Systematic review/meta-analysis/pooled analysis/review |
| 69 | Berlie,H.D. & Kalus,J.S. Thiazolidinediones and the risk of edema: A meta-analysis. Diabetes Research and Clinical Practice.76 (2) (pp 279-289), 2007.Date of Publication: May 2007. 2007;(2):279-89. | Systematic review/meta-analysis/pooled analysis/review |
| 70 | Berndt-Zipfel,C., Michelson,G., Dworak,M., Mitry,M., Loffler,A. Vildagliptin in addition to metformin improves retinal blood flow and erythrocyte deformability in patients with type 2 diabetes mellitus - results from an exploratory study. Cardiovascul | unclear if previous blood glucose lowering therapies were washed out/discontinued |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 71 | Berneis,K., Rizzo,M., Stettler,C., Chappuis,B., Braun,M., Diem,P. Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with Type 2 diabetes. Expert Opinion on Pharma | comparison with unlicensed drug or drug indication |
| 72 | Best,J.H., Boye,K.S., Rubin,R.R., Cao,D., Kim,T.H. Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily. Diabetic Medicine 2009;26(7):722-28. | comparison with unlicensed drug or drug indication |
| 73 | Best,J.H., Rubin,R.R., Peyrot,M., Li,Y., Yan,P., Malloy,J. Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment. Di | outcomes not of interest |
| 74 | Beyer,J., Haas,R., Enzmann,F., Lauerbach,M., Rademacher,J., Althoff,P.H., et al. 12 month's therapy with biosynthetic human insulin. Results of a double-blind comparative study with swine and bovine insulin in insulin-dependent diabetics during a mul | Non-English paper |
| 75 | Bibra,H., Siegmund,T., Ceriello,A., Volozhyna,M. Optimized postprandial glucose control is associated with improved cardiac/vascular function - comparison of three insulin regimens in well-controlled type 2 diabetes. Hormone & Metabolic Research 2009;4 | Drug comparison not of interest-insulin vs. insulin |
| 76 | BIRKELAND,K.I., HANSSEN,K.F., URDAL,P., BERG,K. A long-term, randomized, comparative study of insulin versus sulfonylurea therapy in type 2 diabetes. Journal of Internal Medicine 1994;236(3):305-13. | Drug comparison not of interest-insulin vs. 1 OAD |
| 77 | BIRKELAND,K.I., Kilhovd,B., Thorsby,P., Torjesen,P.A., Ganss,R., VAALER,S. Heterogeneity of non-insulin-dependent diabetes expressed as variability in insulin sensitivity, +Ý-cell function and cardiovascular risk profile. Diabetic Medicine 2003;20(1) | not an RCT (no randomisation) |
| 78 | BIRKELAND,K.I., Rishaug,U., HANSSEN,K.F. NIDDM: a rapid progressive disease Results from a long-term, randomised, comparative study of insulin or sulphonylurea treatment. 1996;39(12):1629-33. | Drug comparison not of interest-insulin vs. 1 OAD |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 79 | Black,Corri, Donnelly,Peter, McIntyre,Linda, Royle,Pamela, Shepherd,Jonathan J. Meglitinide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2007;():n. pag.. | Systematic review/meta-analysis/pooled analysis/review |
| 80 | Blevins,T., Han,J., Nicewarner,D., Chen,S., Oliveira,J.H.A. Exenatide is non-inferior to insulin in reducing HbA1c: An integrated analysis of 1423 patients with type 2 diabetes. Postgraduate Medicine.122 (3) (pp 118-128), 2010.Date of Publication: May | Systematic review/meta-analysis/pooled analysis/review |
| 81 | Blevins,T., Pullman,J., Malloy,J., Yan,P., Taylor,K., Schulteis,C., Trautmann,M. DURATION-5: Exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. Journal of | unclear if previous blood glucose lowering therapies were washed out/discontinued |
| 82 | Blickle,J.F., Hancu,N., Piletic,M., Profozic,V., Shestakova,M., Dain,M.P., Jacqueminet,S. Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 83 | Blonde,L., Dagogo-Jack,S., Banerji,M.A., Pratley,R.E., Marcellari,A., Braceras,R., Purkayastha,D. Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: results of the GALIANT trial--a | comparing different types of sulfonylurea alone |
| 84 | Blonde,L., Klein,E.J., Han,J., Zhang,B., Mac,S.M., Poon,T.H., et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes, Obesit | dose comparison of same drug |
| 85 | Blonde,L., Rosenstock,J., Mooradian,A.D., Piper,B.-A. Glyburide/metformin combination product is safe and efficacious in patients with type 2 diabetes failing sulphonylurea therapy. Diabetes, Obesity and Metabolism.4 (6) (pp 368-375), 2002.Date of Publ | unclear washout of previous blood glucose lowering therapy but termed monotherapy and <12 month duration |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 86 | Bode,B.W., Brett,J., Falahati,A. Comparison of the efficacy and tolerability profile of liraglutide, a once-daily human GLP-1 analog, in patients with type 2 diabetes >=65 and <65 years of age: A pooled analysis from phase III studies. American Journal | Systematic review/meta-analysis/pooled analysis/review |
| 87 | Bode,B.W., Testa,M.A., Magwire,M., Hale,P.M., Hammer,M., Blonde,L., Garber,A. Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patien | comparison with unlicensed drug or drug indication |
| 88 | Boehm,B.O., Home,P.D., Behrend,C., Kamp,N.M. Premixed insulin aspart- 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patients. Diabetic Medicine 2002;19(5):393-99. | unclear if previous blood glucose lowering therapies were washed out/discontinued |
| 89 | Bolen,S., Feldman,L., Vassy,J., Wilson,L., Yeh,H.C., Marinopoulos,S., et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Annals of Internal Medicine 2007;147(6):386-99. | Systematic review/meta-analysis/pooled analysis/review |
| 90 | Bolli,G.B., Munteanu,M., Dotsenko,S., Niemoeller,E., Boka,G. Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1). Diabet.Med. 2013;():n. pag.. | rescue medication was provided to participants and unclear if analysis has been adjusted or switching of treatment |
| 91 | Bosi,E., Camisasca,R.P., Collober,C., Rochotte,E. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007;30(4):890-95. | dose comparison of same drug |
| 92 | Boussageon,R. & Gamble,J.M. Clinically relevant efficacy of insulin therapy in patients with type 2 diabetes. Therapie 2013;68(6):415-17. | commentary/letter/editorial |
| 93 | Boussageon,R., Supper,I., Bejan-Angoulvant,T., Kellou,N., Cucherat,M., Boissel,J.-P., et al. Reappraisal of metformin efficacy in the treatment of type 2 diabetes: A meta-analysis of randomised controlled trials. PLoS Medicine.9 (4) , 2012.Article Nu | Systematic review/meta-analysis/pooled analysis/review |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 94 | Bowering,K., Reed,V.A., Felicio,J.S., Landry,J. A study comparing insulin lispro mix 25 with glargine plus lispro therapy in patients with Type 2 diabetes who have inadequate glycaemic control on oral anti-hyperglycaemic medication: results of the PARA | unclear if previous blood glucose lowering therapies were washed out/discontinued |
| 95 | Boye,K.S., Matza,L.S., Oglesby,A., Malley,K., Kim,S., Hayes,R.P. Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes. Health and Quality of Life Outcomes.4 , 2006.Article Number: 80.Date of Publ | outcomes not of interest |
| 96 | Bretzel,R.G., Eckhard,M., Landgraf,W., Owens,D.R. Initiating insulin therapy in type 2 diabetic patients failing on oral hypoglycemic agents: basal or prandial insulin? The APOLLO trial and beyond. Diabetes Care 2009;32():Suppl-5. | abstract only/not full paper |
| 97 | Bretzel,R.G., Nuber,U., Landgraf,W., Owens,D.R., Bradley,C. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. The La | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 98 | Bretzel,Reinhard G., Arnolds,Sabine, Medding,J.+. A Direct Efficacy and Safety Comparison of Insulin Aspart, Human Soluble Insulin, and Human Premix Insulin (70/30) in Patients With Type 2 Diabetes. Diabetes Care 2004;27(5):1023-27. | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 99 | Brian,Cross L. Potential use of GLP-1 receptor agonists in type 2 diabetes mellitus. American Journal of Pharmacy Benefits.5 (6) (pp 139-150), 2013.Date of Publication: November/December 2013. 2013;(6):139-50. | Systematic review/meta-analysis/pooled analysis/review |
| 100 | Briet,C., Saraval-Gross,M., Kajbaf,F., Fournier,A. Erythrocyte metformin levels in patients with type 2 diabetes and varying severity of chronic kidney disease. Clinical Kidney Journal.5 (pp 65-67), 2012.Date of Publication: 2012. 2012;(1):65-67. | not an RCT (no randomisation) |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 101 | Brown,N.J., Byiers,S., Carr,D., Maldonado,M. Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema. Hypertension.54 (3) (pp 516-523), 2009.Date of Publication: 01 Sep 2009. 2009;(3):516-23. | Systematic review/meta-analysis/pooled analysis/review |
| 102 | Bunck,M.C., Corner,A., Eliasson,B., Heine,R.J., Shaginian,R.M., Taskinen,M.R., et al. Effects of exenatide on measures of beta-cell function after 3 years in metformin-treated patients with type 2 diabetes. Diabetes Care 2011;34(9):2041-47. | Drug comparison not of interest-insulin + 1 OAD vs. 2 OADs |
| 103 | Bunck,M.C., Corner,A., Eliasson,B., Heine,R.J., Shaginian,R.M., Wu,Y., et al. One-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress. Atherosclerosis 2010;212(1):223-29. | Drug comparison not of interest-insulin + 1 OAD vs. 2 OADs |
| 104 | Bunck,M.C., Diamant,M., Eliasson,B., Corner,A., Shaginian,R.M., Heine,R.J., et al. Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition. Diabetes Care 2010;33(8):1734-37. | Drug comparison not of interest-insulin + 1 OAD vs. 2 OADs |
| 105 | Bunck,M.C., Eliasson,B., Corner,A., Heine,R.J., Shaginian,R.M., Taskinen,M.R., et al. Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes. Diabetes, Obesity & Metabolism 2011;13(4):37 | outcomes not of interest |
| 106 | Bunck,M.C., Poelma,M., Eekhoff,E.M., Schweizer,A., Heine,R.J., Nijpels,G., Foley,J.E. Effects of vildagliptin on postprandial markers of bone resorption and calcium homeostasis in recently diagnosed, well-controlled type 2 diabetes patients. Journal | no Hba1c measures |
| 107 | Burant,C.F., Viswanathan,P., Marcinak,J., Cao,C., Vakilynejad,M. TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2012;379(9824):1403-11. | inadequate wash out period (<4 weeks) |
| 108 | Buse J,Sesti G,Schmidt WE,Montanya E,Chang CT,Xu Y,et al. Switching from twice-daily exenatide to once-daily liraglutide improves glycemic control in T2D on oral agents. | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 109 | Buse,J.B., Bergenstal,R.M., Glass,L.C., Heilmann,C.R., Lewis,M.S., Kwan,A.Y., Hoogwerf,B.J. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Annals of Internal Medicine 2011;154(2): | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 110 | Buse,J.B., Drucker,D.J., Taylor,K.L., Kim,T., Walsh,B., Hu,H., et al. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care 2010;33(6):1255-61. | dose comparison of same drug |
| 111 | Buse,J.B., Henry,R.R., Han,J., Kim,D.D., Fineman,M.S., Baron,A.D. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27(11):2628-35. | dose comparison of same drug |
| 112 | Buse,J.B., Nauck,M., Forst,T., Sheu,W.H., Shenouda,S.K., Heilmann,C.R., et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet 2013;381(9861):117-24. | unclear if previous blood glucose lowering therapies were washed out/discontinued |
| 113 | Buse,J.B., Rosenstock,J., Sesti,G., Schmidt,W.E., Montanya,E., Brett,J.H., et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374 | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 114 | Buse,J.B., Wolffenbuttel,B.H., Herman,W.H., Hippler,S., Martin,S.A., Jiang,H.H., Shenouda,S.K. The DURAbility of Basal versus Lispro mix 75/25 insulin Efficacy (DURABLE) trial: comparing the durability of lispro mix 75/25 and glargine. Diabetes Care | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 115 | Buse,J.B., Wolffenbuttel,B.H., Herman,W.H., Shemonsky,N.K., Jiang,H.H., Fahrbach,J.L., Scism-Bacon,J.L. DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 ver | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 116 | Cai,L., Cai,Y., Lu,Z.J., Zhang,Y. The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials. Journal of Clinical Pharmacy & Therapeutics 2012;37(4):386-98. | Systematic review/meta-analysis/pooled analysis/review |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 117 | Cai,X. & Han,X. Comparisons of the efficacy of alpha glucosidase inhibitors on type 2 diabetes patients between Asian and Caucasian. PLoS ONE.8 , 2013.Article Number: e79421.Date of Publication: 13 Nov 2013. 2013;(11):n. pag.. | Systematic review/meta-analysis/pooled analysis/review |
| 118 | Callaghan,B.C. & Little,A.A. Enhanced glucose control for preventing and treating diabetic neuropathy. [Review]. Cochrane Database of Systematic Reviews 2012;6():CD007543. | duplicate or same study results |
| 119 | Campbell I,Robertson-Mackay F,Streets E,Gibbons F,Holman RR. Maintenance of glycaemic control with acarbose in diet treated Type 2 diabetic patients. | abstract only/not full paper |
| 120 | Campbell-Scherer,D.L. Exenatide may improve maintenance of HbA1c targets, with less hypoglycaemia, but more early adverse effects when compared with low-dose glimepiride. Evidence-Based Medicine.18 (5) (pp e42), 2013.Date of Publication: October 2013. 201 | commentary/letter/editorial |
| 121 | Ceriello,A., Del,Prato S., Bue-Valleskey,J., Beattie,S., Gates,J., de la Pena,A. Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascula | Drug comparison not of interest-insulin vs. insulin |
| 122 | Chan WB,Chow DD,Yeung VTF,Chan JCN,So WY,Cochram CS. Effect of insulin lispro on glycaemic control in chinese diabetic patients receiving twice-daily regimens of insulin. | Not specifically type 2 diabetes |
| 123 | Chan,J.C., Scott,R., Arjona Ferreira,J.C., Sheng,D., Gonzalez,E., Davies,M.J., et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes, Obesity & Metabolism 2008;10(7):545-55. | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 124 | Chan,J.Y., Leyk,M., Frier,B.M. Relationship between HbA1c and hypoglycaemia in patients with type 2 diabetes treated with different insulin regimens in combination with metformin. Diabetes/Metabolism Research Reviews 2009;25(3):224-31. | Systematic review/meta-analysis/pooled analysis/review |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 125 | Charbonnel,B., DeFronzo,R., Davidson,J., Schmitz,O., Birkeland,K., Pirags,V. Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive19). Journal of Clinical Endocrinology an | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 126 | Charbonnel,B., Steinberg,H., Eymard,E., Xu,L., Thakkar,P., Prabhu,V. Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabete | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 127 | Charpentier,G., Fleury,F., Kabir,M., Vaur,L. Improved glycaemic control by addition of glimepiride to metformin monotherapy in Type 2 diabetic patients. Diabetic Medicine.18 (10) (pp 828-834), 2001.Date of Publication: 2001. 2001;(10):828-34. | unclear washout of previous blood glucose lowering therapy but termed monotherapy and <12 month duration |
| 128 | Chaudhuri,A., Ghanim,H., Vora,M., Sia,C.L., Korzeniewski,K., Dhindsa,S., Makdissi,A. Exenatide exerts a potent antiinflammatory effect. Journal of Clinical Endocrinology and Metabolism.97 (1) (pp 198-207), 2012.Date of Publication: January 2012. 201 | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 129 | Chaudhuri,A., Rosenstock,J., DiGenio,A., Meneghini,L., Hollander,P., McGill,J.B., et al. Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysis. Diabetes/Metabolism Resear | Systematic review/meta-analysis/pooled analysis/review |
| 130 | Chen,H.S., Wu,T.E., Jap,T.S., Hsiao,L.C., Lee,S.H. Beneficial effects of insulin on glycemic control and beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy. Diabetes Care 2008;31( | Drug comparison not of interest-insulin vs. insulin |
| 131 | Chia,C.W. Incretin-based therapies in type 2 diabetes mellitus. Journal of Clinical Endocrinology & Metabolism 2008;93(10):3703-16. | Systematic review/meta-analysis/pooled analysis/review |
| 132 | Chien,H.-H., Chang,C.-T., Chu,N.-F., Hsieh,S.-H., Huang,Y.-Y., Lee,I.-T., et al. Effect of glyburide-metformin combination tablet in patients with type 2 diabetes. Journal of the Chinese Medical Association.70 (11) (pp 473-480), 2007.Date of Publicat | inadequate wash out period (<4 weeks) |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 133 | Chilcott,J., Wight,J., Jones,M.L. The clinical effectiveness and cost-effectiveness of pioglitazone for type 2 diabetes mellitus: A rapid and systematic review. Health Technology Assessment.5 (19) (pp i+iii-iv+1-61), 2001.Date of Publication: 2001. 2001 | Systematic review/meta-analysis/pooled analysis/review |
| 134 | Chou,H.S., Truitt,K.E., Moberly,J.B., Merante,D., Choi,Y. A 26-week, placebo- and pioglitazone-controlled monotherapy study of rivoglitazone in subjects with type 2 diabetes mellitus. Diabetes, Obesity & Metabolism 2012;14(11):1000-09. | inadequate wash out period (<4 weeks) |
| 135 | Chuang L,Tai T,Juang JH,Chiang YD,Ki K,Jorgensen LN,Yeo LP. Effect of a prandial glucose regulator (NovoNorm) at two doses (0.5 mg and 2 mg) on glycemic control in type 2 diabetes in Taiwan. | unclear if previous blood glucose lowering therapies were washed out/discontinued |
| 136 | Clar,C. & Royle,P. Adding pioglitazone to insulin containing regimens in type 2 diabetes: systematic review and meta-analysis. PLoS ONE [Electronic Resource] 2009;4(7):e6112. | Systematic review/meta-analysis/pooled analysis/review |
| 137 | Clements,M.R., Tits,J., Kinsley,B.T., Rastam,J. Improved glycaemic control of thrice-daily biphasic insulin aspart compared with twice-daily biphasic human insulin; a randomized, open-label trial in patients with type 1 or type 2 diabetes. Diabetes, Ob | Drug comparison not of interest-insulin vs. insulin |
| 138 | Colca,J.R., VanderLugt,J.T., Adams,W.J., Shashlo,A., McDonald,W.G., Liang,J. Clinical proof-of-concept study with MSDC-0160, a prototype mTOT-modulating insulin sensitizer. Clinical pharmacology and therapeutics 2013;93(4):352-59. | abstract only/not full paper |
| 139 | Comaschi,M., Corsi,A., Di,Pietro C., Bellatreccia,A., Mariz,S. The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia. Nutrition Metaboli | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 140 | Comaschi,M., Demicheli,A., Di,Pietro C., Bellatreccia,A., Mariz,S. Effects of pioglitazone in combination with metformin or a sulfonylurea compared to a fixed-dose combination of metformin and glibenclamide in patients with type 2 diabetes. Diabetes T | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 141 | Coniff RF,Shapiro JA,Seaton TB. Long-term efficacy and safety of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus. | dosing regimen includes higher than recommended doses and no details of mean doses or proportion of people taking different doses |
| 142 | Cooper,M.B., Al,Majali K., Bailey,C.J. Reduced postprandial proinsulinaemia and 32-33 split proinsulinaemia after a mixed meal in type 2 diabetic patients following sensitization to insulin with pioglitazone. Clinical Endocrinology 2008;68(5):738-46. | aim to maintain glycaemic control at baseline level |
| 143 | Cucinotta,D., Smirnova,O., Christiansen,J.S., Kanc,K., le,Devehat C., Wojciechowska,M., Lopez,de la Torre. Three different premixed combinations of biphasic insulin aspart - comparison of the efficacy and safety in a randomized controlled clinical t | unclear treatment groups or intervention |
| 144 | Cummins,E., Royle,P., Snaith,A., Greene,A., Robertson,L., McIntyre,L. Clinical effectiveness and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes: Systematic review and economic evaluation. Health Technology Assessment.14 ( | Systematic review/meta-analysis/pooled analysis/review |
| 145 | Curtis,B.H., Rees,T.M., Gaskins,K.A., Sierra-Johnson,J., Liu,R. Efficacy and safety of insulin lispro in geriatric patients with type 2 diabetes: a retrospective analysis of seven randomized controlled clinical trials. Aging-Clinical and Experimen | Systematic review/meta-analysis/pooled analysis/review |
| 146 | Dailey,G., Admane,K., Mercier,F. Relationship of insulin dose, A1c lowering, and weight in type 2 diabetes: Comparing insulin glargine and insulin detemir. Diabetes Technology and Therapeutics.12 (12) (pp 1019-1027), 2010.Date of Publication: 01 Dec 201 | Systematic review/meta-analysis/pooled analysis/review |
| 147 | D'Alessio,D.A., Denney,A.M., Hermiller,L.M., Prigeon,R.L., Martin,J.M., Tharp,W.G., et al. Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes. Journal of Clinical End | unclear if previous blood glucose lowering therapies were washed out/discontinued |
| 148 | Dalzell GW,Hadden DR. A randomized trial tolbutamide and metformin for persistent severe hyperglycaemia in non insulin dependent diabetes mellitus (NIDDM). | abstract only/not full paper |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 149 | Dashora,U.K., Sibal,L., Ashwell,S.G. Insulin glargine in combination with nateglinide in people with Type 2 diabetes: a randomized placebo-controlled trial. Diabetic Medicine 2007;24(4):344-49. | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 150 | Davey,P., Grainger,D., MacMillan,J., Rajan,N., Aristides,M. Clinical outcomes with insulin lispro compared with human regular insulin: A meta-analysis. Clinical Therapeutics.19 (4) (pp 656-674), 1997.Date of Publication: 1997. 1997;(4):656-74. | Systematic review/meta-analysis/pooled analysis/review |
| 151 | Davidson,J., Vexiau,P., Cucinotta,D., Vaz,J. Biphasic insulin aspart 30: Literature review of adverse events associated with treatment. Clinical Therapeutics.27 (SUPPL.2) (pp S75-S88), 2006.Date of Publication: 2006. 2006;(SUPPL. 2):S75-88. | Systematic review/meta-analysis/pooled analysis/review |
| 152 | Davidson,J.A. & Perez,A. Addition of pioglitazone to stable insulin therapy in patients with poorly controlled type 2 diabetes: Results of a double-blind, multicentre, randomized study. Diabetes, Obesity and Metabolism.8 (2) (pp 164-174), 2006.Date of Pu | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 153 | Davidson,J.A., Wolffenbuttel,B.H., Arakaki,R.F., Caballero,A.E. Impact of race/ethnicity on efficacy and safety of two starter insulin regimens in patients with type 2 diabetes: a posthoc analysis of the DURABLE trial. Ethnicity and Disease 2013;23( | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 154 | Davidson,J.A., Brett,J., Falahati,A. Mild renal impairment and the efficacy and safety of liraglutide. Endocrine Practice 2011;17(3):345-55. | Systematic review/meta-analysis/pooled analysis/review |
| 155 | Davidson,J.A., Lacaya,L.B., Jiang,H., Heilmann,C.R., Scism-Bacon,J.L., Gates,J.R. Impact of race/ethnicity on the efficacy and safety of commonly used insulin regimens: a post hoc analysis of clinical trials in type 2 diabetes mellitus. Endocrine Pra | Systematic review/meta-analysis/pooled analysis/review |
| 156 | Davidson,J.A., Liebl,A., Christiansen,J.S., Fulcher,G., Ligthelm,R.J., Brown,P., Gylvin,T. Risk for nocturnal hypoglycemia with biphasic insulin aspart 30 compared with biphasic human insulin 30 in adults with type 2 diabetes mellitus: a meta-analys | Systematic review/meta-analysis/pooled analysis/review |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 157 | Davidson,M.B., Raskin,P., Tanenberg,R.J., Vlajnic,A. A stepwise approach to insulin therapy in patients with type 2 diabetes mellitus and basal insulin treatment failure. Endocrine practice : official journal of the American College of Endocrinology an | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 158 | Davies,M., Evans,R., Storms,F., Gomis,R. Initiation of insulin glargine in suboptimally controlled patients with type 2 diabetes: sub-analysis of the AT.LANTUS trial comparing treatment outcomes in subjects from primary and secondary care in the UK. Di | focus on algorithms (patient vs. physican driven) |
| 159 | Davies,M., Heller,S., Sreenan,S., Sapin,H., Adetunji,O. Once-weekly exenatide versus once- or twice-daily insulin detemir: randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or i | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 160 | Davies,M., Lavalle-Gonzalez,F., Storms,F., Gomis,R. Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial. Diabetes, Obesity & Metabolism 2008;10(5):387- | focus on algorithms (patient vs. physican driven) |
| 161 | Davies,M., Pratley,R., Hammer,M., Thomsen,A.B. Liraglutide improves treatment satisfaction in people with Type 2 diabetes compared with sitagliptin, each as an add on to metformin. Diabetic medicine : a journal of the British Diabetic Association 2011; | outcomes not of interest |
| 162 | Davies,M., Sinnassamy,P., Storms,F., Gomis,R. Insulin glargine-based therapy improves glycemic control in patients with type 2 diabetes sub-optimally controlled on premixed insulin therapies. Diabetes Research & Clinical Practice 2008;79(2):368-75. | focus on algorithms (patient vs. physican driven) |
| 163 | Davies,M.J., Derezinski,T., Pedersen,C.B. Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia. Diabetes Technology & Therapeutics 2008;10(4):273-77. | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 164 | Davies,M.J., Donnelly,R., Barnett,A.H., Jones,S., Nicolay,C. Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 165 | Davies,M.J., Thaware,P.K., Tringham,J.R., Howe,J., Jarvis,J., Johnston,V., et al. A randomized controlled trial examining combinations of repaglinide, metformin and NPH insulin. Diabetic Medicine 2007;24(7):714-19. | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 166 | Davis,S.N., Johns,D., Maggs,D., Xu,H., Northrup,J.H. Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents. Diabetes Care 2007;30(11):2767-72. | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 167 | de,Jager J., Kooy,A., Lehert,Ph, Bets,D., Wulffele,M.G., Teerlink,T., et al. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: A randomized, placebo-controlled tri | Drug comparison not of interest-insulin + 1 OAD vs. insulin |
| 168 | De,Mattia G. & Laurenti,O. Comparison of glycaemic control in patients with Type 2 diabetes on basal insulin and fixed combination oral antidiabetic treatment: results of a pilot study. Acta Diabetologica 2009;46(1):67-73. | cross over trial (no washout details or inappropriate analyses and no outcomes reported for first treatment period) |
| 169 | Deacon,C.F. & Mannucci,E. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis. Diabetes, Obesity & Metabolism 201 | Systematic review/meta-analysis/pooled analysis/review |
| 170 | DeFronzo,R.A., Tripathy,D., Schwenke,D.C., Banerji,M.A., Bray,G.A., Buchanan,T.A., et al. Prevention of diabetes with pioglitazone in ACT NOW: Physiologic correlates. Diabetes.62 (11) (pp 3920-3926), 2013.Date of Publication: November 2013. 2013 | Not specifically type 2 diabetes |
| 171 | DeFronzo,R.A., Ratner,R.E., Han,J., Kim,D.D., Fineman,M.S. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28(5):1092-1000. | dose comparison of same drug |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 172 | DeFronzo,R.A., Stonehouse,A.H., Han,J. Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials. Diabetic Medicine 2010;27(3):309-17. | Systematic review/meta-analysis/pooled analysis/review |
| 173 | Dejgaard,A., Lynggaard,H., Rastam,J. No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis. Diabetologia 2009;52(12):2507-12. | Systematic review/meta-analysis/pooled analysis/review |
| 174 | Del,Prato S. & Bianchi,C. Insulin as an early treatment for type 2 diabetes: ORIGIN or end of an old question? Diabetes Care 2013;36():Suppl-204. | commentary/letter/editorial |
| 175 | Del,Prato S. Linagliptin for the treatment of type 2 diabetes. Expert Opinion on Pharmacotherapy 2011;12(17):2759-62. | commentary/letter/editorial |
| 176 | Del,Prato S., Barnett,A.H., Huisman,H., Neubacher,D., Woerle,H.J. Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabete | rescue medication was provided to participants and unclear if analysis has been adjusted or switching of treatment |
| 177 | Del,Prato S., Heine,R.J., Keilson,L., Guitard,C., Shen,S.G. Treatment of patients over 64 years of age with type 2 diabetes: experience from nateglinide pooled database retrospective analysis. Diabetes Care 2003;26(7):2075-80. | Systematic review/meta-analysis/pooled analysis/review |
| 178 | DeLAWTER,DeWITT E. Human Insulin: A Double-Blind Clinical Study of Its Effectiveness. Southern medical journal 1985;78(6):633-35. | not an RCT (no randomisation) |
| 179 | Derosa G,Franzetti I,Gadaleta G,Ciccarelli L,Fogari R. Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: comparison between glimepiride and metformin. | newly diagnosed participants but not explicit if they are drug naive |
| 180 | Derosa,G. Efficacy and safety profile evaluation of acarbose alone and in association with other antidiabetic drugs: a systematic review. [Review]. Clinical Therapeutics 2012;34(6):1221-36. | duplicate or same study results |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 181 | Derosa,G., Ragonesi,P.D., Fogari,E., Cicero,A.F.G., Bianchi,L., Bonaventura,A. Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile: A 2-year study evaluation. Fundamental and Clinical Pharmacology.28 | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 182 | Derosa,G., Carbone,A., D'Angelo,A., Querci,F., Fogari,E. A randomized, double-blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and beta-cell function. Expert Opinion on Pharmacotherapy.13 (17) (pp 2433-244 | across treatment strategy |
| 183 | Derosa,G., Cicero,A.F., Franzetti,I.G., Querci,F., Carbone,A., Piccinni,M.N., D'Angelo,A. A randomized, double-blind, comparative therapy evaluating sitagliptin versus glibenclamide in type 2 diabetes patients already treated with pioglitazone and m | no inclusion/exclusion criteria or patients drug naive and not representative |
| 184 | Derosa,G., Cicero,A.F.G., Franzetti,I.G., Querci,F., Carbone,A., Piccinni,M.N., D'Angelo,A. A comparison between sitagliptin or glibenclamide in addition to metformin + pioglitazone on glycaemic control and beta-cell function: The triple oral therap | Drug comparison not of interest - insulin + 3 OADs vs insulin + 3 OADs |
| 185 | Derosa,G., D'Angelo,A., Fogari,E., Salvadeo,S., Gravina,A., Ferrari,I. Nateglinide and glibenclamide metabolic effects in naive type 2 diabetic patients treated with metformin. Journal of Clinical Pharmacy & Therapeutics 2009;34(1):13-23. | duplicate or same study results |
| 186 | Derosa,G., Dangelo,A., Ragonesi,P.D., Ciccarelli,L., Piccinni,M.N., Pricolo,F., et al. Effects of rosiglitazone and pioglitazone combined with metformin on the prothrombotic state of patients with type 2 diabetes mellitus and metabolic syndrome. Jour | comparison with unlicensed drug or drug indication |
| 187 | Derosa,G., D'Angelo,A., Ragonesi,P.D., Ciccarelli,L., Piccinni,M.N., Pricolo,F., et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin. Internal Medicine Journal 2007;37(2): | comparison with unlicensed drug or drug indication |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 188 | Derosa,G., D'Angelo,A., Ragonesi,P.D., Ciccarelli,L., Piccinni,M.N., Pricolo,F., et al. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic | comparison with unlicensed drug or drug indication |
| 189 | Derosa,G., Fogari,E., Cicero,A.F., D'Angelo,A., Ciccarelli,L., Piccinni,M.N., et al. Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin. Hypertension Research - Clinica | comparison with unlicensed drug or drug indication |
| 190 | Derosa,G., Maffioli,P., D'Angelo,A., Fogari,E., Bianchi,L. Acarbose on insulin resistance after an oral fat load: a double-blind, placebo controlled study. Journal of Diabetes & its Complications 2011;25(4):258-66. | duplicate or same study results |
| 191 | Derosa,G., Maffioli,P., Ferrari,I., Mereu,R., Ragonesi,P.D., Querci,F., et al. Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients. Hormone & Metabolic Research 2010;42(9):6 | unclear if previous blood glucose lowering therapies were washed out/discontinued |
| 192 | Derosa,G., Maffioli,P., Salvadeo,S.A., Ferrari,I., Ragonesi,P.D., Querci,F., et al. Exenatide versus glibenclamide in patients with diabetes. Diabetes Technology & Therapeutics 2010;12(3):233-40. | unclear if previous blood glucose lowering therapies were washed out/discontinued |
| 193 | Derosa,G., Ragonesi,P.D., Carbone,A., Fogari,E., D'Angelo,A. Vildagliptin action on some adipocytokine levels in type 2 diabetic patients: a 12-month, placebo-controlled study. Expert Opinion on Pharmacotherapy 2012;13(18):2581-91. | across treatment strategy |
| 194 | DeVries,J.H., Bain,S.C., Rodbard,H.W., Seufert,J., D'Alessio,D., Thomsen,A.B., Zychma,M. Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets. | Drug comparison not of interest-insulin + 1 OAD vs. 2 OADs |
| 195 | Dicembrini,I. Lixisenatide: Clinical profile and available evidence. Diabetes Management.4 (1) (pp 71-84), 2014.Date of Publication: January 2014. 2014;(1):71-84. | Systematic review/meta-analysis/pooled analysis/review |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 196 | Diehl,Andrew K. & Sugarek,Nancy J. Medication Compliance in Non-insulin-dependent Diabetes: A Randomized Comparison of Chlorpropamide and Insulin. Diabetes Care 1985;8(3):219-23. | Drug comparison not of interest-insulin vs. 1 OAD |
| 197 | Dimic,D., Velojic,Golubovic M., Antic,S. Evaluation of the repaglinide efficiency in comparison to the glimepiride in the type 2 diabetes patients poorly regulated by the metmorfine administration. Bratislavske Lekarske Listy 2009;110(6):335-39. | not an RCT (no randomisation) |
| 198 | Dorkhan,M. & Frid,A. Differences in effects of insulin glargine or pioglitazone added to oral anti-diabetic therapy in patients with type 2 diabetes: what to add--insulin glargine or pioglitazone? Diabetes Research & Clinical Practice 2008;82(3):340-45. | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 199 | Dorkhan,M., Dencker,M., Stagmo,M. Effect of pioglitazone versus insulin glargine on cardiac size, function, and measures of fluid retention in patients with type 2 diabetes. Cardiovascular Diabetology 2009;8():15. | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 200 | Dornan,Timothy L., Heller,Simon R., Peck,Gillian M. Double-Blind Evaluation of Efficacy and Tolerability of Metformin in NIDDM. Diabetes Care 1991;14(4):342-44. | follow up period outside protocol specified range |
| 201 | Doucet,J., Chacra,A., Maheux,P., Lu,J., Harris,S. Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus. Current Medical Research & Opinion 2011;27(4):863-69. | Systematic review/meta-analysis/pooled analysis/review |
| 202 | Drucker,D.J., Buse,J.B., Taylor,K., Kendall,D.M., Trautmann,M., Zhuang,D. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. The Lancet.372 (9645) (pp 1240-1250), 2008.Date | unclear if previous blood glucose lowering therapies were washed out/discontinued |
| 203 | Ebato,C., Shimizu,T., Arakawa,M., Mita,T., Fujitani,Y., Watada,H., Kawamori,R. Effect of sulfonylureas on switching to insulin therapy (twice-daily biphasic insulin aspart 30): comparison of twice-daily biphasic insulin aspart 30 with or without gli | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 204 | Einarson,T.R. & Garg,M. Composite endpoints in trials of type-2 diabetes. Diabetes, Obesity and Metabolism 2014;16(6):492-99. | Systematic review/meta-analysis/pooled analysis/review |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 205 | Eldor,R. In vivo actions of peroxisome proliferator-activated receptors: Glycemic control, insulin sensitivity, and insulin secretion. Diabetes Care.36 (SUPPL.2) (pp S162-S174), 2013.Date of Publication: August 2013. 2013;(SUPPL.2):S162-74. | commentary/letter/editorial |
| 206 | Engel,S.S., Round,E., Golm,G.T. Erratum to Safety and tolerability of Sitagliptin in type 2 diabetes: Pooled analysis of 25 clinical studies (Diabetes Ther, (2013), 4, (119-145), 10.1007/s13300-013-0024-0). Diabetes Therapy.4 (pp 487), 2013.Date of Pu | Systematic review/meta-analysis/pooled analysis/review |
| 207 | Engel,S.S., Williams-Herman,D.E., Golm,G.T., Clay,R.J., MacHotka,S.V., Kaufman,K.D. Sitagliptin: Review of preclinical and clinical data regarding incidence of pancreatitis. International Journal of Clinical Practice.64 (7) (pp 984-990), 2010.Date of | Systematic review/meta-analysis/pooled analysis/review |
| 208 | Engelen,L., Lund,S.S., Ferreira,I., Tarnow,L., Parving,H.H., Gram,J., et al. Improved glycemic control induced by both metformin and repaglinide is associated with a reduction in blood levels of 3-deoxyglucosone in nonobese patients with type 2 diabe | cross over trial (no washout details or inappropriate analyses and no outcomes reported for first treatment period) |
| 209 | Erdmann,E. & Spanheimer,R. Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, renin-angiotensin system blockers, or insulin: Results from the PROactive study (PROactive 20). | unclear treatment groups or intervention |
| 210 | Erdmann,E., Dormandy,J.A., Charbonnel,B., Massi-Benedetti,M., Moules,I.K. The Effect of Pioglitazone on Recurrent Myocardial Infarction in 2,445 Patients With Type 2 Diabetes and Previous Myocardial Infarction. Results From the PROactive (PROactive 05 | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 211 | Eshghi,S.R.T. Effects of aerobic exercise with or without metformin on plasma incretins in type 2 diabetes. Canadian Journal of Diabetes.37 (6) (pp 375-380), 2013.Date of Publication: December 2013. 2013;(6):375-80. | <12 week treatment duration |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 212 | Esposito,K. & Chiodini,P. A nomogram to estimate the proportion of patients at hemoglobin A1c target <7% with noninsulin antidiabetic drugs in type 2 diabetes: a systematic review of 137 randomized controlled trials with 39,845 patients. Acta Diabetolog | Systematic review/meta-analysis/pooled analysis/review |
| 213 | Esposito,K., Chiodini,P., Capuano,A., Maiorino,M.I. Baseline glycemic parameters predict the hemoglobin A1c response to DPP-4 inhibitors: Meta-regression analysis of 78 randomized controlled trials with 20, 053 patients. Endocrine.46 (pp 43-51), 201 | Systematic review/meta-analysis/pooled analysis/review |
| 214 | Esposito,K., Chiodini,P., Bellastella,G., Maiorino,M.I. Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78 945 patients. [Review]. Diabet | Systematic review/meta-analysis/pooled analysis/review |
| 215 | Esposito,K., Ciotola,M., Maiorino,M.I., Gualdiero,R., Schisano,B., Ceriello,A., et al. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial | comparison with unlicensed drug or drug indication |
| 216 | Esposito,K., Cozzolino,D., Bellastella,G., Maiorino,M.I., Chiodini,P., Ceriello,A. Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes, Obesity & Metabolism 2011;13(7): | Systematic review/meta-analysis/pooled analysis/review |
| 217 | Esposito,K., Giugliano,D., Nappo,F., Marfella,R. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 2004;110(2):214-19. | dosing regimen includes higher than recommended doses and no details of mean doses or proportion of people taking different doses |
| 218 | Esposito,K., Mosca,C., Brancario,C., Chiodini,P., Ceriello,A. GLP-1 receptor agonists and HBA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Current Medical Research & Opinion 2011;27(8):1519-28. | Systematic review/meta-analysis/pooled analysis/review |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 219 | Esteghamati,A., Noshad,S., Rabizadeh,S., Ghavami,M. Comparative effects of metformin and pioglitazone on omentin and leptin concentrations in patients with newly diagnosed diabetes: a randomized clinical trial. Regulatory Peptides 2013;182():1-6. | outcomes not of interest |
| 220 | Esterson,Y.B., Zhang,K., Koppaka,S., Kehlenbrink,S., Kishore,P., Raghavan,P., Maginley,S.R. Insulin sensitizing and anti-inflammatory effects of thiazolidinediones are heightened in obese patients. Journal of Investigative Medicine.61 (pp 1152 | <12 week treatment duration |
| 221 | F"lsch UR,Spengler M,Boehme K,Sommerauer B. Efficacy of glucosidase inhibitors compared to sulphonylureas in the treatment and metabolic control of diet treated Type II diabetic subjects: Two long-term comparative studies. | dosing regimen includes higher than recommended doses and no details of mean doses or proportion of people taking different doses |
| 222 | Fadini,G.P., De Kreutzenberg,S.V., Mariano,V., Boscaro,E., Bertolini,F., Mancuso,P., et al. Optimized glycaemic control achieved with add-on basal insulin therapy improves indexes of endothelial damage and regeneration in type 2 diabetic patients wit | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 223 | Fajardo,Montanana C. & Hernandez,Herrero C. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial. Diabetic Medi | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 224 | Fakhoury,W., Lockhart,I., Kotchie,R.W., Aagren,M. Indirect comparison of once daily insulin detemir and glargine in reducing weight gain and hypoglycaemic episodes when administered in addition to conventional oral anti-diabetic therapy in patients wit | Systematic review/meta-analysis/pooled analysis/review |
| 225 | Fakhoury,W.K. & LeReun,C. A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes (Structured abstract). Pharmacology 2010;86(1):44-57. | Systematic review/meta-analysis/pooled analysis/review |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 226 | Fangh+¤nel,Guillermo, S+¡nchez-Reyes,Leticia, Trujillo,Cesar, Sotres,David. Metformin's Effects on Glucose and Lipid Metabolism in Patients with Secondary Failure to Sulfonylureas. Diabetes Care 1996;19(11):1185-89. | Drug comparison not of interest-insulin vs. 1 OAD |
| 227 | Farcasiu,E., Ivanyi,T., Mozejko-Pastewka,B., Birkus,Z., Csog,J., Kowalska,I., et al. Efficacy and safety of prandial premixed therapy using insulin lispro mix 50/50 3 times daily compared with progressive titration of insulin lispro mix 75/25 or biph | rescue medication was provided to participants and unclear if analysis has been adjusted or switching of treatment |
| 228 | Feinbock,C. & Luger,A. Prospective multicentre trial comparing the efficacy of, and compliance with, glimepiride or acarbose treatment in patients with Type 2 diabetes not controleld with diet alone. Diabetes, Nutrition & Metabolism-Clinical & Experiment | inadequate wash out period (<4 weeks) |
| 229 | Feinglos,M.N., Saad,M.F., Pi-Sunyer,F.X., An,B., Santiago,O. Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes. Diabetic Medicine 2005;22(8):1016-23. | comparison with unlicensed drug or drug indication |
| 230 | Ferrannini,E., Betteridge,D.J., Dormandy,J.A., Charbonnel,B., Wilcox,R.G., Spanheimer,R., et al. High-density lipoprotein-cholesterol and not HbA1c was directly related to cardiovascular outcome in PROactive. Diabetes, Obesity and Metabolism.13 (8) ( | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 231 | Fineberg,S.E. Glipizide versus tolbutamide, an open trial. 1980;18(1):49-54. | comparing different types of sulfonylurea alone |
| 232 | Fineman,M.S., Mace,K.F., Diamant,M., Darsow,T., Cirincione,B.B., Booker Porter,T.K., Kinninger,L.A. Clinical relevance of anti-exenatide antibodies: Safety, efficacy and cross-reactivity with long-term treatment. Diabetes, Obesity and Metabolism.14 | Systematic review/meta-analysis/pooled analysis/review |
| 233 | Fletcher,J.A., Barnett,A.H., Pyke,D.A., Volkmann,H.P., Hartog,M., Perrett,A.D., et al. Transfer from animal insulins to semisynthetic human insulin: a study in four centres. Diabetes research (Edinburgh, Scotland) 1990;14(4):151-58. | Not specifically type 2 diabetes |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 234 | Fogelfeld,L., Dharmalingam,M., Robling,K., Jones,C., Swanson,D. A randomized, treat-to-target trial comparing insulin lispro protamine suspension and insulin detemir in insulin-naive patients with Type 2 diabetes. Diabetic Medicine 2010;27(2):181-88. | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 235 | Fonseca,V., Davidson,J., Home,P., Snyder,J., Jellinger,P., Dyhr,Toft A. Starting insulin therapy with basal insulin analog or premix insulin analog in T2DM: A pooled analysis of treat-to-target trials. Current Medical Research and Opinion.26 (7) (pp | Systematic review/meta-analysis/pooled analysis/review |
| 236 | Fonseca,V., Gill,J., Zhou,R. An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia. Diabetes, Obesity & Metabolism 2011;13(9):814-22. | Systematic review/meta-analysis/pooled analysis/review |
| 237 | Fonseca,V., Schweizer,A., Albrecht,D., Baron,M.A., Chang,I. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007;50(6):1148-55. | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 238 | Fonseca,V.A., DeVries,J.H., Henry,R.R., Donsmark,M. Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: Insights from a patient-level pooled analysis of six randomized clinical trials. Journal of Diabetes and its | Systematic review/meta-analysis/pooled analysis/review |
| 239 | Fonseca,V.A., Alvarado-Ruiz,R., Raccah,D., Boka,G., Miossec,P., Gerich,J.E. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabete | comparison with unlicensed drug or drug indication |
| 240 | Fonseca,Vivian, Bell,David S., Berger,Sheldon, Thomson,Stephen. A comparison of bedtime insulin glargine with bedtime neutral protamine hagedorn insulin in patients with type 2 diabetes: subgroup analysis of patients taking once-daily insulin in a mult | duplicate or same study results |
| 241 | Forst T,Hohberg C,Fuellert SD,L• bben G,Konrad T,L”big M,et al. Pharmacological PPARgamma stimulation in contrast to beta cell stimulation results in an improvement in adiponectin and proinsulin intact levels and reduces intima media thickness in patients | unclear if previous blood glucose lowering therapies were washed out/discontinued |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 242 | Forst,T., Dworak,M., Berndt-Zipfel,C., Loffler,A., Klamp,I. Effect of vildagliptin compared to glimepiride on postprandial proinsulin processing in the beta cell of patients with type 2 diabetes mellitus. Diabetes, Obesity & Metabolism 2013;15(6):576- | abstract only/not full paper |
| 243 | Forst,T., Larbig,M., Hohberg,C., Forst,S., Diessel,S., Borchert,M., Roth,W. Adding insulin glargine vs. NPH insulin to metformin results in a more efficient postprandial beta-cell protection in individuals with type 2 diabetes. Diabetes, Obesity & M | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 244 | Forti,A., Garcia,E.G., Yu,M.B., Jimenez,M.C., Brodows,R.G. Efficacy and safety of exenatide administered before the two largest daily meals of Latin American patients with type 2 diabetes. Current Medical Research & Opinion 2008;24(9):2437-47. | unclear if previous blood glucose lowering therapies were washed out/discontinued |
| 245 | Frederich,R., Alexander,J.H., Fiedorek,F.T., Donovan,M., Berglind,N., Harris,S., et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgraduate Medicine 2010;122(3):16-27. | Systematic review/meta-analysis/pooled analysis/review |
| 246 | Frederich,R., McNeill,R., Berglind,N. The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naive patients with type 2 diabetes mellitus: a randomized controlled trial. Diabetology & metabolic syndrome 2012;4(1):36. | rescue medication was provided to participants and unclear if analysis has been adjusted or switching of treatment |
| 247 | Fritsche,A., Larbig,M., Owens,D., Haring,H.U. Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes-results of the GINGER study. Diabetes, Obesity & Metabolism 2010;12(2):115-23. | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 248 | Fujioka,K. & Pans,M. Glycemic control in patients with type 2 diabetes mellitus switched from twice-daily immediate-release metformin to a once-daily extended-release formulation. Clinical Therapeutics.25 (2) (pp 515-529), 2003.Date of Publication: 01 Fe | inadequate wash out period (<4 weeks) |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 249 | Galle,J., Kleophas,W., Dellanna,F., Schmid,V.H., Forkel,C., Dikta,G., et al. Comparison of the Effects of Pioglitazone versus Placebo when Given in Addition to Standard Insulin Treatment in Patients with Type 2 Diabetes Mellitus Requiring Hemodialysi | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 250 | Gallwitz,B. How do we continue treatment in patients with type 2 diabetes when therapeutic goals are not reached with oral antidiabetes agents and lifestyle? Incretin versus insulin treatment. [Review]. Diabetes Care 2013;36():Suppl-9. | Systematic review/meta-analysis/pooled analysis/review |
| 251 | Gallwitz,B., Bohmer,M., Segiet,T., Molle,A., Milek,K., Becker,B., et al. Exenatide twice daily versus premixed insulin aspart 70/30 in metformin-treated patients with type 2 diabetes: a randomized 26-week study on glycemic control and hypoglycemia. D | Drug comparison not of interest-insulin + 1 OAD vs. 2 OADs |
| 252 | Gallwitz,B., Vaag,A., Falahati,A. Adding liraglutide to oral antidiabetic drug therapy: onset of treatment effects over time. International Journal of Clinical Practice 2010;64(2):267-76. | duplicate or same study results |
| 253 | Gamble,J., Simpson,S.H., Brown,L.C. Insulin versus an oral antidiabetic agent as add-on therapy in type 2 diabetes after failure of an oral antidiabetic regimen: a meta-analysis. Open Medicine : A Peer-reviewed, Independent, Open-access Journal 2008;2(2 | Systematic review/meta-analysis/pooled analysis/review |
| 254 | Gangji,A.S., Cukierman,T., Gerstein,H.C., Goldsmith,C.H. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care 2007;30(2):389-94. | Systematic review/meta-analysis/pooled analysis/review |
| 255 | Gao,W., Dong,J., Liu,J., Li,Y., Liu,F., Yang,L. Efficacy and safety of initial combination of DPP-IV inhibitors and metformin versus metformin monotherapy in type 2 diabetes: A systematic review of randomized controlled trials. Diabetes, Obesity | Systematic review/meta-analysis/pooled analysis/review |
| 256 | Gao,X. Multicentre, double-blind, randomized study of mitiglinide compared with nateglinide in type 2 diabetes mellitus patients in China. Journal of International Medical Research 2009;37(3):812-21. | comparison with unlicensed drug or drug indication |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 257 | Garber,A., Henry,R., Ratner,R., Garcia-Hernandez,P.A., Rodriguez-Pattzi,H., Olvera-Alvarez,I., et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment tri | comparison with unlicensed drug or drug indication |
| 258 | Garber,A., Henry,R.R., Ratner,R., Hale,P., Chang,C.T., Bode,B. Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in p | comparison with unlicensed drug or drug indication |
| 259 | Garber,A.J., Clauson,P., Pedersen,C.B. Lower risk of hypoglycemia with insulin detemir than with neutral protamine hagedorn insulin in older persons with type 2 diabetes: a pooled analysis of phase III trials. Journal of the American Geriatrics Society | Systematic review/meta-analysis/pooled analysis/review |
| 260 | Garber,A.J., King,A.B., Del,Prato S., Sreenan,S., Balci,M.K., Munoz-Torres,M., et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-B | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 261 | Garber,A.J., Schweizer,A., Baron,M.A. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: A randomized, placebo-controlled study. Diabetes, Obesity and Metaboli | Drug comparison not of interest - 2 OADs vs 1 OAD |
| 262 | Garg,S.K. & Aurand,L.A. Diabetes duration and the efficacy and safety of insulin glargine versus comparator treatment in patients with type 2 diabetes mellitus. Endocrine Practice 2014;20(2):120-28. | Systematic review/meta-analysis/pooled analysis/review |
| 263 | Gastaldelli,A. The effect of chronic twice daily exenatide treatment on beta-cell function in new onset type 2 diabetes. Clinical Endocrinology.80 (pp 545-553), 2014.Date of Publication: April 2014. 2014;(4):545-53. | comparison with unlicensed drug or drug indication |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 264 | Gastaldelli,A., Ferrannini,E., Miyazaki,Y., Matsuda,M., Mari,A. Thiazolidinediones improve beta-cell function in type 2 diabetic patients. American Journal of Physiology - Endocrinology & Metabolism 2007;292(3):E871-83. | unclear dosing regimen and no details relating to mean doses |
| 265 | Geng,D.-F., Jin,D.-M., Wu,W., Fang,C. Effect of alpha-glucosidase inhibitors on the progression of carotid intima-media thickness: A meta-analysis of randomized controlled trials. Atherosclerosis.218 (1) (pp 214-219), 2011.Date of Publication: Septembe | Systematic review/meta-analysis/pooled analysis/review |
| 266 | Gentile,S., Turco,S., Guarino,G., Oliviero,B., Rustici,A. [Non-insulin-dependent diabetes mellitus associated with nonalcoholic liver cirrhosis: an evaluation of treatment with the intestinal alpha-glucosidase inhibitor acarbose]. Annali italiani di m | Non-English paper |
| 267 | Gerrald,K.R., Van,Scoyoc E., Wines,R.C., Runge,T. Saxagliptin and sitagliptin in adult patients with type 2 diabetes: A systematic review and meta-analysis. Diabetes, Obesity and Metabolism.14 (6) (pp 481-492), 2012.Date of Publication: June 2012. 2012 | Systematic review/meta-analysis/pooled analysis/review |
| 268 | Gerstein,H.C., Yale,J.F., Harris,S.B., Issa,M., Stewart,J.A. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulpho | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 269 | Giles,T.D., Elkayam,U., Bhattacharya,M., Perez,A. Comparison of pioglitazone vs glyburide in early heart failure: insights from a randomized controlled study of patients with type 2 diabetes and mild cardiac disease. Congestive Heart Failure 2010;16(3) | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 270 | Giles,T.D., Miller,A.B., Elkayam,U., Bhattacharya,M. Pioglitazone and Heart Failure: Results From a Controlled Study in Patients With Type 2 Diabetes Mellitus and Systolic Dysfunction. Journal of Cardiac Failure.14 (6) (pp 445-452), 2008.Date of Public | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 271 | Giugliano,D., Maiorino,M., Bellastella,G., Chiodini,P. Relationship of baseline HbA1c, HbA1c change and HbA1c target of < 7% with insulin analogues in type 2 diabetes: a meta-analysis of randomised controlled trials. [Review]. International Journal of | Systematic review/meta-analysis/pooled analysis/review |
| 272 | Giugliano,D., Maiorino,M.I., Bellastella,G., Chiodini,P. Multiple HbA1c targets and insulin analogues in type 2 diabetes: A systematic review. Journal of Diabetes and its Complications.25 (4) (pp 275-281), 2011.Date of Publication: July-August 2011. 20 | Systematic review/meta-analysis/pooled analysis/review |
| 273 | Giugliano,D., Maiorino,M.I., Bellastella,G., Chiodini,P. Treatment regimens with insulin analogues and haemoglobin A1c target of <7% in type 2 diabetes: A systematic review. Diabetes Research and Clinical Practice.92 (1) (pp 1-10), 2011.Date of Publica | Systematic review/meta-analysis/pooled analysis/review |
| 274 | Glass,L.C., Qu,Y., Lenox,S., Kim,D., Gates,J.R., Brodows,R., Trautmann,M. Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: a pooled post-hoc analysis. Current Medical Research & Opinion 2008;24(3):639- | Systematic review/meta-analysis/pooled analysis/review |
| 275 | Goergen,S.K., Rumbold,G., Compton,G. Systematic review of current guidelines, and their evidence base, on risk of lactic acidosis after administration of contrast medium for patients receiving metformin. Radiology.254 (1) (pp 261-269), 2010.Date of Publ | Systematic review/meta-analysis/pooled analysis/review |
| 276 | Goldberg,R.B., Einhorn,D., Lucas,C.P., Rendell,M.S., Damsbo,P., Huang,W.C., Strange,P. A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes. Diabetes Care 1998;21(11):1897-9003. | inadequate wash out period (<4 weeks) |
| 277 | Goldenberg,R. Insulin plus incretin agent combination therapy in type 2 diabetes: a systematic review. Current Medical Research and Opinion 2014;30(3):431-45. | Systematic review/meta-analysis/pooled analysis/review |
| 278 | Goldstein,B.J. & Pans,M. Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonyl | unclear washout of previous blood glucose lowering therapy but termed monotherapy and <12 month duration |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 279 | Gomis,R. & Raptis,S.A. Appropriate timing of Glimepiride administration in patients with type 2 diabetes millitus: A study in Mediterranean countries. Endocrine.13 (1) (pp 117-121), 2000.Date of Publication: 2000. 2000;(1):117-21. | focus on timing of administration |
| 280 | Gomis,R., Owens,D.R., Taskinen,M.R., Del,Prato S., Patel,S., Pivovarova,A. Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: Up to 2 years expo | not an RCT (no randomisation) |
| 281 | Gonzalez-Clemente,J.M. Improvement of glycaemic control by nateglinide decreases systolic blood pressure in drug-naive patients with type 2 diabetes. European Journal of Clinical Investigation.38 (3) (pp 174-179), 2008.Date of Publication: March 2008. 200 | comparison with unlicensed drug or drug indication |
| 282 | Gonzalez-Ortiz,M., Guerrero-Romero,J.F., Violante-Ortiz,R., Wacher-Rodarte,N., Martinez-Abundis,E., Aguilar-Salinas,C., et al. Efficacy of glimepiride/metformin combination versus glibenclamide/metformin in patients with uncontrolled type 2 diabetes | unclear if previous blood glucose lowering therapies were washed out/discontinued |
| 283 | Goodman AM. Efficacy and safety of metformin Results of a multicenter trial. | abstract only/not full paper |
| 284 | Goodman,M. & Thurston,H. Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Hormone & Metabolic Research 2009;41(5):368-73. | focus on timing of administration |
| 285 | Goosen,K. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes, Obesity and Metabolism 2012;14(12):1061-72. | Systematic review/meta-analysis/pooled analysis/review |
| 286 | Goring,S., Hawkins,N., Wygant,G., Roudaut,M., Townsend,R. Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis. Diabetes, Obesity and Metabolism 2014;16( | Systematic review/meta-analysis/pooled analysis/review |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 287 | Goudswaard,Alex N., Furlong,Niall J., Valk,Gerlof D., Stolk,Ronald P. Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2004;():n. pag.. | Systematic review/meta-analysis/pooled analysis/review |
| 288 | Gough,S.C., Bhargava,A., Jain,R., Mersebach,H. Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, ran | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 289 | Grant,Peter J. The Effects of High- and Medium-Dose Metformin Therapy on Cardiovascular Risk Factors in Patients With Type II Diabetes. Diabetes Care 1996;19(1):64-66. | unclear if previous blood glucose lowering therapies were washed out/discontinued |
| 290 | Grey,A., Bolland,M., Fenwick,S., Horne,A., Gamble,G. The skeletal effects of pioglitazone in type 2 diabetes or impaired glucose tolerance: A randomized controlled trial. European Journal of Endocrinology.170 (pp 255-262), 2014.Date of Publication | Not specifically type 2 diabetes |
| 291 | Groop,P.H., Cooper,M.E., Perkovic,V., Emser,A. Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes Care.36 (pp 3460-3468), 2013.Date of Publication: November 2013. | Systematic review/meta-analysis/pooled analysis/review |
| 292 | Groop,P.H., Del,Prato S., Taskinen,M.R., Owens,D.R., Gong,Y., Crowe,S., Patel,S. Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment. Diabetes, Obesity and Metabolism 2014;16(6):560-68. | Systematic review/meta-analysis/pooled analysis/review |
| 293 | Gross,J.L., Kramer,C.K., Leitao,C.B., Hawkins,N., Viana,L.V., Schaan,B.D., et al. Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis. [Review]. Anna | Systematic review/meta-analysis/pooled analysis/review |
| 294 | Gross,J.L., Nakano,M., Colon-Vega,G., Ortiz-Carasquillo,R., Ferguson,J.A., Althouse,S., et al. Initiation of prandial insulin therapy with AIR inhaled insulin or insulin lispro in patients with type 2 diabetes: A randomized noninferiority trial. Diab | comparison with unlicensed drug or drug indication |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 295 | Gupta,A.K., Bray,G.A., Greenway,F.L., Martin,C.K., Johnson,W.D. Pioglitazone, but not metformin, reduces liver fat in Type-2 diabetes mellitus independent of weight changes. Journal of Diabetes & its Complications 2010;24(5):289-96. | unclear if previous blood glucose lowering therapies were washed out/discontinued |
| 296 | Gupta,A.K., Smith,S.R., Greenway,F.L. Pioglitazone treatment in type 2 diabetes mellitus when combined with portion control diet modifies the metabolic syndrome. Diabetes, Obesity & Metabolism 2009;11(4):330-37. | unclear if previous blood glucose lowering therapies were washed out/discontinued |
| 297 | Gutniak,Mark & Karlander,Sven Gunnar. Glyburide Decreases Insulin Requirement, Increases (+Ý-Cell Response to Mixed Meal, and Does Not Affect Insulin Sensitivity: Effects of Short-and Long-Term Combined Treatment in Secondary Failure to Sulfonylurea. Dia | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 298 | Haak,T., Meinicke,T., Jones,R., Weber,S. Initial combination of linagliptin and metformin in patients with type 2 diabetes: efficacy and safety in a randomised, double-blind 1-year extension study. International Journal of Clinical Practice 2013;67(12) | Drug comparison not of interest - 2 OADs vs 1 OAD |
| 299 | Haffner,Steven M., Hanefeld,Markolf, Fischer,Sabine, Fu+§ker,Katja. Glibenclamide, but Not Acarbose, Increases Leptin Concentrations Parallel to Changes in Insulin in Subjects With NIDDM. Diabetes Care 1997;20(9):1430-34. | unclear if previous blood glucose lowering therapies were washed out/discontinued |
| 300 | Han,S., Iglay,K., Davies,M.J., Zhang,Q. Glycemic effectiveness and medication adherence with fixed-dose combination or coadministered dual therapy of antihyperglycemic regimens: A meta-analysis. Current Medical Research and Opinion.28 (6) (pp 969-977), | Systematic review/meta-analysis/pooled analysis/review |
| 301 | Hanefeld,M., Bouter,K.P., Dickinson,S. Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia. Diabetes Care 2000;23(2):202-07. | comparison with unlicensed drug or drug indication |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 302 | Hanefeld,Markolf, Fischer,Sabine, Schulze,Jan, Spengler,Manfred, Wargenau,Manfred, Schollberg,Karl. Therapeutic Potentials of Acarbose as First-Line Drug in NIDDM Insufficiently Treated With Diet Alone. Diabetes Care 1991;14(8):732-37. | critical inconsistencies in reported data |
| 303 | Harashima,K., Hayashi,J., Miwa,T. Long-term pioglitazone therapy improves arterial stiffness in patients with type 2 diabetes mellitus. Metabolism: Clinical & Experimental 2009;58(6):739-45. | not an RCT (no randomisation) |
| 304 | Harrison,L.B., Adams-Huet,B., Li,X. Intensive therapy in newly diagnosed type 2 diabetes: results of a 6-year randomized trial. Journal of Investigative Medicine 2014;62(4):676-86. | duplicate or same study results |
| 305 | Harrison,L.B., Adams-Huet,B., Raskin,P. beta-cell function preservation after 3.5 years of intensive diabetes therapy. Diabetes Care.35 (7) (pp 1406-1412), 2012.Date of Publication: July 2012. 2012;(7):1406-12. | rescue medication was provided to participants and unclear if analysis has been adjusted or switching of treatment |
| 306 | Hasche,H., Mertes,G., Bruns,C., Englert,R., Genthner,P., Heim,D., et al. Effects of acarbose treatment in Type 2 diabetic patients under dietary training: A multicentre, double-blind, placebo-controlled, 2-year study. Diabetes, Nutrition and Metaboli | rescue medication was provided to participants and unclear if analysis has been adjusted or switching of treatment |
| 307 | Hayes,R.P., Curtis,B., Ilag,L., Nelson,D.R. Expectations about insulin therapy, perceived insulin-delivery system social acceptability, and insulin treatment satisfaction contribute to decreases in insulin therapy self-efficacy in patients with type | outcomes not of interest |
| 308 | He,S., Tang,Y.H., Zhao,G., Yang,X. Pioglitazone prescription increases risk of bladder cancer in patients with type 2 diabetes: an updated meta-analysis. Tumour Biology 2014;35(3):2095-1002. | Systematic review/meta-analysis/pooled analysis/review |
| 309 | Heise,T., Mathieu,C., Hey-Hadavi,J., Strack,T. Glycemic control with preprandial versus basal insulin in patients with type 2 diabetes mellitus poorly controlled by oral antidiabetes agents. Diabetes Technology & Therapeutics 2010;12(2):135-41. | comparison with unlicensed drug or drug indication |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 310 | Heliovaara,M.K., Herz,M., Teppo,A.M., Leinonen,E. Pioglitazone has anti-inflammatory effects in patients with Type 2 diabetes. Journal of Endocrinological Investigation 2007;30(4):292-97. | unclear if previous blood glucose lowering therapies were washed out/discontinued |
| 311 | Hemmingsen B,Schroll JB,Lund SS,Wetterslev J,Gluud C,Vaag A,Sonne DP,Lundstr›m LH,Almdal T. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus. | Systematic review/meta-analysis/pooled analysis/review |
| 312 | Hemmingsen,B., Christensen,L.L., Wetterslev,J., Vaag,A., Gluud,C., Lund,S.S. Comparison of metformin and insulin versus insulin alone for type 2 diabetes: systematic review of randomised clinical trials with meta-analyses and trial sequential analyse | Systematic review/meta-analysis/pooled analysis/review |
| 313 | Henry,R., Buse,J., Sesti,G., Davies,M., Jensen,K., Brett,J. Efficacy of anthiyperglycemic therapies and the influence of baseline hemoglobin A1C: A meta-analysis of the liraglutide development program. Endocrine Practice.17 (6) (pp 906-913), 2011.Dat | Systematic review/meta-analysis/pooled analysis/review |
| 314 | Henry,R.R., Staels,B., Fonseca,V.A., Chou,M.Z., Teng,R., Golm,G.T., et al. Efficacy and safety of initial combination treatment with sitagliptin and pioglitazone-a factorial study. Diabetes, Obesity and Metabolism.16 (pp 223-230), 2014.Date of P | rescue medication was provided to participants and unclear if analysis has been adjusted or switching of treatment |
| 315 | Henry,R.R., Smith,S.R., Schwartz,S.L., Mudaliar,S.R., Deacon,C.F., Holst,J.J., et al. Effects of saxagliptin on beta-cell stimulation and insulin secretion in patients with type 2 diabetes. Diabetes, Obesity & Metabolism 2011;13(9):850-58. | no Hba1c measures |
| 316 | Hermann LS,Bitzen PO,Kjellstrom T,Lindgarde F,Schersten B. Comparative efficacy of metformin and glibenclamide in patients with non-insulin-dependent diabetes mellitus. | duplicate or same study results |
| 317 | Hermann LS,Kjellstrom T,Nilsson EP. Effects of metformin and glibenclamide alone and in combination on serum lipids and lipoproteins in patients with non-insulin-dependent diabetes mellitus. | duplicate or same study results |
| 318 | Hermann LS,Ranstam J,Vaaler S,Melander A. Effects of antihyperglycaemic therapies on proinsulin and relation between proinsulin and cardiovascular risk factors in type 2 diabetes. | duplicate or same study results |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 319 | Hermann,L.S. & Karlsson,J.E. Prospective comparative study in NIDDM patients of metformin and glibenclamide with special reference to lipid profiles. 1991;41(3):263-65. | unclear if previous blood glucose lowering therapies were washed out/discontinued |
| 320 | Hermann,L.S. & Scherst+©n,B. Antihyperglycaemic Efficacy, Response Prediction and Doseâ€"Response Relations of Treatment with Metformin and Sulphonylurea, Alone and in Primary Combination. Diabetic Medicine 1994;11(10):953-60. | duplicate or same study results |
| 321 | Hermann,L.S., Kalen,J., Katzman,P., Lager,I., Nilsson,A., Norrhamn,O., Sartor,G. Long-term glycaemic improvement after addition of metformin to insulin in insulin-treated obese type 2 diabetes patients. Diabetes, Obesity and Metabolism.3 (6) (pp 428 | Drug comparison not of interest-insulin + 1 OAD vs. insulin |
| 322 | Hermansen,K., Kipnes,M., Luo,E., Fanurik,D. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes, Obes | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 323 | Hermansen,K., Kolotkin,R.L., Hammer,M., Zdravkovic,M. Patient-reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin. Primary care diabetes 2010;4(2):113-17. | outcomes not of interest |
| 324 | Hernandez,A.V., Usmani,A., Rajamanickam,A. Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials (Structur | Systematic review/meta-analysis/pooled analysis/review |
| 325 | Hillebrand I,Englert R. Efficacy and tolerability of a 12-week treatment with acarbose (BAY g5421), miglitol (BAY m1099) and glibenclamid. | abstract only/not full paper |
| 326 | Hirao,K., Arai,K., Yamauchi,M., Takagi,H. Six-month multicentric, open-label, randomized trial of twice-daily injections of biphasic insulin aspart 30 versus multiple daily injections of insulin aspart in Japanese type 2 diabetic patients (JDDM 11). Di | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 327 | Hirsch,I.B., Yuan,H., Campaigne,B.N. Impact of prandial plus basal vs basal insulin on glycemic variability in type 2 diabetic patients. Endocrine Practice 2009;15(4):343-48. | Systematic review/meta-analysis/pooled analysis/review |
| 328 | Hirst,J.A., Farmer,A.J., Ali,R., Roberts,N.W. Quantifying the effect of metformin treatment and dose on glycemic control. Diabetes Care 2012;35(2):446-54. | Systematic review/meta-analysis/pooled analysis/review |
| 329 | Ho,L.T., Lam,H.C., Wu,M.S., Kwok,C.F., Jap,T.S., Tang,K.T., Wang,L.M. A twelve month double-blind randomized study of the efficacy and immunogenicity of human and porcine insulins in non-insulin-dependent diabetics. Zhonghua yi xue za zhi= Chinese m | unclear if previous blood glucose lowering therapies were washed out/discontinued |
| 330 | Hoffmann J. Acarbose and glibenclamide in type-II diabetes. A comparative study on efficacy and side effects (therapeutical news). | Non-English paper |
| 331 | Hollander P,Bunkerslawson T,Bergenstal R,Mazze R. A randomized clinical trial of glyburide versus insulin using staged diabetes management to achieve euglycemia in NIDDM. | abstract only/not full paper |
| 332 | Hollander,P., Cooper,J., Bregnh›j,J. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 333 | Hollander,P., Raslova,K., Skjoth,T.V., Rastam,J. Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial. Diabetes, Obesity & Metabolism 2011;13(3):268-75. | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 334 | Holman,R.R. & Steemson,J. Sulphonylurea failure in type 2 diabetes: treatment with a basal insulin supplement. Diabetic Medicine 1987;4(5):457-62. | <12 week treatment duration |
| 335 | Holman,R.R., Farmer,A.J., Davies,M.J., Levy,J.C., Darbyshire,J.L., Keenan,J.F., Paul,S.K. Three-year efficacy of complex insulin regimens in type 2 diabetes. New England Journal of Medicine 2009;361(18):1736-47. | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 336 | Holman,R.R., Thorne,K.I., Farmer,A.J., Davies,M.J., Keenan,J.F., Paul,S., Levy,J.C. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. New England Journal of Medicine 2007;357(17):1716-30. | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 337 | Home,P.D., Fritsche,A., Schinzel,S. Meta-analysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine. [Review]. Diabetes, Obesity & Metabolism 2010;12(9):772-79. | Systematic review/meta-analysis/pooled analysis/review |
| 338 | Hompesch,M., Morrow,L., Watkins,E., Roepstorff,C. Pharmacokinetic and pharmacodynamic responses of insulin degludec in african american, white, and hispanic/latino patients with type 2 diabetes mellitus. Clinical Therapeutics 2014;36(4):507-15. | <12 week treatment duration |
| 339 | Hompesch,M., Muchmore,D.B., Morrow,L. Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidase. Diabetes Technology and Therapeutics.15 (pp S45-S47), 2013.Date of Publicat | abstract only/not full paper |
| 340 | Hong,E.S., Khang,A.R., Yoon,J.W., Kang,S.M., Choi,S.H., Park,K.S., et al. Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study. Diabetes, Obesity & Metabolism | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 341 | Hong,J. Metformin reduced CV events compared with glipizide in patients with type 2 diabetes and CAD. Annals of Internal Medicine.158 (8) (pp JC4), 2013.Date of Publication: 16 Apr 2013. 2013;(8):JC4. | abstract only/not full paper |
| 342 | Hong,J., Zhang,Y., Lai,S., Lv,A., Su,Q., Dong,Y., et al. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care.36 (5) (pp 1304-1311), 2013.Date of Publication: May | rescue medication was provided to participants and unclear if analysis has been adjusted or switching of treatment |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 343 | Horowitz,M., Vilsboll,T., Zdravkovic,M., Hammer,M. Patient-reported rating of gastrointestinal adverse effects during treatment of type 2 diabetes with the once-daily human GLP-1 analogue, liraglutide. Diabetes, Obesity & Metabolism 2008;10(7):593-96. | comparison with unlicensed drug or drug indication |
| 344 | Horvath,K., Jeitler,K., Berghold,A., Ebrahim,S.H., Gratzer,T.W., Plank,J., et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2007;(2):n. pag.. | Systematic review/meta-analysis/pooled analysis/review |
| 345 | Houlden,R., Ross,S., Harris,S., Yale,J.F., Sauriol,L. Treatment satisfaction and quality of life using an early insulinization strategy with insulin glargine compared to an adjusted oral therapy in the management of Type 2 diabetes: the Canadian INSIG | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 346 | Hsia,S.H. Insulin glargine compared to NPH among insulin-naive, U.S. inner city, ethnic minority type 2 diabetic patients. Diabetes Research & Clinical Practice 2011;91(3):293-99. | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 347 | Hsieh,C.-H., He,C.-T., Lee,C.-H., Wu,L.-Y. Both slow-release and regular-form metformin improve glycemic control without altering plasma visfatin level in patients with type 2 diabetes mellitus. Metabolism: Clinical and Experimental.56 (8) (pp 1087-109 | inadequate wash out period (<4 weeks) |
| 348 | Hsieh,S.H., Lin,J.D., Cheng,H.Y., Ho,C. Sustained-release versus immediate-release glipizide for treatment of type 2 diabetes mellitus in chinese patients: A randomized, double-blind, double-dummy, parallel-group, 12-week clinical study. Clinical Thera | unclear if previous blood glucose lowering therapies were washed out/discontinued |
| 349 | Hughes,A.D., Park,C., March,K., Coady,E., Khir,A. A randomized placebo controlled double blind crossover study of pioglitazone on left ventricular diastolic function in type 2 diabetes. International Journal of Cardiology 2013;167(4):1329-32. | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 350 | Hwang,Y.C., Kang,M., Ahn,C.W., Park,J.S., Baik,S.H., Chung,D.J., et al. Efficacy and safety of glimepiride/metformin sustained release once daily vs. glimepiride/metformin twice daily in patients with type 2 diabetes. International Journal of Clinica | unclear if previous blood glucose lowering therapies were washed out/discontinued |
| 351 | Hwu,Chii Min, Ho,Low Tone, Fuh,Martin M.T., Siu,Shing Chung, Sutanegara,Dwi, Piliang,Sjafii. Acarbose improves glycemic control in insulin-treated Asian type 2 diabetic patients: Results from a multinational, placebo-controlled study. Diabetes Resear | Drug comparison not of interest-insulin + 1 OAD vs. insulin |
| 352 | Ilag,L.L., Kerr,L., Malone,J.K. Prandial Premixed Insulin Analogue Regimens Versus Basal Insulin Analogue Regimens in the Management of Type 2 Diabetes: An Evidence-Based Comparison. Clinical Therapeutics.29 (6 PART 1) (pp 1254-1270), 2007.Date of Publi | Systematic review/meta-analysis/pooled analysis/review |
| 353 | Iltz,J.L., Baker,D.E., Setter,S.M. Exenatide: An incretin mimetic for the treatment of type 2 diabetes mellitus. Clinical Therapeutics.28 (5) (pp 652-665), 2006.Date of Publication: May 2006. 2006;(5):652-65. | Systematic review/meta-analysis/pooled analysis/review |
| 354 | Inagaki,N., Ueki,K., Yamamura,A. Long-term safety and efficacy of exenatide twice daily in Japanese patients with suboptimally controlled type 2 diabetes. Journal of Diabetes Investigation 2011;2(6):448-56. | duplicate or same study results |
| 355 | Inagaki,N., Watada,H., Murai,M., Kagimura,T., Gong,Y. Linagliptin provides effective, well-tolerated add-on therapy to pre-existing oral antidiabetic therapy over 1 year in Japanese patients with type 2 diabetes. Diabetes, Obesity and Metabolism 2 | rescue medication was provided to participants and unclear if analysis has been adjusted or switching of treatment |
| 356 | Inagaki,N., Atsumi,Y., Oura,T. Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parall | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 357 | Iqbal,N., Parker,A., Frederich,R. Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: Pooled analysis of 20 clinical trials. Cardiovascular Diabetology.13 , 2014.Article Number: 33.Date of Publication: 04 | Systematic review/meta-analysis/pooled analysis/review |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 358 | Jacob,A.N., Salinas,K., Adams-Huet,B. Weight gain in type 2 diabetes mellitus. Diabetes, Obesity & Metabolism 2007;9(3):386-93. | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 359 | Jacober,S.J. & Scism-Bacon,J.L. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naive patients with type 2 diabetes receiving oral antidiabetes agents. Diabetes, Obesity & Metabolism 2006;8(4):448-55. | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 360 | Jacober,S.J., Rosenstock,J., Bergenstal,R.M., Prince,M.J. Contrasting weight changes with LY2605541, a novel long-acting insulin, and insulin glargine despite similar improved glycaemic control in T1DM and T2DM. Diabetes, Obesity and Metabolism.16 ( | duplicate or same study results |
| 361 | Jadzinsky,M., Pfutzner,A., Paz-Pacheco,E., Xu,Z., Allen,E., Chen,R. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controll | across treatment strategy |
| 362 | Jain,S.M., Mao,X., Escalante-Pulido,M., Vorokhobina,N., Lopez,I. Prandial-basal insulin regimens plus oral antihyperglycaemic agents to improve mealtime glycaemia: initiate and progressively advance insulin therapy in type 2 diabetes. Diabetes, Obesit | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 363 | Jarnert,C., Landstedt-Hallin,L., Malmberg,K., Melcher,A., Ohrvik,J., Persson,H. A randomized trial of the impact of strict glycaemic control on myocardial diastolic function and perfusion reserve: A report from the DADD (Diabetes mellitus and Diastol | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 364 | Jeong,K.-H. The efficacy and safety of liraglutide. International Journal of Clinical Pharmacy.33 (5) (pp 740-749), 2011.Date of Publication: October 2011. 2011;(5):740-49. | Systematic review/meta-analysis/pooled analysis/review |
| 365 | Jibran,R., Suliman,M.I., Qureshi,F. Safety and efficay of repaglinide compared with glibenclamide in the management of type 2 diabetic Pakistani patients. Pakistan Journal of Medical Sciences 2006;22(4):385-90. | not an RCT (no randomisation) |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 366 | Johansen,O.E., Boehm,B.O., Grill,V., Torjesen,P.A., Bhattacharya,S., Patel,S. C-peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: Exploratory results from a 2-year double-blind, randomized, contr | duplicate or same study results |
| 367 | Jonker,J.T., Wang,Y., de,Haan W., Diamant,M., Rijzewijk,L.J., van der Meer,R.W., et al. Pioglitazone decreases plasma cholesteryl ester transfer protein mass, associated with a decrease in hepatic triglyceride content, in patients with type 2 diabete | duplicate or same study results |
| 368 | Jovanovic,L. & Peters,A.L. Durability of glycemic control with insulin lispro mix 75/25 versus insulin glargine for older patients with type 2 diabetes. Aging Clinical and Experimental Research.26 (pp 115-121), 2014.Date of Publication: April 2014. 2014 | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 369 | Jovanovic,L., Hassman,D.R., Gooch,B., Jain,R., Greco,S., Khutoryansky,N. Treatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone. Diabetes Research & Clinical Practice 2004;63(2):127-34. | inadequate wash out period (<4 weeks) |
| 370 | Joya-Galeana,J., Fernandez,M., Cervera,A., Reyna,S., Ghosh,S., Triplitt,C., et al. Effects of insulin and oral anti-diabetic agents on glucose metabolism, vascular dysfunction and skeletal muscle inflammation in type 2 diabetic subjects. Diabetes/Met | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 371 | Jung,J.A., Kaku,K., Kim,J.H., Kim,J.R., Ko,J.W. Additive postprandial glucose-lowering effects of mitiglinide and sitagliptin in patients with type 2 diabetes mellitus. Advances in Therapy.30 (11) (pp 1018-1029), 2013.Date of Publication: November | comparison with unlicensed drug or drug indication |
| 372 | Juurinen,L., Tiikkainen,M., Saltevo,J., Nikkila,K., Lanki,H., Leppavuori,E., et al. Nateglinide combination therapy with basal insulin and metformin in patients with Type 2 diabetes. Diabetic Medicine 2009;26(4):409-15. | Drug comparison not of interest- insulin + 1 OAD vs. insulin + 2 OADs |
| 373 | Kadowaki,T. 28-week, randomized, multicenter, open-label, parallel-group phase III trial to investigate the efficacy and safety of biphasic insulin aspart 70 thrice-daily injections vs twice-daily injections of biphasic insulin aspart 30 in patients with | Drug comparison not of interest-insulin vs. insulin |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 374 | Kadowaki,T., Namba,M., Imaoka,T., Yamamura,A., Goto,W., Boardman,M.K. Improved glycemic control and reduced bodyweight with exenatide: A double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 | unclear if previous blood glucose lowering therapies were washed out/discontinued |
| 375 | Kadowaki,T., Namba,M., Yamamura,A., Sowa,H., Wolka,A.M. Exenatide exhibits dose-dependent effects on glycemic control over 12 weeks in Japanese patients with suboptimally controlled type 2 diabetes. Endocrine Journal 2009;56(3):415-24. | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 376 | Kaku,K. & Rasmussen,M.F. Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes. Diabetes, Obe | Drug comparison not of interest - 2 OADs vs 1 OAD |
| 377 | Kaku,K., Daida,H., Kashiwagi,A., Yamashina,A., Yamazaki,T., Momomura,S., et al. Long-term effects of pioglitazone in Japanese patients with type 2 diabetes without a recent history of macrovascular morbidity. Current Medical Research & Opinion 2009;2 | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 378 | Kaku,K., Rasmussen,M.F., Nishida,T. Fifty-two-week, randomized, multicenter trial to compare the safety and efficacy of the novel glucagon-like peptide-1 analog liraglutide vs glibenclamide in patients with type2 diabetes. Journal of Diabetes Investigat | comparison with unlicensed drug or drug indication |
| 379 | Kalra,S., Plata-Que,T., Kumar,D., Mumtaz,M., Sondergaard,F., Kozlovski,P. Initiation with once-daily BIAsp 30 results in superior outcome compared to insulin glargine in Asians with type 2 diabetes inadequately controlled by oral anti-diabetic drugs. | unclear if previous blood glucose lowering therapies were washed out/discontinued |
| 380 | Kamel AN,Cetinarslan B,Uysal AR,Baskal N,Corapcioglu D,Tonyukuk V. Efficacy of monotherapy with acarbose, glibenclamide, gliclazide, metformin or placebo in NIDDM patients. | abstract only/not full paper |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 381 | Kanazawa,I., Yamaguchi,T., Yano,S., Yamamoto,M., Yamauchi,M., Kurioka,S. Baseline atherosclerosis parameter could assess the risk of bone loss during pioglitazone treatment in type 2 diabetes mellitus. Osteoporosis International.21 (12) (pp 2013-2018 | unclear if previous blood glucose lowering therapies were washed out/discontinued |
| 382 | Kanazawa,I., Yamamoto,M., Yamaguchi,T. Effects of metformin and pioglitazone on serum pentosidine levels in type 2 diabetes mellitus. Experimental & Clinical Endocrinology & Diabetes 2011;119(6):362-65. | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 383 | Kanazu,S., Horie,Y., Narukawa,M., Nonaka,K., Taniguchi,T., Arjona Ferreira,J.C. Predicting steady-state HbA1c responses to sitagliptin in patients with type 2 diabetes mellitus. Diabetes, Obesity & Metabolism 2009;11(8):813-18. | Systematic review/meta-analysis/pooled analysis/review |
| 384 | Kanda T. Effects of oral antidiabetic agent on carbohydrate and lipid metabolism in mildly obese patients with diabetes mellitus: a randomized comparative study of acarbose and sulfonylurea (. | not available from the British library |
| 385 | Kania,D.S. & Gonzalvo,J.D. Saxagliptin: a clinical review in the treatment of type 2 diabetes mellitus. [Review]. Clinical Therapeutics 2011;33(8):1005-22. | Systematic review/meta-analysis/pooled analysis/review |
| 386 | Kann,P.H., Wascher,T., Zackova,V., Moeller,J., Medding,J., Szocs,A., et al. Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride. Experimental & Clinica | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 387 | Kapitza,C., Forst,T., Coester,H.V., Poitiers,F. Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin. Diabetes, Obesity & Metabolism 2013;15( | <12 week treatment duration |
| 388 | Karagiannis,T., Paschos,P., Paletas,K., Matthews,D.R. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ 2012;344():e1369. | Systematic review/meta-analysis/pooled analysis/review |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 389 | Karl,D., Zhou,R., Vlajnic,A. Fasting plasma glucose 6-12weeks after starting insulin glargine predicts likelihood of treatment success: A pooled analysis. Diabetic Medicine.29 (7) (pp 933-936), 2012.Date of Publication: July 2012. 2012;(7):933-36. | Systematic review/meta-analysis/pooled analysis/review |
| 390 | Kashiwagi,A., Kadowaki,T., Tajima,N., Nonaka,K., Taniguchi,T., Nishii,M. Sitagliptin added to treatment with ongoing pioglitazone for up to 52 weeks improves glycemic control in Japanese patients with type 2 diabetes. Journal of Diabetes Investi | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 391 | Katavetin,P. & Eiam-Ong,S. Pioglitazone reduces urinary protein and urinary transforming growth factor-beta excretion in patients with type 2 diabetes and overt nephropathy. Journal of the Medical Association of Thailand.89 (2) (pp 170-177), 2006.Date of | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 392 | Kato,T. & Inoue,T. Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study. Cardiovascular Diabetology 2010;9():12. | comparison with unlicensed drug or drug indication |
| 393 | Kawai,T., Funae,O., Shimada,A., Tabata,M., Hirata,T., Atsumi,Y. Effects of pretreatment with low-dose metformin on metabolic parameters and weight gain by pioglitazone in Japanese patients with type 2 diabetes. Internal Medicine 2008;47(13):1181-88. | not an RCT (no randomisation) |
| 394 | Kawalec,P. The safety of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter 2 (SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes/Metab | Systematic review/meta-analysis/pooled analysis/review |
| 395 | Kawamori,R., Kaku,K., Hanafusa,T., Oikawa,T. Effect of combination therapy with repaglinide and metformin hydrochloride on glycemic control in Japanese patients with type 2 diabetes mellitus. Journal of Diabetes Investigation.5 (pp 70-79), 2014.Date | Drug comparison not of interest - 2 OADs vs 1 OAD |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 396 | Kawamori,R., Iwamoto,Y., Kadowaki,T., Iwasaki,M., Kim,S.W., Woo,J.T., Baik,S.H. Effects of insulin glulisine as mono- or add-on therapy in patients with type 2 diabetes mellitus. Diabetes, Obesity & Metabolism 2009;11(9):900-09. | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 397 | Kawamori,R., Kaku,K., Hanafusa,T., Kashiwabara,D., Kageyama,S. Efficacy and safety of repaglinide vs nateglinide for treatment of Japanese patients with type 2 diabetes mellitus. Journal of Diabetes Investigation.3 (3) (pp 302-308), 2012.Date of Publi | comparison with unlicensed drug or drug indication |
| 398 | Kazda,C., Hulstrunk,H., Helsberg,K., Langer,F., Forst,T. Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: A randomized controlled trial in patients with type 2 diabetes beginning | Drug comparison not of interest-insulin vs. insulin |
| 399 | Kendall,D.M., Riddle,M.C., Rosenstock,J., Zhuang,D., Kim,D.D., Fineman,M.S. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28(5):1083-9 | Drug comparison not of interest - 3 OADs vs. 2 OADs |
| 400 | Khan,M. & Murray,F.T. Pioglitazone and reductions in post-challenge glucose levels in patients with type 2 diabetes. Diabetes, Obesity and Metabolism.8 (1) (pp 31-38), 2006.Date of Publication: January 2006. 2006;(1):31-38. | Parent paper included and data extracted |
| 401 | Khunti,K., Srinivasan,B.T., Shutler,S. Effect of insulin glargine on glycaemic control and weight in obese and non-obese people with type 2 diabetes: data from the AT.LANTUS trial. Diabetes, Obesity & Metabolism 2010;12(8):683-88. | focus on algorithms (patient vs. physican driven) |
| 402 | Kim,D., Macconell,L., Zhuang,D., Kothare,P.A., Trautmann,M., Fineman,M. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007;30(6):1487 | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 403 | Kim,S.W., Baik,S.H., Yoon,K.H., Lee,H.W. Efficacy and safety of vildagliptin/pioglitazone combination therapy in Korean patients with diabetes. World Journal of Diabetes 2010;1(5):153-60. | Parent paper included and data extracted |
| 404 | Kim,Y.G., Hahn,S., Oh,T.J., Kwak,S.H. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. [Review]. Diabetologia 2013;56(4):696-708. | Systematic review/meta-analysis/pooled analysis/review |
| 405 | King,D.E. The impact of pioglitazone on ADMA and oxidative stress markers in patients with type 2 diabetes. Primary care diabetes 2012;6(2):157-61. | outcomes not of interest |
| 406 | Koivisto,V., Cleall,S., Pontiroli,A.E. Comparison of insulin lispro protamine suspension versus insulin glargine once daily in basal-bolus therapies with insulin lispro in type 2 diabetes patients: a prospective randomized open-label trial. Diabetes, Ob | comparison with unlicensed drug or drug indication |
| 407 | Kooy,A., de,Jager J., Lehert,P., Bets,D., Wulffele,M.G., Donker,A.J. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Archives of Internal Medicine 2009;169(6):616-25. | Drug comparison not of interest-insulin + 1 OAD vs. 1 OAD |
| 408 | Koren,S., Shemesh-Bar,L., Tirosh,A., Peleg,R.K., Berman,S., Hamad,R.A., et al. The effect of sitagliptin versus glibenclamide on arterial stiffness, blood pressure, lipids, and inflammation in type 2 diabetes mellitus patients. Diabetes Technology & | unclear if previous blood glucose lowering therapies were washed out/discontinued |
| 409 | Koska,J., Saremi,A., Bahn,G. The effect of intensive glucose lowering on lipoprotein particle profiles and inflammatory markers in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care.36 (pp 2408-2414), 2013.Date of Publication: 2013. 2013;(8):24 | not an RCT (no randomisation) |
| 410 | Kothny,W. & Shao,Q. One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment. Diabetes, Obesity & Metabolism 2012;14(11):1032-39. | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 411 | Koyama,H., Tanaka,S., Monden,M., Shoji,T., Morioka,T., Fukumoto,S., et al. Comparison of effects of pioglitazone and glimepiride on plasma soluble RAGE and RAGE expression in peripheral mononuclear cells in type 2 diabetes: Randomized controlled | unclear if previous blood glucose lowering therapies were washed out/discontinued |
| 412 | Kozlovski,P., Foley,J., Shao,Q. Vildagliptin-insulin combination improves glycemic control in Asians with type 2 diabetes. World Journal of Diabetes 2013;4(4):151-56. | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 413 | Krasner,N.M. & Ido,Y. Glucagon-Like Peptide-1 (GLP-1) Analog Liraglutide Inhibits Endothelial Cell Inflammation through a Calcium and AMPK Dependent Mechanism. PLoS ONE [Electronic Resource] 2014;9(5):e97554. | not an RCT (no randomisation) |
| 414 | Kusaka,I., Nagasaka,S., Horie,H. Metformin, but not pioglitazone, decreases postchallenge plasma ghrelin levels in type 2 diabetic patients: a possible role in weight stability? Diabetes, Obesity & Metabolism 2008;10(11):1039-46. | unclear if previous blood glucose lowering therapies were washed out/discontinued |
| 415 | Kvapil,M. & Swatko,A. Biphasic insulin aspart 30 plus metformin: An effective combination in type 2 diabetes. Diabetes, Obesity and Metabolism.8 (1) (pp 39-48), 2006.Date of Publication: January 2006. 2006;(1):39-48. | Drug comparison not of interest-insulin + 1 OAD vs. 2 OADs |
| 416 | Labrousse-Lhermine,F., Cazals,L., Ruidavets,J.B., GEDEC Study Group. Long-term treatment combining continuous subcutaneous insulin infusion with oral hypoglycaemic agents is effective in type 2 diabetes. Diabetes & Metabolism 2007;33(4):253-60. | focus on continuous subcutaneous insulin |
| 417 | Lago,R.M. & Singh,P.P. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet.370 (9593) (pp 1129-1136), 2007.Date of Publication: | Systematic review/meta-analysis/pooled analysis/review |
| 418 | Lam,H.C., Tang,K.T., Wang,J.T., Liu,Y.F., Wang,L.M. Immunogenicity of monocomponent human and porcine insulin in non-insulin dependent diabetes mellitus. Zhonghua yi xue za zhi= Chinese medical journal; Free China ed 1988;41(3):217. | unclear if previous blood glucose lowering therapies were washed out/discontinued |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 419 | Lamanna,C., Monami,M., Marchionni,N. Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes, Obesity & Metabolism 2011;13(3):221-28. | Systematic review/meta-analysis/pooled analysis/review |
| 420 | Landgraf,R. & Bilo,H.J. A comparison of repaglinide and glibenclamide in the treatment of type 2 diabetic patients previously treated with sulphonylureas. European Journal of Clinical Pharmacology 1999;55(3):165-71. | unclear if previous blood glucose lowering therapies were washed out/discontinued |
| 421 | Landman,G.W., de Bock,G.H., van Hateren,K.J., van Dijk,P.R., Groenier,K.H., Gans,R.O., Houweling,S.T. Safety and efficacy of gliclazide as treatment for type 2 diabetes: a systematic review and meta-analysis of randomized trials. PLoS ONE [Ele | Systematic review/meta-analysis/pooled analysis/review |
| 422 | Lankisch,M.R., Ferlinz,K.C., Leahy,J.L., Scherbaum,W.A. Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs. Diabetes, | focus on timing of administration |
| 423 | Larkins,R.G., Zajac,J., Saunders,R., Read,A. A COMPARATIVE DOUBLEâ€• BLIND TRIAL OF THE EFFECTIVENESS AND ANTIGENICITY OF SEMISYNTHETIC HUMAN INSULIN AND PURIFIED PORCINE INSULIN IN NEWLY TREATED DIABETIC SUBJECTS. Australian and New Zealand journal of | Not specifically type 2 diabetes |
| 424 | Lasserson,D.S., Glasziou,P., Perera,R., Holman,R.R. Optimal insulin regimens in type 2 diabetes mellitus: Systematic review and meta-analyses. Diabetologia.52 (10) (pp 1990-2000), 2009.Date of Publication: October 2009. 2009;(10):1990-2000. | Systematic review/meta-analysis/pooled analysis/review |
| 425 | Lavalle-Gonzalez,F.J., Januszewicz,A., Davidson,J., Tong,C., Qiu,R. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 2013; | comparison with unlicensed drug or drug indication |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 426 | Lee,L.J., Fahrbach,J.L., Nelson,L.M., McLeod,L.D., Martin,S.A., Sun,P. Effects of insulin initiation on patient-reported outcomes in patients with type 2 diabetes: results from the durable trial. Diabetes Research & Clinical Practice 2010;89(2):157-6 | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 427 | Lee,P., Chang,A., Blaum,C., Vlajnic,A., Gao,L. Comparison of safety and efficacy of insulin glargine and neutral protamine hagedorn insulin in older adults with type 2 diabetes mellitus: Results from a pooled analysis. Journal of the American Geriatri | Systematic review/meta-analysis/pooled analysis/review |
| 428 | Lee,Y.H., Lee,B.W., Chun,S.W., Cha,B.S. Predictive characteristics of patients achieving glycaemic control with insulin after sulfonylurea failure. International Journal of Clinical Practice 2011;65(10):1076-84. | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 429 | Levin,P.A., Zhang,Q., Mersey,J.H., Lee,F.Y., Bromberger,L.A., Bhushan,M. Glycemic Control With Insulin Glargine Plus Insulin Glulisine Versus Premixed Insulin Analogues in Real-World Practices: A Cost-Effectiveness Study With a Randomized Pragmatic T | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 430 | Lexis,C.P.H. Metformin for cardiovascular disease: Promise still unproven. Lancet Diabetes and Endocrinology.2 (pp 94-95), 2014.Date of Publication: February 2014. 2014;(2):94-95. | commentary/letter/editorial |
| 431 | Li,H., Li,W., Gu,Y., Han,Y., Wang,J., Xu,B., et al. Comparison of continual insulin or secretagogue treatment in type 2 diabetic patients with alternate insulin-secretagogue administration. Diabetes Research and Clinical Practice.84 (2) (pp 158-162), | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 432 | Li,J., Tian,H., Li,Q., Wang,N., Wu,T., Liu,Y., et al. Improvement of insulin sensitivity and beta-cell function by nateglinide and repaglinide in type 2 diabetic patients - a randomized controlled double-blind and double-dummy multicentre clinical tr | comparing different types of sulfonylurea alone |
| 433 | Li,L., Shen,J., Bala,M.M., Busse,J.W., Ebrahim,S., Vandvik,P.O., et al. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies. BMJ 2014 | Systematic review/meta-analysis/pooled analysis/review |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 434 | Li,L., Yang,M., Li,Z., Yan,X., Guo,H., Pan,H., et al. Efficacy and safety of mitiglinide versus nateglinide in newly diagnose patients with type 2 diabetes mellitus: a randomized double blind trial. Diabetes, Obesity & Metabolism 2012;14(2):187-89. | comparison with unlicensed drug or drug indication |
| 435 | Li,W.-X., Gou,J.-F., Tian,J.-H., Yan,X. Glucagon-like peptide-1 receptor agonists versus insulin glargine for type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials. Current Therapeutic Research - Clinical and E | Systematic review/meta-analysis/pooled analysis/review |
| 436 | Liao,L., Yang,M., Qiu,L.L., Mou,Y.R., Zhao,J.J. Appropriate insulin initiation dosage for insulin-naive type 2 diabetes outpatients receiving insulin monotherapy or in combination with metformin and/or pioglitazone. Chinese Medical Journal 2010;123(24 | Drug comparison not of interest- insulin + 1 OAD vs. insulin + 2 OADs |
| 437 | Liebl,A., Davidson,J., Mersebach,H., Dykiel,P. A novel insulin combination of insulin degludec and insulin aspart achieves a more stable overnight glucose profile than insulin glargine: results from continuous glucose monitoring in a proof-of-concept t | outcomes not of interest |
| 438 | Liebl,A., Prager,R., Binz,K., Kaiser,M., Bergenstal,R., Gallwitz,B. Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial. Diabetes, Obesity & Metabolism 2009;11(1):45-52. | Drug comparison not of interest-insulin vs. insulin |
| 439 | Ligthelm,R.J., Gylvin,T., DeLuzio,T. A comparison of twice-daily biphasic insulin aspart 70/30 and once-daily insulin glargine in persons with type 2 diabetes mellitus inadequately controlled on basal insulin and oral therapy: a randomized, open-label s | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 440 | Ligthelm,R.J., Mouritzen,U., Lynggaard,H., Landin-Olsson,M., Fox,C., le,Devehat C., Romero,E. Biphasic insulin aspart given thrice daily is as efficacious as a basal-bolus insulin regimen with four daily injections: a randomised open-label parallel | Drug comparison not of interest-insulin vs. insulin |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 441 | Ligueros-Saylan,M., Foley,J.E., Schweizer,A., Couturier,A. An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled data | Systematic review/meta-analysis/pooled analysis/review |
| 442 | Lin,S.D., Wang,J.S., Hsu,S.R., Sheu,W.H., Tu,S.T., Lee,I.T., et al. The beneficial effect of alpha-glucosidase inhibitor on glucose variability compared with sulfonylurea in Taiwanese type 2 diabetic patients inadequately controlled with metformin: p | unclear if previous blood glucose lowering therapies were washed out/discontinued |
| 443 | Lincoff,A.M., Wolski,K., Nicholls,S.J. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials. Journal of the American Medical Association.298 (10) (pp 1180-1188), 2007.Date of Publ | Systematic review/meta-analysis/pooled analysis/review |
| 444 | Lingvay,I., Legendre,J.L., Kaloyanova,P.F., Zhang,S., Adams-Huet,B. Insulin-based versus triple oral therapy for newly diagnosed type 2 diabetes: which is better? Diabetes Care 2009;32(10):1789-95. | rescue medication was provided to participants and unclear if analysis has been adjusted or switching of treatment |
| 445 | Lingvay,I., Roe,E.D., Duong,J. Effect of insulin versus triple oral therapy on the progression of hepatic steatosis in type 2 diabetes. Journal of Investigative Medicine 2012;60(7):1059-63. | rescue medication was provided to participants and unclear if analysis has been adjusted or switching of treatment |
| 446 | Liu,S.C. & Tu,Y.K. Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: A network meta-analysis. Diabetes, Obesity and Metabolism.14 (9) (pp 810-820), 2012.Date of Public | Systematic review/meta-analysis/pooled analysis/review |
| 447 | Liutkus,J., Rosas,Guzman J., Norwood,P., Pop,L., Northrup,J. A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin. Diabetes, Obesity and Metabolism.12 (12) (pp 1058-1065), 2010.Date of | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 448 | Loke,Y.K. & Kwok,C.S. Comparative cardiovascular effects of thiazolidinediones: Systematic review and meta-analysis of observational studies. BMJ.342 (7799) (pp 692), 2011.Date of Publication: 26 Mar 2011. 2011;(7799):692. | Systematic review/meta-analysis/pooled analysis/review |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 449 | Lu,C.-H., Chang,C.-C., Chuang,L.-M., Wang,C.Y., Jiang,Y.D. Double-blind, randomized, multicentre study of the efficacy and safety of gliclazide-modified release in the treatment of Chinese type 2 diabetic patients. Diabetes, Obesity and Metabolism.8 ( | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 450 | Lukashevich,V. & Prato,S.D. Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea. Diabetes, Obesity and Metabolism 2014;16(5):403-09. | Drug comparison not of interest - 3 OADs vs. 2 OADs |
| 451 | Lukashevich,V., Schweizer,A., Foley,J.E., Dickinson,S. Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment. Vascular Health & Risk Management 2013;9():21-28. | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 452 | Lukashevich,V., Schweizer,A., Shao,Q., Groop,P.-H. Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: A prospective 24-week randomized placebo-controlled trial. Diabetes, Obesity | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 453 | Lund,S.S. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care 2013;36:1304-1311. Diabetes Care.37 (pp e19-e20), 2014.Date of Publication: January 2014. 2014;(1):e19-2 | commentary/letter/editorial |
| 454 | Lund,S.S., Tarnow,L., Stehouwer,C.D., Schalkwijk,C.G., Frandsen,M., Smidt,U.M., et al. Targeting hyperglycaemia with either metformin or repaglinide in non-obese patients with type 2 diabetes: results from a randomized crossover trial. Diabetes, Obes | cross over trial (no washout details or inappropriate analyses and no outcomes reported for first treatment period) |
| 455 | Lund,S.S., Tarnow,L., Stehouwer,C.D., Schalkwijk,C.G., Teerlink,T., Gram,J., et al. Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with typ | cross over trial (no washout details or inappropriate analyses and no outcomes reported for first treatment period) |
| 456 | Luo,J., Jacober,S.J., Prince,M.J. The effect of adjusting for baseline hypoglycemia when analyzing hypoglycemia data: a systematic analysis of 15 diabetes clinical trials. Diabetes Technology and Therapeutics 2013;15(8):654-61. | Systematic review/meta-analysis/pooled analysis/review |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 457 | Lupoli,R., Di,Minno A., Tortora,A., Ambrosino,P. Effects of treatment with metformin on TSH levels: A meta-analysis of literature studies. Journal of Clinical Endocrinology and Metabolism.99 (pp E143-E148), 2014.Date of Publication: January 2014. 20 | Systematic review/meta-analysis/pooled analysis/review |
| 458 | Mabilleau,G. Use of glucagon-like peptide-1 receptor agonists and bone fractures: A meta-analysis of randomized clinical trials (-1:meta). Journal Of Diabetes 2014;6(3):260-66. | not available from the British library |
| 459 | Macconell,L., Brown,C., Gurney,K. Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: Integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials. Diabetes, Metabolic Syndrome | Systematic review/meta-analysis/pooled analysis/review |
| 460 | MacConell,L., Pencek,R., Li,Y. Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years. Diabetes, Metabolic Syndrome and Obesity Targets and Therapy 2013;6():31-41. | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 461 | Machado,H.A., Vieira,M., Cunha,M.R., Correia,M.R., Fukui,R.T., Santos,R.F., et al. Metformin, but not glimepiride, improves carotid artery diameter and blood flow in patients with type 2 diabetes mellitus. Clinics (Sao Paulo, Brazil) 2012;67(7):711-1 | cross over trial (no washout details or inappropriate analyses and no outcomes reported for first treatment period) |
| 462 | Mafauzy,M. Repaglinide versus glibenclamide treatment of Type 2 diabetes during Ramadan fasting. Diabetes Research & Clinical Practice 2002;58(1):45-53. | dosing regimen includes higher than recommended doses and no details of mean doses or proportion of people taking different doses |
| 463 | Maiti,R., Jaida,J., Leander,P.J., Irfanuddin,M. Cardioprotective role of insulin: Advantage analogues. Journal of Research in Medical Sciences 2012;17(7):642-48. | unclear if previous blood glucose lowering therapies were washed out/discontinued |
| 464 | Makdissi,A., Ghanim,H., Vora,M., Green,K., Abuaysheh,S., Chaudhuri,A. Sitagliptin exerts an antinflammatory action. Journal of Clinical Endocrinology & Metabolism 2012;97(9):3333-41. | unclear if previous blood glucose lowering therapies were washed out/discontinued |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 465 | Malha,L.P. & Taan,G. Glycemic effects of vildagliptin in patients with type 2 diabetes before, during and after the period of fasting in Ramadan. Therapeutic Advances in Endocrinology and Metabolism 2014;5(1):3-9. | <12 week treatment duration |
| 466 | Mannucci,E. & Monami,M. The impossible return to the Garden of Eden: the ORIGIN trial and the original sin of early insulin treatment of type 2 diabetes. Nutrition Metabolism and Cardiovascular Diseases 2013;23(8):e35-36. | commentary/letter/editorial |
| 467 | Mannucci,E., Monami,M., Lamanna,C., Gensini,G.F. Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials. Diabetes, Obesity and Metabolism.10 (12) (pp 1221-1238), 2008.Date of Publication: 2008. 2008;(12):1221- | Systematic review/meta-analysis/pooled analysis/review |
| 468 | Mari,A., Gastaldelli,A., Foley,J.E., Pratley,R.E. Beta-cell function in mild type 2 diabetic patients: effects of 6-month glucose lowering with nateglinide. Diabetes Care 2005;28(5):1132-38. | comparison with unlicensed drug or drug indication |
| 469 | Mari,A., Scherbaum,W.A., Nilsson,P.M., Lalanne,G., Schweizer,A., Dunning,B.E., Jauffret,S. Characterization of the influence of vildagliptin on model-assessed -cell function in patients with type 2 diabetes and mild hyperglycemia. Journal of Clinica | duplicate or same study results |
| 470 | Marre,M., Howlett,H., Lehert,P. Improved glycaemic control with metformin-glibenclamide combined tablet therapy (Glucovance) in Type 2 diabetic patients inadequately controlled on metformin. Diabetic Medicine.19 (8) (pp 673-680), 2002.Date of Publicatio | inadequate wash out period (<4 weeks) |
| 471 | Marre,M., Shaw,J., Brandle,M., Bebakar,W.M., Kamaruddin,N.A., Strand,J., et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding | comparison with unlicensed drug or drug indication |
| 472 | Marrero,D., Pan,Q., Barrett-Connor,E., de,Groot M., Zhang,P., Percy,C., et al. Impact of diagnosis of diabetes on health-related quality of life among high risk individuals: the Diabetes Prevention Program outcomes study. Quality of Life Researc | Not specifically type 2 diabetes |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 473 | Marso,S.P., Poulter,N.R., Nissen,S.E., Nauck,M.A., Zinman,B., Daniels,G.H., et al. Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. American Heart Journal 2013;166(5):823-30. | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 474 | Masuda,H., Sakamoto,M., Irie,J., Kitaoka,A., Shiono,K., Inoue,G., Atsuda,K. Comparison of twice-daily injections of biphasic insulin lispro and basal-bolus therapy: glycaemic control and quality-of-life of insulin-naive type 2 diabetic patients. Dia | Drug comparison not of interest-insulin vs. insulin |
| 475 | Matikainen,N. The effect of vildagliptin therapy on atherogenic postprandial remnant particles and LDL particle size in subjects with type 2 diabetes. Diabetic Medicine 2013;30(6):756-57. | abstract only/not full paper |
| 476 | Mattoo,V., Eckland,D., Widel,M., Duran,S., Fajardo,C., Strand,J., et al. Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: Results | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 477 | McCormick,L.M., Kydd,A.C., Read,P.A., Ring,L.S., Bond,S.J. Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 di | outcomes not of interest |
| 478 | McFarland,M.S. & Brock,M. Place in therapy for liraglutide and saxagliptin for type 2 diabetes. [Review]. Southern Medical Journal 2011;104(6):426-39. | Systematic review/meta-analysis/pooled analysis/review |
| 479 | McGill,J.B. Insights from the Liraglutide Clinical Development Program--the Liraglutide Effect and Action in Diabetes (LEAD) studies. Postgraduate Medicine 2009;121(3):16-25. | Systematic review/meta-analysis/pooled analysis/review |
| 480 | McGill,J.B., Vlajnic,A., Knutsen,P.G., Recklein,C. Effect of gender on treatment outcomes in type 2 diabetes mellitus. Diabetes Research and Clinical Practice.102 (3) (pp 167-174), 2013.Date of Publication: December 2013. 2013;(3):167-74. | Systematic review/meta-analysis/pooled analysis/review |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 481 | McGill,J.B., Sloan,L., Newman,J., Patel,S., Sauce,C. Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study. Diabetes Care 2013;36(2):237- | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 482 | McIntosh,B., Cameron,C., Singh,S.R., Yu,C. Choice of therapy in patients with type 2 diabetes inadequately controlled with metformin and a sulphonylurea: a systematic review and mixed-treatment comparison meta-analysis. Open Medicine : A Peer-reviewed, | Systematic review/meta-analysis/pooled analysis/review |
| 483 | McIntosh,B., Cameron,C., Singh,S.R., Yu,C., Ahuja,T., Welton,N.J. Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis. [Review]. Ope | Systematic review/meta-analysis/pooled analysis/review |
| 484 | Meneghini,L., Atkin,S.L., Gough,S.C., Raz,I., Blonde,L., Shestakova,M., et al. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 485 | Meneghini,L., Mersebach,H., Kumar,S., Svendsen,A.L. Comparison of 2 intensification regimens with rapid-acting insulin aspart in type 2 diabetes mellitus inadequately controlled by once-daily insulin detemir and oral antidiabetes drugs: The step-wise r | focus on timing of administration |
| 486 | Meneghini,L.F. & Traylor,L. Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus. Endocrine Practice 2010;16(4):588-99. | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 487 | Meneilly,G.S., Ryan,E.A., Radziuk,J., Lau,D.C., Yale,J.F., Morais,J., et al. Effect of acarbose on insulin sensitivity in elderly patients with diabetes. Diabetes Care 2000;23(8):1162-67. | duplicate or same study results |
| 488 | Miller,M.E., Williamson,J.D., Gerstein,H.C., Byington,R.P., Cushman,W.C., Ginsberg,H.N., Ambrosius,W.T. Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adul | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 489 | Mimori N,Terao S,Holmes D. Vildagliptin improves glucose control as evidenced by HbA1c after 12 weeks in Japanese patients with type 2 diabetes. | abstract only/not full paper |
| 490 | Mintz,M.L. Saxagliptin versus glipizide as add-on therapy to metformin: assessment of hypoglycemia. Current Medical Research and Opinion 2014;30(5):761-70. | duplicate or same study results |
| 491 | Mirmiranpour,H., Mousavizadeh,M., Noshad,S., Ghavami,M., Ebadi,M., Ghasemiesfe,M. Comparative effects of pioglitazone and metformin on oxidative stress markers in newly diagnosed type 2 diabetes patients: A randomized clinical trial. Journal of Diabe | not placebo controlled or unclear placebo |
| 492 | Miser,W.F., Arakaki,R., Jiang,H., Scism-Bacon,J., Anderson,P.W. Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 493 | Miwa,S., Watada,H., Ohmura,C., Tanaka,Y. Efficacy and safety of once daily gliclazide (20 mg/day) compared with nateglinide. Endocrine Journal 2004;51(4):393-98. | comparison with unlicensed drug or drug indication |
| 494 | Miyashita,Y., Nishimura,R., Nemoto,M., Matsudaira,T., Kurata,H., Yokota,T., et al. Prospective randomized study for optimal insulin therapy in type 2 diabetic patients with secondary failure. Cardiovascular Diabetology 2008;7():16. | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 495 | Moffitt,P.S., Colagiuri,St, Miller,J.J. Human (semisynthetic) insulin and porcine insulin in the treatment of non-insulin-dependent diabetes. A double-blind, comparative clinical trial. The Medical journal of Australia 1984;140(4):200-02. | unclear if previous blood glucose lowering therapies were washed out/discontinued |
| 496 | Monami,M. & Marchionni,N. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials. European Journal of Endocrinology 2009;160(6):909-17. | Systematic review/meta-analysis/pooled analysis/review |
| 497 | Monami,M. & Marchionni,N. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. Diabetes Research & Clinical Practice 2008;81(2):184-89. | Systematic review/meta-analysis/pooled analysis/review |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 498 | Monami,M. Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials. Diabetes, Obesity and Metabolism 2014;16(1):48-56. | Systematic review/meta-analysis/pooled analysis/review |
| 499 | Monami,M., Adalsteinsson,J.E., Desideri,C.M., Ragghianti,B. Fasting and post-prandial glucose and diabetic complication. A meta-analysis. Nutrition, Metabolism and Cardiovascular Diseases.23 (pp 591-598), 2013.Date of Publication: July 2013. 2013;(7 | Systematic review/meta-analysis/pooled analysis/review |
| 500 | Monami,M., Dicembrini,I., Nardini,C. Glucagon-like peptide-1 receptor agonists and pancreatitis: A meta-analysis of randomized clinical trials. Diabetes Research and Clinical Practice.103 (pp 269-275), 2014.Date of Publication: February 2014. 2014;(2) | Systematic review/meta-analysis/pooled analysis/review |
| 501 | Monami,M., Cremasco,F., Lamanna,C., Colombi,C., Desideri,C.M., Iacomelli,I., Marchionni,N. Glucagon-like peptide-1 receptor agonists and cardiovascular events: A meta-analysis of randomized clinical trials. Experimental Diabetes Research.2011 , 2011 | Systematic review/meta-analysis/pooled analysis/review |
| 502 | Monami,M., Cremasco,F., Lamanna,C., Marchionni,N. Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials. Diabetes/Metabolism Research Reviews 2011;27(4):362-72. | Systematic review/meta-analysis/pooled analysis/review |
| 503 | Monami,M., Dicembrini,I., Antenore,A. Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials. Diabetes Care 2011;34(11):2474-76. | Systematic review/meta-analysis/pooled analysis/review |
| 504 | Monami,M., Dicembrini,I., Marchionni,N., Rotella,C.M. Effects of glucagon-like Peptide-1 receptor agonists on body weight: a meta-analysis. Experimental Diabetes Research 2012;2012():672658. | Systematic review/meta-analysis/pooled analysis/review |
| 505 | Monami,M., Dicembrini,I., Martelli,D. Safety of dipeptidyl peptidase-4 inhibitors: A meta-analysis of randomized clinical trials. Current Medical Research and Opinion.27 (SUPPL.3) (pp 57-64), 2011.Date of Publication: November 2011. 2011;(SUPPL. 3):57-6 | Systematic review/meta-analysis/pooled analysis/review |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 506 | Monami,M., Iacomelli,I., Marchionni,N. Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutrition Metabolism & Cardiovascular Diseases 2010;20(4):224-35. | Systematic review/meta-analysis/pooled analysis/review |
| 507 | Monami,M., Lamanna,C., Desideri,C.M. DPP-4 inhibitors and lipids: Systematic review and meta-analysis. Advances in Therapy.29 (1) (pp 14-25), 2012.Date of Publication: January 2012. 2012;(1):14-25. | Systematic review/meta-analysis/pooled analysis/review |
| 508 | Monami,M., Lamanna,C., Marchionni,N. Comparison of different drugs as add-on treatments to metformin in type 2 diabetes: a meta-analysis. Diabetes Research & Clinical Practice 2008;79(2):196-203. | Systematic review/meta-analysis/pooled analysis/review |
| 509 | Monami,M., Lamanna,C., Marchionni,N. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 2 diabetes: a meta-analysis. Experimental & Clinical Endocrinology & Diabetes 2009;117(5):220-22. | Systematic review/meta-analysis/pooled analysis/review |
| 510 | Monnier,L., Colette,C., Comenducci,A. Add-on therapies to metformin in type 2 diabetes: what modulates the respective decrements in postprandial and basal glucose? Diabetes Technology & Therapeutics 2012;14(10):943-50. | Systematic review/meta-analysis/pooled analysis/review |
| 511 | Moon,J.S., Ha,K.S., Yoon,J.S., Lee,H.W., Lee,H.C. The effect of glargine versus glimepiride on pancreatic beta-cell function in patients with type 2 diabetes uncontrolled on metformin monotherapy: open-label, randomized, controlled study. Acta Dia | Drug comparison not of interest-insulin + 1 OAD vs. 2 OADs |
| 512 | Moretto,T.J., Milton,D.R., Ridge,T.D., Macconell,L.A., Okerson,T., Wolka,A.M. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, p | comparison with unlicensed drug or drug indication |
| 513 | Morikawa,A., Ishizeki,K., Iwashima,Y., Yokoyama,H., Muto,E., Oshima,E., et al. Pioglitazone reduces urinary albumin excretion in renin-angiotensin system inhibitor-treated type 2 diabetic patients with hypertension and microalbuminuria: The APRIME st | unclear if previous blood glucose lowering therapies were washed out/discontinued |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 514 | Mosenzon,O. Intensification of insulin therapy for type 2 diabetic patients in primary care: basal-bolus regimen versus premix insulin analogs: when and for whom?. [Review]. Diabetes Care 2013;36():Suppl-8. | Systematic review/meta-analysis/pooled analysis/review |
| 515 | Mosenzon,O., Raz,I., Scirica,B.M., Hirshberg,B., Stahre,C.I., Steg,P.G., et al. Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trial. D | unclear if previous blood glucose lowering therapies were washed out/discontinued |
| 516 | Moses,R. Repaglinide in combination therapy with metformin in Type 2 diabetes. Experimental & Clinical Endocrinology & Diabetes 1999;107():Suppl-9. | unclear washout of previous blood glucose lowering therapy but termed monotherapy and <12 month duration |
| 517 | Moses,R., Slobodniuk,R., Boyages,S., Colagiuri,S., Kidson,W., Carter,J., et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 1999;22(1):119-24. | unclear washout of previous blood glucose lowering therapy but termed monotherapy and <12 month duration |
| 518 | Moses,R.G., Kalra,S., Brook,D., Sockler,J., Monyak,J., Visvanathan,J. A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a | Drug comparison not of interest - 3 OADs vs. 2 OADs |
| 519 | Mu,P.-W., Chen,Y.-M., Lu,H.-Y., Wen,X.-Q., Zhang,Y.-H., Xie,R.-Y., et al. Effects of a combination of oral anti-diabetes drugs with basal insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes. Di | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 520 | Mudaliar,S., Chang,A.R., Aroda,V.R., Chao,E., Burke,P., Baxi,S., et al. Effects of intensive insulin therapy alone and with added pioglitazone on renal salt/water balance and fluid compartment shifts in type 2 diabetes. Diabetes, Obesity and Metaboli | Drug comparison not of interest-insulin + 1 OAD vs. insulin |
| 521 | Mukai,J., Tada,H., Watanabe,Y., Miura,M., Katsuyama,S., Shoji,T., et al. Lipids behavior and adverse effects for oral antidiabetic agents in patients with Type 2 diabetes treated with sulfonylureas alone based on systematic review. Yakugaku Zasshi - | Systematic review/meta-analysis/pooled analysis/review |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 522 | Mukherjee,J.J. Assessment of glycaemic control in patients with diabetes mellitus on insulin therapy. Journal of the Indian Medical Association.111 (pp 761-765), 2013.Date of Publication: November 2013. 2013;(11):761-65. | Systematic review/meta-analysis/pooled analysis/review |
| 523 | Nagajothi,N., Adigopula,S., Balamuthusamy,S., Velazquez-Cecena,J.-L., Raghunathan,K., Khraisat,A., et al. Pioglitazone and the risk of myocardial infarction and other major adverse cardiac events: A meta-analysis of randomized, controlled trials. Ame | Systematic review/meta-analysis/pooled analysis/review |
| 524 | Nakano,K., Hasegawa,G., Fukui,M., Yamasaki,M., Ishihara,K., Takashima,T., et al. Effect of pioglitazone on various parameters of insulin resistance including lipoprotein subclass according to particle size by a gel-permeation high-performance liquid | unclear if previous blood glucose lowering therapies were washed out/discontinued |
| 525 | NATHAN,DAVID M. & ROUSSELL,A.N.N.E. Glyburide or Insulin for Metabolic Control in Non-Insulin-Dependent Diabetes MellitusA Randomized, Double-Blind Study. Annals of Internal Medicine 1988;108(3):334-40. | Drug comparison not of interest-insulin vs. 1 OAD |
| 526 | Nauck,M. Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine 2009;121(3):5-15. | comparison with unlicensed drug or drug indication |
| 527 | Nauck,M., Frid,A., Hermansen,K., Thomsen,A.B., During,M., Shah,N., Tankova,T. Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 stud | Systematic review/meta-analysis/pooled analysis/review |
| 528 | Nauck,M.A. Pancreatitis and incretin-based drugs: Clarity or confusion? Lancet Diabetes and Endocrinology.2 (pp 92-93), 2014.Date of Publication: February 2014. 2014;(2):92-93. | commentary/letter/editorial |
| 529 | Nauck,M.A., Meininger,G., Sheng,D., Terranella,L., Stein,P.P., Tesone,P., et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately contro | duplicate or same study results |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 530 | Nelson,S.E. Detemir as a once-daily basal insulin in type 2 diabetes. Clinical Pharmacology: Advances and Applications.3 (1) (pp 27-37), 2011.Date of Publication: 2011. 2011;(1):27-37. | Systematic review/meta-analysis/pooled analysis/review |
| 531 | Neugebauer,R. & Fireman,B. Impact of specific glucose-control strategies on microvascular and macrovascular outcomes in 58,000 adults with type 2 diabetes. Diabetes Care.36 (pp 3510-3516), 2013.Date of Publication: November 2013. 2013;(11):3510-16. | not an RCT (no randomisation) |
| 532 | Nikfar,S. & Abdollahi,M. The efficacy and tolerability of exenatide in comparison to placebo; a systematic review and meta-analysis of randomized clinical trials. [Review]. Journal of Pharmacy & Pharmaceutical Sciences 2012;15(1):1-30. | Systematic review/meta-analysis/pooled analysis/review |
| 533 | Niskanen,L., Jensen,L.E., Rastam,J., Nygaard-Pedersen,L., Erichsen,K. Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diab | Drug comparison not of interest-insulin vs. insulin |
| 534 | Niskanen,L., Leiter,L.A., Franek,E., Weng,J., Damci,T., Munoz-Torres,M., et al. Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial. European Journal of Endocr | critical inconsistencies in reported data |
| 535 | Nissen,S.E., Nicholls,S.J., Wolski,K., Nesto,R., Kupfer,S., Perez,A., et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008;2 | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 536 | Niswender,K., Pi-Sunyer,X., Buse,J., Jensen,K.H., Toft,A.D. Weight change with liraglutide and comparator therapies: An analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity and Metabolism.15 (1) ( | Systematic review/meta-analysis/pooled analysis/review |
| 537 | Nonaka K,Kakikawa T,Sato A,et al. Twelve-week efficacy and tolerability of sitagliptin, a dipeptidyl peptidase-IV inhibitor, in Japanese patients with T2DM. | abstract only/not full paper |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 538 | Norris,S.L. & Carson,S. Comparative effectiveness of pioglitazone and rosiglitazone in type 2 diabetes, prediabetes, and the metabolic syndrome: A meta-analysis. Current Diabetes Reviews.3 (2) (pp 127-140), 2007.Date of Publication: May 2007. 2007;(2):12 | Systematic review/meta-analysis/pooled analysis/review |
| 539 | Norris,S.L., Lee,N., Thakurta,S. Exenatide efficacy and safety: a systematic review. Diabetic Medicine 2009;26(9):837-46. | Systematic review/meta-analysis/pooled analysis/review |
| 540 | Noury J,Nandeuil A. Comparative three-month study of the efficacies of metformin and gliclazide in the treatment of NIDD. | unclear if previous blood glucose lowering therapies were washed out/discontinued |
| 541 | Nowicki,M., Rychlik,I., Haller,H., Warren,M.L., Suchower,L., Gause-Nilsson,I. Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment. Diabetes, Obesity & Metabolism 2011;13(6):523-3 | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 542 | Nunez,D.J., Bush,M.A., Collins,D.A., McMullen,S.L., Gillmor,D., Apseloff,G., et al. Gut Hormone Pharmacology of a Novel GPR119 Agonist (GSK1292263), Metformin, and Sitagliptin in Type 2 Diabetes Mellitus: Results from Two Randomized Studies. PLo | Systematic review/meta-analysis/pooled analysis/review |
| 543 | Nyback-Nakell,A. & Adamson,U. Adding glimepiride to insulin+metformin in type 2 diabetes of more than 10 years' duration-A randomised, double-blind, placebo-controlled, cross-over study. Diabetes Research and Clinical Practice 2014;103(2):286-91. | cross over trial (no washout details or inappropriate analyses and no outcomes reported for first treatment period) |
| 544 | Ohta,A., Suwa,T., Sada,Y., Kato,H., Koganei,R., Asai,S. Comparison of daily glucose excursion by continuous glucose monitoring between type 2 diabetic patients receiving biphasic insulin aspart 30 or biphasic human insulin 30. Journal of Diabete | Drug comparison not of interest-insulin vs. insulin |
| 545 | O'Keefe,J.H. & Abuannadi,M. Strategies for optimizing glycemic control and cardiovascular prognosis in patients with type 2 diabetes mellitus. Mayo Clinic Proceedings.86 (pp 128-138), 2011.Date of Publication: February 2011. 2011;(2):128-38. | Systematic review/meta-analysis/pooled analysis/review |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 546 | Okerson,T., Yan,P., Stonehouse,A. Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes. American Journal of Hypertension.23 (3) (pp 334-339), 2010.Date of Publication: March 2010. 2010;(3):334-39. | Systematic review/meta-analysis/pooled analysis/review |
| 547 | Onishi,Y., Ono,Y., Rabol,R. Superior glycaemic control with once-daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: a randomized, controlled phase 3 trial. Diabe | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 548 | ORIGIN,Trial,I, Mellbin,L.G., Ryden,L., Riddle,M.C., Probstfield,J., Rosenstock,J., Diaz,R. Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. European Heart Journal 2013;34(40):3137-44. | unclear treatment groups or intervention |
| 549 | Ott,C., Raff,U., Schmidt,S., Kistner,I., Friedrich,S., Bramlage,P. Effects of saxagliptin on early microvascular changes in patients with type 2 diabetes. Cardiovascular Diabetology.13 , 2014.Article Number: 19.Date of Publication: 14 Jan 2014. | <12 week treatment duration |
| 550 | Owens,D.R., Luzio,S.D., Sert-Langeron,C. Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month 'proof-of-concept' study. Diabetes, Obesity & Metabo | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 551 | Oz,Gul O., Tuncel,E., Yilmaz,Y., Ulukaya,E., Gul,C.B., Kiyici,S., et al. Comparative effects of pioglitazone and rosiglitazone on plasma levels of soluble receptor for advanced glycation end products in type 2 diabetes mellitus patients. Metabolism: | not placebo controlled or unclear placebo |
| 552 | Oz,O., Tuncel,E., Eryilmaz,S., Fazlioglu,M., Gul,C.B., Ersoy,C., et al. Arterial elasticity and plasma levels of adiponectin and leptin in type 2 diabetic patients treated with thiazolidinediones. Endocrine.33 (1) (pp 101-105), 2008.Date of Publicati | newly diagnosed participants but not explicit if they are drug naive |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 553 | Ozbek,M., Erdogan,M., Karadeniz,M., Cetinkalp,S., Ozgen,A.G., Saygili,F., Yilmaz,C. Preprandial repaglinide decreases exogenous insulin requirements and HbA1c levels in type 2 diabetic patients taking intensive insulin treatment. Acta Diabetologica | not an RCT (no randomisation) |
| 554 | Pala,L., Mannucci,E., Dicembrini,I. A comparison of mealtime insulin aspart and human insulin in combination with metformin in type 2 diabetes patients. Diabetes Research & Clinical Practice 2007;78(1):132-35. | abstract only/not full paper |
| 555 | Pan,C., Xing,X., Han,P., Zheng,S., Ma,J., Liu,J., et al. Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus. Diabetes, Obesity & Metabolism 2012;14(8):737-44. | dose comparison of same drug |
| 556 | Pan,Q., Delahanty,L.M., Jablonski,K.A., Knowler,W.C., Kahn,S.E., Florez,J.C. Variation at the melanocortin 4 receptor gene and response to weight-loss interventions in the diabetes prevention program. Obesity 2013;21(9):E520-26. | outcomes not of interest |
| 557 | Papa,G., Fedele,V., Chiavetta,A., Lorenti,I., Leotta,C., Luca,S., et al. Therapeutic options for elderly diabetic subjects: open label, randomized clinical trial of insulin glargine added to oral antidiabetic drugs versus increased dosage of oral ant | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 558 | Papanas,N., Tziakas,D., Chalikias,G., Floros,D., Trypsianis,G., Papadopoulou,E., et al. Gliclazide treatment lowers serum ICAM-1 levels in poorly controlled type 2 diabetic patients. Diabetes and Metabolism.32 (4) (pp 344-349), 2006.Date of Publicati | inadequate wash out period (<4 weeks) |
| 559 | Pencek,R., Brunell,S.C., Li,Y., Hoogwerf,B.J. Use of concomitant glucose-lowering therapies and associated treatment results observed in clinical trials of twice-daily exenatide. Endocrine Practice.18 (2) (pp 227-237), 2012.Date of Publication: 01 Mar | Systematic review/meta-analysis/pooled analysis/review |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 560 | Perez,A., Jacks,R., Arora,V. Effects of pioglitazone and metformin fixed-dose combination therapy on cardiovascular risk markers of inflammation and lipid profile compared with pioglitazone and metformin monotherapy in patients with type 2 diabetes. Jou | inadequate wash out period (<4 weeks) |
| 561 | Perez,A., Zhao,Z., Jacks,R. Efficacy and safety of pioglitazone/metformin fixed-dose combination therapy compared with pioglitazone and metformin monotherapy in treating patients with T2DM. Current Medical Research & Opinion 2009;25(12):2915-23. | inadequate wash out period (<4 weeks) |
| 562 | Perez-Monteverde,A., Seck,T., Xu,L., Lee,M.A., Sisk,C.M., Williams-Herman,D.E., et al. Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naive patients with type 2 diabetes. Intern | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 563 | Perriello,G., Pampanelli,S., Brunetti,P., Di,Pietro C., Mariz,S. Long-term effects of pioglitazone versus gliclazide on hepatic and humoral coagulation factors in patients with type 2 diabetes. Diabetes & Vascular Disease Research 2007;4(3):226-30. | unclear if previous blood glucose lowering therapies were washed out/discontinued |
| 564 | Perriello,G., Pampanelli,S., Di,Pietro C. Comparison of glycaemic control over 1 year with pioglitazone or gliclazide in patients with Type 2 diabetes. Diabetic Medicine.23 (3) (pp 246-252), 2006.Date of Publication: March 2006. 2006;(3):246-52. | unclear if previous blood glucose lowering therapies were washed out/discontinued |
| 565 | Petrica,L., Petrica,M., Vlad,A., Dragos,Jianu C., Gluhovschi,G., Ianculescu,C., et al. Nephro- and neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial. | unclear if previous blood glucose lowering therapies were washed out/discontinued |
| 566 | Pfutzner,A., Paz-Pacheco,E., Allen,E., Frederich,R., Chen,R. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes, Obesity & Metabolism 2011;13(6):567-76. | across treatment strategy |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 567 | Philis-Tsimikas,A., Brod,M., Niemeyer,M. Insulin degludec once-daily in type 2 diabetes: simple or step-wise titration (BEGIN: once simple use). Advances in Therapy 2013;30(6):607-22. | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 568 | Philis-Tsimikas,A., Del,Prato S., Satman,I., Bhargava,A., Dharmalingam,M., Skjoth,T.V. Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents. Diabetes, Obesity and Metabolism 2013 | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 569 | Philis-Tsimikas,A., Charpentier,G., Clauson,P., Ravn,G.M., Roberts,V.L. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clinical Therapeutics 2006;28(10):156 | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 570 | Phillips,Patrick, Karrasch,Jeff, Scott,Russell, Wilson,Dennis. Acarbose Improves Glycemic Control in Overweight Type 2 Diabetic Patients Insufficiently Treated With Metformin. Diabetes Care 2003;26(2):269-73. | across treatment strategy |
| 571 | Phung,O.J. & Sobieraj,D.M. Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes, Obesity and Metabolism 2014;16(5):410-17. | Systematic review/meta-analysis/pooled analysis/review |
| 572 | Phung,O.J., Scholle,J.M., Talwar,M. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA 2010;303(14):1410-18. | Systematic review/meta-analysis/pooled analysis/review |
| 573 | Pinelli,N.R. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: A systematic review and meta-analysis<br>OT - Efficacite et securite des agonistes de l | Systematic review/meta-analysis/pooled analysis/review |
| 574 | Pinelli,N.R., Cha,R., Brown,M.B. Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: A meta-analysis. Annals of Pharmacotherapy.42 (11) (pp 1541-1551), 2008.Date of Publication: November 2008. 2008;(11):1541-51. | Systematic review/meta-analysis/pooled analysis/review |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 575 | Pinget,M., Goldenberg,R., Niemoeller,E., Muehlen-Bartmer,I. Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P). Diabetes, Obesity and Metabolism.15 (11) (pp 1000-1007), | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 576 | Pistrosch,F., Kohler,C., Schaper,F., Landgraf,W. Effects of insulin glargine versus metformin on glycemic variability, microvascular and beta-cell function in early type 2 diabetes. Acta Diabetologica 2013;50(4):587-95. | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 577 | Polonsky,W., Traylor,L., Wei,W., Shi,R., Ameer,B. More satisfied, but why? A pooled patient-level analysis of treatment satisfaction following the initiation of insulin glargine vs. comparators in insulin-naive patients with type 2 diabetes mellit | Systematic review/meta-analysis/pooled analysis/review |
| 578 | Ponssen,H.H., Elte,J.W.F., Lehert,P., Schouten,J.P. Combined metformin and insulin therapy for patients with type 2 diabetes mellitus. Clinical Therapeutics.22 (6) (pp 709-718), 2000.Date of Publication: 2000. 2000;(6):709-18. | Drug comparison not of interest-insulin + 1 OAD vs. insulin |
| 579 | Pontiroli,A.E. & Miele,L. Increase of body weight during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis. [Review]. Diabetes, Obesity & Metabolism 2011;13(11):1008-19. | Systematic review/meta-analysis/pooled analysis/review |
| 580 | Pontiroli,A.E. & Miele,L. Metabolic control and risk of hypoglycaemia during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis. [Review]. Diabetes, Obesity & Metabolism 2012;14(5):433-46. | Systematic review/meta-analysis/pooled analysis/review |
| 581 | Pontiroli,A.E., Dino,G., Capra,F. Combined therapy with glibenclamide and ultralente insulin in lean patients with NIDDM with secondary failure of sulfonylureas. Follow up at two years. Diabete & metabolisme 1989;16(4):323-27. | comparison with unlicensed drug or drug indication |
| 582 | Poolsup,N. & Suksomboon,N. Efficacy of various antidiabetic agents as add-on treatments to metformin in type 2 diabetes mellitus: systematic review and meta-analysis. Isrn Endocrinology Print 2012;2012():798146. | Systematic review/meta-analysis/pooled analysis/review |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 583 | Pop-Busui,R., Lu,J., Brooks,M.M., Albert,S., Althouse,A.D., Escobedo,J., et al. Impact of glycemic control strategies on the progression of diabetic peripheral neuropathy in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI | unclear treatment groups or intervention |
| 584 | Pradhan,A.D., Everett,B.M., Cook,N.R., Rifai,N. Effects of initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes: the LANCET randomized trial. JAMA 2009;302(11):1186-94. | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 585 | Pratley,R.E., Nauck,M.A., Barnett,A.H., Feinglos,M.N., Ovalle,F., Harman-Boehm,I., et al. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, ope | not available from the British library |
| 586 | Pratley,R.E., Kipnes,M.S., Fleck,P.R., Wilson,C., Mekki,Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes, Obesity & Metabolism 2009;11 | comparison with unlicensed drug or drug indication |
| 587 | Pratley,R.E., Nauck,M.A., Bailey,T., Montanya,E., Filetti,S., Garber,A.J., et al. Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 dia | dose comparison of same drug |
| 588 | Pratley,R.E., Rosenstock,J., Pi-Sunyer,F.X., Banerji,M.A., Schweizer,A., Couturier,A. Management of type 2 diabetes in treatment-naive elderly patients: Benefits and risks of vildagliptin monotherapy. Diabetes Care.30 (12) (pp 3017-3022), 2007.Date o | Systematic review/meta-analysis/pooled analysis/review |
| 589 | Pugh,J.A. Sitagliptin improved glycemic control and beta-cell function in type 2 diabetes. ACP Journal Club 2007;146(2):39-Apr. | commentary/letter/editorial |
| 590 | Punthakee,Z., Bosch,J., Dagenais,G., Diaz,R., Holman,R., Probstfield,J., et al. Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial. Diabetologia 2012;55(1):36-45. | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 591 | Qayyum,R., Bolen,S., Maruthur,N., Feldman,L., Wilson,L.M., Marinopoulos,S.S., et al. Systematic review: comparative effectiveness and safety of premixed insulin analogues in type 2 diabetes. Annals of Internal Medicine 2008;149(8):549-59. | Systematic review/meta-analysis/pooled analysis/review |
| 592 | Raccah,D., Haak,T.J., Huet,D., Monnier,L., Robertson,D., Labard,P. Comparison of stepwise addition of prandial insulin to a basal-bolus regimen when basal insulin is insufficient for glycaemic control in type 2 diabetes: results of the OSIRIS study. | unclear if previous blood glucose lowering therapies were washed out/discontinued |
| 593 | Rakel,A., Renier,G., Roussin,A., Buithieu,A. Beneficial effects of gliclazide modified release compared with glibenclamide on endothelial activation and low-grade inflammation in patients with type 2 diabetes. Diabetes, Obesity and Metabolism.9 (1) (pp | outcomes not of interest |
| 594 | Raskin,P. Glycaemic control with liraglutide: the phase 3 trial programme. [Review]. International Journal of Clinical Practice 2010;Supplement.(167):21-27. | Systematic review/meta-analysis/pooled analysis/review |
| 595 | Raskin,P., Heller,S., Honka,M., Chang,P.C., Boss,A.H. Pulmonary function over 2 years in diabetic patients treated with prandial inhaled Technosphere insulin or usual antidiabetes treatment: A randomized trial. Diabetes Technology and Therapeutics | abstract only/not full paper |
| 596 | Raskin,P., Allen,E., Hollander,P., Lewin,A., Gabbay,R.A., Hu,P., Bode,B. Initiating insulin therapy in type 2 diabetes: A comparison of biphasic and basal insulin analogs. Diabetes Care.28 (2) (pp 260-265), 2005.Date of Publication: February 2005. 2 | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 597 | Raskin,P., Gylvin,T., Weng,W. Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes. Diabetes/Metabolism Research Reviews 2009;25(6):542-48. | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 598 | Raskin,P., Klaff,L., McGill,J., South,S.A., Hollander,P., Khutoryansky,N., Hale,P.M. Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin. Diabetes Care 2003;26(7):2063-68. | unclear if previous blood glucose lowering therapies were washed out/discontinued |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 599 | Raskin,P., Lewin,A., Reinhardt,R., Lyness,W. Twice-daily and three-times-daily dosing of a repaglinide/metformin fixed-dose combination tablet provide similar glycaemic control. Diabetes, Obesity & Metabolism 2009;11(10):947-52. | dose comparison of same drug |
| 600 | Raskin,P., Lewin,A., Reinhardt,R., Lyness,W. Twice-daily dosing of a repaglinide/metformin fixed-dose combination tablet provides glycaemic control comparable to rosiglitazone/metformin tablet. Diabetes, Obesity & Metabolism 2009;11(9):865-73. | dose comparison of same drug |
| 601 | Raskin,P., Matfin,G., Schwartz,S.L., Chaykin,L., Chu,P.L., Braceras,R. Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: The ACTION Study (Achieving Control Through Insulin plus Oral | Drug comparison not of interest-insulin + 2 OADs vs. 2 OADs |
| 602 | Raslovÿ,K., Tamer,S.C., Clauson,P. Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index. Clinical Drug Investigation 2007;2 | Systematic review/meta-analysis/pooled analysis/review |
| 603 | Ratner,R., Han,J., Nicewarner,D., Yushmanova,I., Hoogwerf,B.J. Cardiovascular safety of exenatide BID: An integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovascular Diabetology.10 , 2011.Article Number: 22 | Systematic review/meta-analysis/pooled analysis/review |
| 604 | Ratner,R., Wynne,A., Nakhle,S., Brusco,O., Vlajnic,A. Influence of preprandial vs. postprandial insulin glulisine on weight and glycaemic control in patients initiating basal-bolus regimen for type 2 diabetes: a multicenter, randomized, parallel, open | focus on timing of administration |
| 605 | Ravnik-Oblak,Maja. Insulin versus a combination of insulin and sulfonylurea in the treatment of NIDDM patients with secondary oral failure. Diabetes Research and Clinical Practice 1995;30(1):27-35. | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 606 | Rawdaree,P., Deerochanawong,C., Peerapatdit,T., Thongtang,N., Suwanwalaikorn,S., Khemkha,A., et al. Efficacy and safety of generic and original pioglitazone in type 2 diabetes mellitus: a multicenter, a double-blinded, randomized-controlled study. Jo | comparing different types of sulfonylurea alone |
| 607 | Rayman,G. & Profozic,V. Insulin glulisine imparts effective glycaemic control in patients with Type 2 diabetes. Diabetes research and clinical practice 2007;76(2):304-12. | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 608 | Raz,I., Wilson,P.W., Strojek,K., Kowalska,I., Bozikov,V., Gitt,A.K., et al. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care 2009;32(3):381-86. | Drug comparison not of interest-insulin vs. insulin |
| 609 | Rees,T., Curtis,B., Gaskins,K., Sierra-Johnson,J., Jiang,H. Efficacy and safety of insulin lispro in obese patients with type 2 diabetes: A retrospective metaanalysis of 7 randomized controlled trials. Endocrine Practice.20 (pp 389-398), 2014.Date | Systematic review/meta-analysis/pooled analysis/review |
| 610 | Retnakaran,R., Qi,Y., Opsteen,C., Vivero,E. Initial short-term intensive insulin therapy as a strategy for evaluating the preservation of beta-cell function with oral antidiabetic medications: a pilot study with sitagliptin. Diabetes, Obesity & Metabol | Drug comparison not of interest- insulin + 1 OAD vs. insulin + 2 OADs |
| 611 | Richard,K.R. & Shelburne,J.S. Tolerability of dipeptidyl peptidase-4 inhibitors: A review. Clinical Therapeutics.33 (11) (pp 1609-1629), 2011.Date of Publication: November 2011. 2011;(11):1609-29. | Systematic review/meta-analysis/pooled analysis/review |
| 612 | Riche,D.M. & East,H.E. Impact of sitagliptin on markers of beta-cell function: A meta-analysis. American Journal of the Medical Sciences.337 (5) (pp 321-328), 2009.Date of Publication: May 2009. 2009;(5):321-28. | Systematic review/meta-analysis/pooled analysis/review |
| 613 | Richter,B., Bandeira-Echtler,E., Bergerhoff,K. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2008;(2):n. pag.. | Systematic review/meta-analysis/pooled analysis/review |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 614 | Richter,B., Bandeira-Echtler,E., Bergerhoff,K. Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes. Vascular Health and Risk Management.4 (4) (pp 753-768), 2008.Date of Publication: 2008. 2008;(4):753-68. | Systematic review/meta-analysis/pooled analysis/review |
| 615 | Richter,B., Bandeira-Echtler,E., Bergerhoff,K., Clar,C. Pioglitazone for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2006;(4):n. pag.. | Systematic review/meta-analysis/pooled analysis/review |
| 616 | Riddle,M.C., Henry,R.R., Poon,T.H., Zhang,B., Mac,S.M., Holcombe,J.H., Kim,D.D. Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or | Systematic review/meta-analysis/pooled analysis/review |
| 617 | Rissanen,A., Howard,C.P., Botha,J. Effect of anti-IL-1beta antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial. Diabetes, Obesity and Metabolism 2012;14( | <12 week treatment duration |
| 618 | Rizos,E.C., Ntzani,E.E., Papanas,N., Tsimihodimos,V., Mitrogianni,Z. Combination Therapies of DPP4 Inhibitors and GLP1 Analogues with Insulin in Type 2 Diabetic Patients: A Systematic Review. Current Vascular Pharmacology 2014;11(6):992-1000. | Systematic review/meta-analysis/pooled analysis/review |
| 619 | Rizzo,M., Chandalia,M., Patti,A.M., Di,Bartolo,V, Rizvi,A.A. Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study. Cardiovascular Diabetology 2014;13(1):49. | not an RCT (no randomisation) |
| 620 | Rizzo,M.R. & Barbieri,M. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care 2012;35(10):2076-82. | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 621 | Roach,P. & Yue,L. Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Humalog Mix25 Study Group. Diabetes Care 1999;22(8):1258-61. | comparison with unlicensed drug or drug indication |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 622 | Roach,P. Comparison of insulin lispro mixture 25/75 with insulin glargine during a 24-h standardized test-meal period in patients with Type 2 diabetes. Diabetic Medicine 2006;23(7):743-49. | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 623 | Robles,G.I. A review of exenatide as adjunctive therapy in patients with type 2 diabetes. Drug Design, Development and Therapy 2009;(3):219-40. | Systematic review/meta-analysis/pooled analysis/review |
| 624 | Rodbard,H.W., Cariou,B., Zinman,B., Handelsman,Y., Philis-Tsimikas,A., Skjoth,T.V., Rana,A. Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial. Diabet | critical inconsistencies in reported data |
| 625 | Rodbard,H.W., Gough,S., Lane,W., Korsholm,L. Reduced risk of hypoglycemia with insulin degludec versus insulin glargine in patients with type 2 diabetes requiring high doses of Basal insulin: a meta-analysis of 5 randomized begin trials. Endocrine P | not available from the British library |
| 626 | Rodbard,H.W., Visco,V.E., Andersen,H. Treatment intensification with stepwise addition of prandial insulin aspart boluses compared with full basal-bolus therapy (FullSTEP Study): a randomised, treat-to-target clinical trial. Lancet Diabetes and Endocr | not available from the British library |
| 627 | Roden,M., Mariz,S., Brazzale,A.R. Free fatty acid kinetics during long-term treatment with pioglitazone added to sulfonylurea or metformin in Type 2 diabetes. Journal of Internal Medicine 2009;265(4):476-87. | duplicate or same study results |
| 628 | Rogala,H. & Czyzyk,A. [Immunogenicity of semisynthetic human insulin Novo--five year prospective studies]. Polskie Archiwum Medycyny Wewnetrznej 1993;89(6):492-98. | Non-English paper |
| 629 | Rosenstock,J. & Marx,N. Cardiovascular effects of diabetes drugs: Making the dark ages brighter with CAROLINA. Annals of Internal Medicine.158 (6) (pp 499), 2013.Date of Publication: 2013. 2013;(6):499. | abstract only/not full paper |
| 630 | Rosenstock,J. & Niggli,M. Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naive patients with type 2 diabetes mellitus. Diabetes, Obesity & Metabolism 2009;11(6):571-78. | comparison with unlicensed drug or drug indication |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 631 | Rosenstock,J. & Sankoh,S. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes, Obesity & Metabolism 2008;10(5):376-86. | inadequate wash out period (<4 weeks) |
| 632 | Rosenstock,J., Hanefeld,M., Shamanna,P., Min,K.W., Boka,G., Miossec,P., Zhou,T. Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in Type 2 diabetes inadequatel | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 633 | Rosenstock,J., Rodbard,H.W., Bain,S.C., D'Alessio,D., Seufert,J., Thomsen,A.B., Svendsen,C.B. One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir ac | Drug comparison not of interest-insulin + 2 OADs vs. 2 OADs |
| 634 | Rosenstock,J., Aggarwal,N., Polidori,D., Zhao,Y., Arbit,D., Usiskin,K., Capuano,G. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 2012;35(6):1 | duplicate or same study results |
| 635 | Rosenstock,J., Aguilar-Salinas,C., Klein,E., Nepal,S., List,J. Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes. Current Medical Research and Opinion.25 (10) (pp 2401-2411), 2009.Date of Publication: October 2009. 200 | inadequate wash out period (<4 weeks) |
| 636 | Rosenstock,J., Ahmann,A.J., Colon,G., Scism-Bacon,J., Jiang,H. Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/ | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 637 | Rosenstock,J., Davies,M., Home,P.D., Larsen,J., Koenen,C. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 638 | Rosenstock,J., Fonseca,V., McGill,J.B., Riddle,M., Halle,J.P., Hramiak,I., Johnston,P. Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, rand | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 639 | Rosenstock,J., Gross,J.L., Aguilar-Salinas,C., Hissa,M., Berglind,N. Long-term 4-year safety of saxagliptin in drug-naive and metformin-treated patients with Type 2 diabetes. Diabetic Medicine 2013;30(12):1472-76. | dose comparison of same drug |
| 640 | Rosenstock,J., Hassman,D.R., Madder,R.D., Brazinsky,S.A., Farrell,J., Khutoryansky,N., Hale,P.M. Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. Diabetes Care 2004;27(6):1265-70. | comparison with unlicensed drug or drug indication |
| 641 | Rosenstock,J., Lorber,D.L., Gnudi,L., Howard,C.P., Bilheimer,D.W., Chang,P.-C., et al. Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial. The Lancet.375 (9733) | comparison with unlicensed drug or drug indication |
| 642 | Rosenstock,J., Seman,L.J., Jelaska,A., Hantel,S., Pinnetti,S. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes, Obesity and Metabolis | Drug comparison not of interest - 2 OADs vs 1 OAD |
| 643 | Rosenstock,J., Shen,S.G., Gatlin,M.R. Combination therapy with nateglinide and a thiazolidinedione improves glycemic control in type 2 diabetes. Diabetes Care 2002;25(9):1529-33. | comparison with unlicensed drug or drug indication |
| 644 | Rosenstock,J., Shenouda,S.K., Bergenstal,R.M., Buse,J.B., Glass,L.C., Heilmann,C.R., et al. Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 di | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 645 | Rosenstock,Julio, Schwartz,Sherwyn L., Clark,Charles M., Park,Glen D., Donley,David W. Basal insulin therapy in type 2 diabetes 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001;24(4):631-36. | duplicate or same study results |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 646 | Rosenthal,J. E002: Hypertension in type 2-diabetic patientsâ€"effects of endogenous insulin and antidiabetic therapies. American Journal of Hypertension 2000;13(S2):81A. | abstract only/not full paper |
| 647 | Ross,S.A., Rafeiro,E., Meinicke,T., Toorawa,R. Efficacy and safety of linagliptin 2.5mg twice daily versus 5mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial. Curre | rescue medication was provided to participants and unclear if analysis has been adjusted or switching of treatment |
| 648 | Round,E.M., Engel,S.S., Golm,G.T., Davies,M.J. Safety of sitagliptin in elderly patients with type 2 diabetes: a pooled analysis of 25 clinical studies. Drugs and Aging 2014;31(3):203-14. | Systematic review/meta-analysis/pooled analysis/review |
| 649 | Russell,S. Incretin-based therapies for type 2 diabetes mellitus: A review of direct comparisons of efficacy, safety and patient satisfaction. International Journal of Clinical Pharmacy.35 (pp 159-172), 2013.Date of Publication: April 2013. 2013;(2):159-7 | Systematic review/meta-analysis/pooled analysis/review |
| 650 | Russell-Jones,D., Cuddihy,R.M., Hanefeld,M., Kumar,A., Gonzalez,J.G., Chan,M., et al. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATI | unclear if previous blood glucose lowering therapies were washed out/discontinued |
| 651 | Rybka. European comparative study of 2 alpha-glucosidase inhibitors, miglitol and acarbose. | abstract only/not full paper |
| 652 | Rys,P., Wojciechowski,P., Siejka,S., Malecki,P. A comparison of biphasic insulin aspart and insulin glargine administered with oral antidiabetic drugs in type 2 diabetes mellitus - a systematic review and meta-analysis. International Journal of Clin | Systematic review/meta-analysis/pooled analysis/review |
| 653 | Rys,P., Pankiewicz,O., Lach,K., Kwaskowski,A., Skrzekowska-Baran,I. Efficacy and safety comparison of rapid-acting insulin aspart and regular human insulin in the treatment of type 1 and type 2 diabetes mellitus: A systematic review. Diabetes and Meta | Systematic review/meta-analysis/pooled analysis/review |
| 654 | Saenz,A., Fernandez-Esteban,I., Mataix,A., Ausejo,M., Roque,M. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2005;(3):CD002966. | Systematic review/meta-analysis/pooled analysis/review |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 655 | Sakharova,O.V., Lleva,R.R., Dziura,J.D., Spollett,G.R., Howell,S.K., Beisswenger,P.J. Effects on post-prandial glucose and AGE precursors from two initial insulin strategies in patients with type 2 diabetes uncontrolled by oral agents. Journal of Dia | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 656 | Salari,P. & Nikfar,S. No Superiority of exenatide over insulin in diabetic patients in Terms of Weight Reduction or Incidence of Adverse Effects: A Meta-analysis. International Journal of Pharmacology.7 (7) (pp 749-756), 2011.Date of Publication: 2011. 2 | Systematic review/meta-analysis/pooled analysis/review |
| 657 | Saloranta,C., Hershon,K., Ball,M., Dickinson,S. Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia. Journal of Clinical Endocrinology & Metabolism 2002;87(9):4171-76. | comparison with unlicensed drug or drug indication |
| 658 | Salpeter,S.R., Greyber,E., Pasternak,G.A. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2010;(4):CD002967. | Systematic review/meta-analysis/pooled analysis/review |
| 659 | Sam,S., Haffner,S., Davidson,M.H., D'Agostino,R.,Sr., Perez,A. Pioglitazone-mediated changes in lipoprotein particle composition are predicted by changes in adiponectin level in type 2 diabetes. Journal of Clinical Endocrinology & Metabolism 2012;97(1 | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 660 | Schatz,H. Preclinical and clinical studies on safety and tolerability of repaglinide. Experimental & Clinical Endocrinology & Diabetes 1999;107():Suppl-8. | Systematic review/meta-analysis/pooled analysis/review |
| 661 | Scheen,A.J., Tan,M.H., Betteridge,D.J., Birkeland,K., Schmitz,O., Charbonnel,B. Long-term glycaemic effects of pioglitazone compared with placebo as add-on treatment to metformin or sulphonylurea monotherapy in PROactive (PROactive 18). Diabetic Medi | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 662 | Schernthaner,G. Cardiovascular risk and thiazolidinediones--what do meta-analyses really tell us?. [Review]. Diabetes, Obesity & Metabolism 2010;12(12):1023-35. | Systematic review/meta-analysis/pooled analysis/review |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 663 | Schernthaner,G., Barnett,A.H., Emser,A., Patel,S., Troost,J., Woerle,H.-J. Safety and tolerability of linagliptin: A pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus. Diabetes, Obesity and Metab | Systematic review/meta-analysis/pooled analysis/review |
| 664 | Schiel,R. Efficacy and treatment satisfaction of once-daily insulin glargine plus one or two oral antidiabetic agents versus continuing premixed human insulin in patients with type 2 diabetes previously on long-term conventional insulin therapy: the Switc | Drug comparison not of interest- insulin + 1 OAD vs. insulin + 2 OADs |
| 665 | Schmidt,W.E., Christiansen,J.S., Hammer,M., Zychma,M.J. Patient-reported outcomes are superior in patients with Type 2 diabetes treated with liraglutide as compared with exenatide, when added to metformin, sulphonylurea or both: results from a randomiz | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 666 | Schnell,O., Mertes,G., Standl,E. Acarbose and metabolic control in patients with type 2 diabetes with newly initiated insulin therapy. Diabetes, Obesity & Metabolism 2007;9(6):853-58. | Drug comparison not of interest-insulin + 1 OAD vs. insulin |
| 667 | Schondorf,T., Musholt,P.B., Hohberg,C., Forst,T., Lehmann,U., Fuchs,W., Lobig,M. The fixed combination of pioglitazone and metformin improves biomarkers of platelet function and chronic inflammation in type 2 diabetes patients: Results from the PIOf | Parent paper included and data extracted |
| 668 | Schopman,J.E., Simon,A.C., Hoefnagel,S.J., Hoekstra,J.B. The incidence of mild and severe hypoglycaemia in patients with type 2 diabetes mellitus treated with sulfonylureas: a systematic review and meta-analysis. Diabetes/Metabolism Research Reviews | Systematic review/meta-analysis/pooled analysis/review |
| 669 | Schwartz,S. Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes? the time has come for GLP-1 receptor agonists! Diabetes Care.36 (pp 2107-2111), 2013.Date of Publication: 2013. 2013;(7):2107-11. | Systematic review/meta-analysis/pooled analysis/review |
| 670 | Schwartz,S.L. Treatment of elderly patients with type 2 diabetes mellitus: A systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors. American Journal Geriatric Pharmacotherapy.8 (5) (pp 405-418), 2010.Date of Publication: October | Systematic review/meta-analysis/pooled analysis/review |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 671 | Schweizer,A. & Dejager,S. Impact of insulin resistance, body mass index, disease duration, and duration of metformin use on the efficacy of vildagliptin. Diabetes Therapy Research, Treatment and Education of Diabetes and Related Disorders 2012;3(1):8. | Systematic review/meta-analysis/pooled analysis/review |
| 672 | Schweizer,A. Experience with vildagliptin in patients > 75 years with type 2 diabetes and moderate or severe renal impairment. Diabetes Therapy.4 (pp 257-267), 2013.Date of Publication: 2013. 2013;(2):257-67. | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 673 | Schweizer,A., Dejager,S., Foley,J.E. Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies. Vascular Health & Risk Management 2011;7():49-57. | Systematic review/meta-analysis/pooled analysis/review |
| 674 | Schweizer,A., Dejager,S., Foley,J.E., Couturier,A., Ligueros-Saylan,M. Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population. Diabetes, Obesity & Metabolism 2 | Systematic review/meta-analysis/pooled analysis/review |
| 675 | Schweizer,A., Dejager,S., Foley,J.E., Shao,Q. Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population >=75 years: a pooled analysis from a database of clinical trials. Diabetes, Obesity & Metabolism 2011;13(1) | Systematic review/meta-analysis/pooled analysis/review |
| 676 | Scirica,B.M., Bhatt,D.L., Braunwald,E., Steg,P.G., Davidson,J., Hirshberg,B., et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. New England Journal of Medicine 2013;369(14):1317-26. | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 677 | Scott,D.A., Boye,K.S., Timlin,L. A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo. [R | Systematic review/meta-analysis/pooled analysis/review |
| 678 | Scott,R., Loeys,T., Davies,M.J., Engel,S.S. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes, Obesity & Metabolism 2008;10(10):959-69. | comparison with unlicensed drug or drug indication |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 679 | Seaquist,E.R., Miller,M.E., Fonseca,V., Ismail-Beigi,F., Launer,L.J. Effect of thiazolidinediones and insulin on cognitive outcomes in ACCORD-MIND. Journal of Diabetes and its Complications 2013;27(5):485-91. | across treatment strategy |
| 680 | Segal,P., Eliahou,H.E., Petzinna,D., Neuser,D. Long-term efficacy and tolerability of acarbose treatment in patients with type 2 diabetes mellitus. Clinical Drug Investigation 2005;25(9):589-95. | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 681 | Seino,Y. & Rasmussen,M.F. Glucagon-like peptide-1 analog liraglutide in combination with sulfonylurea safely improves blood glucose measures vs sulfonylurea monotherapy in Japanese patients with type 2 diabetes: Results of a 52-week, randomized, multice | comparison with unlicensed drug or drug indication |
| 682 | Seino,Y., Min,K.W., Niemoeller,E. Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea ( | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 683 | Seino,Y., Rasmussen,M.F., Nishida,T. Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes. Current Medical Research & Opinion 2010;26(5):1013-22. | comparison with unlicensed drug or drug indication |
| 684 | Seino,Y., Rasmussen,M.F., Zdravkovic,M. Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes. Diabetes Research & C | comparison with unlicensed drug or drug indication |
| 685 | Selam,J.L., Koenen,C., Weng,W. Improving glycemic control with insulin detemir using the 303 Algorithm in insulin naive patients with type 2 diabetes: a subgroup analysis of the US PREDICTIVE 303 study. Current Medical Research & Opinion 2008;24(1):11-2 | focus on algorithms (patient vs. physican driven) |
| 686 | Selvin,E., Bolen,S., Yeh,H.C., Wiley,C., Wilson,L.M., Marinopoulos,S.S., et al. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Archives of Internal Medicine 2008;168(19):2070-80. | Systematic review/meta-analysis/pooled analysis/review |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 687 | Seufert,J., Brath,H., Pscherer,S., Borck,A. Composite efficacy parameters and predictors of hypoglycaemia in basal-plus insulin therapy-a combined analysis of 713 type 2 diabetic patients. Diabetes, Obesity and Metabolism.16 (pp 248-254), 2014.Date | Systematic review/meta-analysis/pooled analysis/review |
| 688 | Shah,P.K., Mudaliar,S., Chang,A.R., Aroda,V., Andre,M., Burke,P. Effects of intensive insulin therapy alone and in combination with pioglitazone on body weight, composition, distribution and liver fat content in patients with type 2 diabetes. Diabete | Drug comparison not of interest-insulin + 1 OAD vs. insulin |
| 689 | Shank,Myron L. & Del Prato,Stefano. Bedtime insulin/daytime glipizide: effective therapy for sulfonylurea failures in NIDDM. Diabetes 1995;44(2):165-72. | unclear treatment groups or intervention |
| 690 | Sharma,P.K., Bhansali,A., Sialy,R., Malhotra,S. Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus. Clinical Endocrinology 2006;65(6):722-28. | comparing different types of sulfonylurea alone |
| 691 | Sherifali,D., Nerenberg,K., Pullenayegum,E., Cheng,J.E. The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis. [Review]. Diabetes Care 2010;33(8):1859-64. | Systematic review/meta-analysis/pooled analysis/review |
| 692 | Shimoda,S., Iwashita,S., Sekigami,T., Furukawa,N., Matsuo,Y., Ichimori,S., et al. Comparison of the efficacy of sitagliptin and glimepiride dose-up in Japanese patients with type 2 diabetes poorly controlled by sitagliptin and glimepiride in com | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 693 | Shimpi,R.D., Patil,P.H., Kuchake,V.G., Ingle,P.V., Surana,S.J. Comparison of effect of metformin in combination with glimepiride and glibenclamide on glycaemic control in patient with type 2 Diabetes Mellitus. International Journal of PharmTech Resear | unclear if previous blood glucose lowering therapies were washed out/discontinued |
| 694 | Shyangdan,D.S., Royle,P.L., Clar,C., Sharma,P. Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis. BMC Endocrine Disorders 2010;10():20. | Systematic review/meta-analysis/pooled analysis/review |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 695 | Siebenhofer,Andrea, Plank,Johannes, Berghold,Andrea, Jeitler,Klaus, Horvath,Karl, Narath,Markus, Gfrerer,Robert. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database of Systematic Reviews | Systematic review/meta-analysis/pooled analysis/review |
| 696 | Siegelaar,S.E., Kerr,L., Jacober,S.J. A decrease in glucose variability does not reduce cardiovascular event rates in type 2 diabetic patients after acute myocardial infarction: a reanalysis of the HEART2D study. Diabetes Care 2011;34(4):855-57. | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 697 | Signorovitch,J.E., Wu,E.Q., Swallow,E., Kantor,E., Fan,L. Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials. Clinical Drug Investigatio | Systematic review/meta-analysis/pooled analysis/review |
| 698 | Singh,A.K. Advances in basal insulin therapy: Lessons from current evidence. Journal of the Indian Medical Association.111 (pp 735-742), 2013.Date of Publication: November 2013. 2013;(11):735-42. | Systematic review/meta-analysis/pooled analysis/review |
| 699 | Singh,S.R., Ahmad,F., Lal,A., Yu,C., Bai,Z. Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. CMAJ Canadian Medical Association Journal 2009;180(4):385-97. | Systematic review/meta-analysis/pooled analysis/review |
| 700 | Singh-Franco,D., McLaughlin-Middlekauff,J., Elrod,S. The effect of linagliptin on glycaemic control and tolerability in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes, Obesity & Metabolism 2012;14(8):694-708. | Systematic review/meta-analysis/pooled analysis/review |
| 701 | Skov,V., Cangemi,C., Gram,J., Christensen,M.M., Grodum,E., Sorensen,D., Argraves,W.S. Metformin, but not rosiglitazone, attenuates the increasing plasma levels of a new cardiovascular marker, Fibulin-1, in patientswith Type 2 diabetes. Diabete | duplicate or same study results |
| 702 | Smith,S.R., De,Jonge L., Volaufova,J., Li,Y., Xie,H. Effect of pioglitazone on body composition and energy expenditure: A randomized controlled trial. Metabolism: Clinical and Experimental.54 (1) (pp 24-32), 2005.Date of Publication: January 2005. 200 | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 703 | Snaith,A., McIntyre,L., Rothnie,H., Thomas,S., Royle,P. Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2007;(1):n. pag.. | Systematic review/meta-analysis/pooled analysis/review |
| 704 | Sourij,H. & Zweiker,R. Effects of pioglitazone on endothelial function, insulin sensitivity, and glucose control in subjects with coronary artery disease and new-onset type 2 diabetes. Diabetes Care.29 (5) (pp 1039-1045), 2006.Date of Publication: 2006. | newly diagnosed participants but not explicit if they are drug naive |
| 705 | Spanheimer,R., Betteridge,D.J., Tan,M.H., Ferrannini,E. Long-Term Lipid Effects of Pioglitazone by Baseline Anti-Hyperglycemia Medication Therapy and Statin Use from the PROactive Experience (PROactive 14). American Journal of Cardiology.104 (2) (pp 23 | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 706 | Spengler M,H„nsel G,Boehme K. Efficacy of 6 months monotherapy with glucosidase inhibitor acarbose versus sulphonylurea glibenclamid on metabolic control of dietary treated type II diabetics. | dosing regimen includes higher than recommended doses and no details of mean doses or proportion of people taking different doses |
| 707 | Sridhar,S. & Walia,R. Effect of pioglitazone on testosterone in eugonadal men with type 2 diabetes mellitus: a randomized double-blind placebo-controlled study. Clinical Endocrinology 2013;78(3):454-59. | across treatment strategy |
| 708 | Srivastava,S. & Saxena,G.N. Comparing the efficacy and safety profile of sitagliptin versus glimepiride in patients of type 2 diabetes mellitus inadequately controlled with metformin alone. Journal of the Association of Physicians of India 2012;60():27-3 | duplicate or same study results |
| 709 | Standl,E. & Maxeiner,S. Once-daily insulin glargine administration in the morning compared to bedtime in combination with morning glimepiride in patients with type 2 diabetes: An assessment of treatment flexibility. Hormone and Metabolic Research.38 (3) | focus on timing of administration |
| 710 | Storms,G.E.M.G. & Lutterman,J.A. EFFICACY AND IMMUNOGENICITY OF HUMAN AND MONOCOMPONENT PORCINE INSULIN: A RANDOMIZED DOUBLE BLIND STUDY IN DIABETIC PATIENTS PREVIOUSLY TREATED WITH INSULIN. HUMAN INSULIN 1986;():67. | Not specifically type 2 diabetes |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 711 | Strain,W.D., Lukashevich,V., Kothny,W. Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study. Lancet 2013;382(9890): | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 712 | Strojek,K., Bebakar,W.M., Khutsoane,D.T., Pesic,M., Smahelova,A., Thomsen,H.F. Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, mult | unclear if previous blood glucose lowering therapies were washed out/discontinued |
| 713 | Strojek,K., Shi,C., Carey,M.A. Addition of insulin lispro protamine suspension or insulin glargine to oral type 2 diabetes regimens: a randomized trial. Diabetes, Obesity & Metabolism 2010;12(10):916-22. | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 714 | Su,Y., Su,Y.L., Lv,L.F., Wang,L.M. A randomized controlled clinical trial of vildagliptin plus metformin combination therapy in patients with type II diabetes mellitus. Experimental and Therapeutic Medicine.7 (pp 799-803), 2014.Date of Publication: | Drug comparison not of interest - 2 OADs vs 1 OAD |
| 715 | Suzuki,K. & Morikawa,H. Investigation of the introduction of three times daily injections of Insulin Lispro Mixture-50 on an outpatient basis: therapeutic effects of 12 months' treatment with and without concomitant sulfonylurea. Journal Of Diabetes 2012 | abstract only/not full paper |
| 716 | Swinnen,S.G., Dain,M.P., Aronson,R., Davies,M., Gerstein,H.C., Pfeiffer,A.F., et al. A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes in | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 717 | Swinnen,S.G., Dain,M.P., Mauricio,D., DeVries,J.H., Hoekstra,J.B. Continuation versus discontinuation of insulin secretagogues when initiating insulin in type 2 diabetes. Diabetes, Obesity & Metabolism 2010;12(10):923-25. | abstract only/not full paper |
| 718 | Swinnen,Sanne G., Simon-Airin,C.R., Holleman,Frits, Hoekstra,Joost B. Insulin detemir versus insulin glargine for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011;():n. pag.. | Systematic review/meta-analysis/pooled analysis/review |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 719 | Tabatabaei,Malazy O., Heshmat,R., Taheri,E. Comparison of a generic and a brand metformin products in type II diabetes: A double blind randomized clinical trial study. Daru.15 (2) (pp 113-117), 2007.Date of Publication: 2007. 2007;(2):113-17. | comparing different types of sulfonylurea alone |
| 720 | Tajima,N., Kadowaki,T., Okamoto,T., Sato,A., Okuyama,K. Sitagliptin added to voglibose monotherapy improves glycemic control in patients with type 2 diabetes. Journal of Diabetes Investigation.4 (6) (pp 595-604), 2013.Date of Publication: November | Drug comparison not of interest - 2 OADs vs 1 OAD |
| 721 | Tajima,N., Kadowaki,T., Odawara,M., Nishii,M., Taniguchi,T. Addition of sitagliptin to ongoing glimepiride therapy in Japanese patients with type 2 diabetes over 52 weeks leads to improved glycemic control. Diabetology International.2 (1) (pp 32-44), | Drug comparison not of interest - 2 OADs vs 1 OAD |
| 722 | Takai,M., Ishikawa,M., Maeda,H., Kanamori,A., Kubota,A., Amemiya,H., et al. Safety and efficacy of adding sitagliptin to insulin in patients with type 2 diabetes: The ASSIST-K study. Diabetes Research and Clinical Practice.103 (pp e30-e33), 2014 | not an RCT (no randomisation) |
| 723 | Takihata,M., Nakamura,A., Tajima,K., Inazumi,T., Komatsu,Y., Tamura,H., et al. Comparative study of sitagliptin with pioglitazone in Japanese type 2 diabetic patients: the COMPASS randomized controlled trial. Diabetes, Obesity & Metabolism 2013;15(5) | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 724 | Tamemoto,H., Ikoma,A., Saitoh,T., Ishikawa,S.E. Comparison of once-daily glargine plus sulfonylurea with twice-daily 70/30 aspart premix in insulin-naive Japanese patients with diabetes. Diabetes Technology & Therapeutics 2007;9(3):246-53. | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 725 | Tamez P,rez HE,G¢mez de Ossio MD,Ibarra Mart¡nez IB. Normoglucemia in newly diagnosed no insulin dependent diabetes mellitus. Non pharmacologic therapy vs. pharmacologic therapy. | not available from the British library |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 726 | Tan,A., Cao,Y., Xia,N., Mo,Z. The addition of pioglitazone in type 2 diabetics poorly controlled on insulin therapy: A meta-analysis. European Journal of Internal Medicine.21 (5) (pp 398-403), 2010.Date of Publication: October 2010. 2010;(5):398-403. | Systematic review/meta-analysis/pooled analysis/review |
| 727 | Tan,M., Johns,D., Galvez,G.G., Antunez,O., Fabian,G., Flores-Lozano,F., et al. Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-bl | inadequate wash out period (<4 weeks) |
| 728 | Tan,M.H., Johns,D., Strand,J., Halse,J., Madsbad,S., Eriksson,J.W., et al. Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes. Diabetic Medicine 2004;21(8 | inadequate wash out period (<4 weeks) |
| 729 | Tang JZ,Mao JP,Yang ZF,Zhou ZG,Tang WL,Feng Q. Effects of glimepiride and metformin on free fatty acid in patients with Type 2 diabetes mellitus. | Non-English paper |
| 730 | Tatosian,D.A., Guo,Y., Schaeffer,A.K., Gaibu,N., Popa,S., Stoch,A. Dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes treated with saxagliptin, sitagliptin, or vildagliptin. Diabetes Therapy Research, Treatment and Education of Diabet | <12 week treatment duration |
| 731 | Taylor,R., Davies,R., Fox,C., Sampson,M., Weaver,J.U. Appropriate insulin regimes for type 2 diabetes: A multicenter randomized crossover study. Diabetes Care.23 (11) (pp 1612-1618), 2000.Date of Publication: 2000. 2000;(11):1612-18. | Drug comparison not of interest-insulin vs. insulin |
| 732 | Testa,M.A., Gill,J., Su,M., Turner,R.R. Comparative effectiveness of basal-bolus versus premix analog insulin on glycemic variability and patient-centered outcomes during insulin intensification in type 1 and type 2 diabetes: a randomized, controlled, | unclear if previous blood glucose lowering therapies were washed out/discontinued |
| 733 | The University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. | unclear if previous blood glucose lowering therapies were washed out/discontinued |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 734 | The University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. VI. Supplementary report on nonfatal events in patients treated with tolbutamide. | unclear if previous blood glucose lowering therapies were washed out/discontinued |
| 735 | Thomann,R., Schutz,P., Muller,B., Thomke,S. Evaluation of an algorithm for intensive subcutaneous insulin therapy in noncritically ill hospitalised patients with hyperglycaemia in a randomised controlled trial. Swiss Medical Weekly 2013;143():w13808 | Drug comparison not of interest-insulin vs. insulin |
| 736 | Thompson,A.M. & Linnebur,S.A. Glycemic targets and medication limitations for type 2 diabetes mellitus in the older adult. Consultant Pharmacist.29 (pp 110-123), 2014.Date of Publication: February 2014. 2014;(2):110-23. | Systematic review/meta-analysis/pooled analysis/review |
| 737 | Thrasher,J. & Daniels,K. Black/African American patients with type 2 diabetes mellitus: study design and baseline patient characteristics from a randomized clinical trial of linagliptin. Expert Opinion on Pharmacotherapy 2012;13(17):2443-52. | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 738 | Thrasher,J., Daniels,K., Patel,S. Efficacy and Safety of Linagliptin in Black/African American Patients with Type 2 Diabetes: A 6-month, Randomized, Double-blind, Placebo-controlled Study. Endocrine Practice 2014;20(5):412-20. | duplicate or same study results |
| 739 | Tindall,H., Bodansky,H.J., Stickland,M. A strategy for selection of elderly type 2 diabetic patients for insulin therapy, and a comparison of two insulin preparations. Diabetic Medicine 1988;5(6):533-36. | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 740 | Tolman,K.G., Freston,J.W., Kupfer,S. Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US. Drug Safety 2009;32(9):787-800. | unclear if previous blood glucose lowering therapies were washed out/discontinued |
| 741 | Tong,G., Hua,X., Zhong,Y., Zhang,K., Gu,G., Feng,W., et al. Intensive insulin therapy increases sex hormone-binding globulin in newly diagnosed type 2 diabetic patients. European Journal of Endocrinology 2014;170(2):237-45. | <12 week treatment duration |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 742 | Torekov,S.S. Dose response of continuous subcutaneous infusion of recombinant glucagon-like peptide-1 in combination with metformin and sulphonylurea over 12weeks in patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism 2014;16(5):451-5 | comparison with unlicensed drug or drug indication |
| 743 | Tripathy,D., Clement,S.C., Schwenke,D.C., Banerji,M., Bray,G.A., Buchanan,T.A., et al. Baseline Adiponectin Levels Do Not Influence the Response to Pioglitazone in ACT NOW. Diabetes Care 2014;37(6):1706-11. | outcomes not of interest |
| 744 | Trippe,B.S., Shepherd,M.D., Coulter,F.C., Bhargava,A., Brett,J. Efficacy and safety of biphasic insulin aspart 70/30 in type 2 diabetes patients of different race or ethnicity (INITIATEplus trial). Current Medical Research & Opinion 2012;28(7):1203-11 | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 745 | Uchida,T., Kawai,J., Fujitani,Y., Kawamori,R., Watada,H. Efficacy and adverse effects of low-dose nateglinide in early type 2 diabetes: Comparison with acarbose in a crossover study. Diabetology International.1 (1) (pp 35-41), 2010.Date of Publication | comparison with unlicensed drug or drug indication |
| 746 | UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). The Lancet 1998;352(9131):854-65. | unclear dosing regimen and no details relating to mean doses |
| 747 | Umpierrez,G.E. Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes? Insulin therapy has proven itself and is considered the mainstay of treatment. Diabetes Care.36 (pp 2112-2117), 2013.Date of Publication: 2013. 2013 | Systematic review/meta-analysis/pooled analysis/review |
| 748 | Umpierrez,G.E., Gianchandani,R., Smiley,D., Jacobs,S., Wesorick,D.H., Newton,C., et al. Safety and efficacy of sitagliptin therapy for the inpatient management of general medicine and surgery patients with type 2 diabetes: a pilot, randomized, contro | <12 week treatment duration |
| 749 | Umpierrez,G.E., Smiley,D., Hermayer,K., Khan,A., Olson,D.E., Newton,C., et al. Randomized study comparing a Basal-bolus with a basal plus correction insulin regimen for the hospital management of medical and surgical patients with type 2 diabetes: ba | <12 week treatment duration |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 750 | Umpierrez,G.E., Smiley,D., Jacobs,S., Peng,L., Temponi,A., Mulligan,P., et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery). Diabetes Care 2 | Drug comparison not of interest-insulin vs. insulin |
| 751 | Vaccaro,O., Masulli,M., Bonora,E., Del,Prato S., Giorda,C.B., Maggioni,A.P., et al. Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomi | outcomes not of interest |
| 752 | Vaccaro,O., Masulli,M., Bonora,E., Del,Prato S., Nicolucci,A. The TOSCA.IT trial: A study designed to evaluate the effect of pioglitazone versus sulfonylureas on cardiovascular disease in type 2 diabetes. Diabetes Care.35 (12) (pp e82), 2012.Date of P | abstract only/not full paper |
| 753 | Vahatalo,M. & Ronnemaa,T. Recognition of fasting or overall hyperglycaemia when starting insulin treatment in patients with type 2 diabetes in general practice. Scandinavian Journal of Primary Health Care 2007;25(3):147-53. | unclear if previous blood glucose lowering therapies were washed out/discontinued |
| 754 | Vahatalo,M.A. Starting bedtime glargine versus NPH insulin in poorly controlled type 2 diabetic patients with various hyperglycemia types (fasting type or postprandial type). Acta Diabetologica 2014;51(2):233-38. | Drug comparison not of interest-insulin vs. insulin |
| 755 | van de Laar,F.A., Lucassen,P.L., Akkermans,R.P., Van de Lisdonk,E.H., Rutten,G.E. alpha-Glucosidase inhibitors for patients with type 2 diabetes: Results from a Cochrane systematic review and meta-analysis. Diabetes Care.28 (1) (pp 154-163), 2005.Date | Systematic review/meta-analysis/pooled analysis/review |
| 756 | van de Laar,Floris A., Lucassen,Peter L.B.J., Kemp,Jaco, van de Lisdonk,Eloy H., van Weel,Chris. Is acarbose equivalent to tolbutamide as first treatment for newly diagnosed type 2 diabetes in general practice?: A randomised controlled trial. | newly diagnosed participants but not explicit if they are drug naive |
| 757 | Van de Laar,Floris A., Lucassen-Peter,L.B.J., Akkermans,Reinier P., Van de Lisdonk,Eloy H., Rutten-Guy,E.H.M. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2005;():n. pag.. | Systematic review/meta-analysis/pooled analysis/review |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 758 | van Poppel,P.C., Gresnigt,M.S., Smits,P. The dipeptidyl peptidase-4 inhibitor vildagliptin does not affect ex vivo cytokine response and lymphocyte function in patients with type 2 diabetes mellitus. Diabetes Research and Clinical Practice 2014;103(3) | <12 week treatment duration |
| 759 | Van Raalte,D.H., Van Genugten,R.E., Eliasson,B., Moller-Goede,D.L., Mari,A., Tura,A., et al. The effect of alogliptin and pioglitazone combination therapy on various aspects of beta-cell function in patients with recent-onset type 2 diabetes. Eu | comparison with unlicensed drug or drug indication |
| 760 | van,Dieren S., Kengne,A.P., Chalmers,J., Beulens,J.W., Davis,T.M., Fulcher,G., et al. Intensification of medication and glycaemic control among patients with type 2 diabetes - the ADVANCE trial. Diabetes, Obesity and Metabolism 2014;16(5):426-32 | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 761 | Vardarli,I., Arndt,E., Deacon,C.F. Effects of sitagliptin and metformin treatment on incretin hormone and insulin secretory responses to oral and isoglycemic intravenous glucose. Diabetes.63 (pp 663-674), 2014.Date of Publication: February 2014. 2014; | <12 week treatment duration |
| 762 | Velojic-Golubovic,M., Mikic,D., Pesic,M., Dimic,D., Radenkovic,S. Biphasic insulin aspart 30: better glycemic control than with premixed human insulin 30 in obese patients with Type 2 diabetes. Journal of Endocrinological Investigation 2009;32(1):23-2 | not an RCT (no randomisation) |
| 763 | Vignati,L. & Anderson,Jr. Efficacy of insulin lispro in combination with NPH human insulin twice per day in patients with insulin-dependent or non-insulin-dependent diabetes mellitus. Clinical Therapeutics.19 (6) (pp 1408-1421), 1997.Date of Publication: | Drug comparison not of interest-insulin vs. insulin |
| 764 | Vilsb›ll,T., Brock,B., Perrild,H., Levin,K., Lervang,H.H., K›lendorf,K., et al. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type | comparison with unlicensed drug or drug indication |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 765 | Vilsboll,T., Christensen,M., Junker,A.E., Knop,F.K. Effects of glucagon-like peptide-1 receptor agonists on weight loss: Systematic review and meta-analyses of randomised controlled trials. BMJ (Online).344 (7841) , 2012.Article Number: d7771.Date of P | Systematic review/meta-analysis/pooled analysis/review |
| 766 | Vilsboll,T., Rosenstock,J., Yki-Jarvinen,H., Cefalu,W.T., Chen,Y., Luo,E., et al. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes, Obesity & Metabolism 2010;12(2):167-77. | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 767 | Vinik,A.I. Adding insulin glargine versus rosiglitazone: health-related quality-of-life impact in type 2 diabetes. Diabetes Care 2007;30(4):795-800. | comparison with unlicensed drug or drug indication |
| 768 | von,Eynatten M. & Gong,Y. Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: a pooled analysis of six phase III clinical trials. Cardiovascular Diabetology 2013;12():60. | Systematic review/meta-analysis/pooled analysis/review |
| 769 | Vora,J., Hollander,P., Tamer,S.C. Insulin degludec does not increase antibody formation compared to insulin glargine: An evaluation of phase 3a clinical trials. Diabetes Technology and Therapeutics.15 (pp S132), 2013.Date of Publication: 01 Jun 2013. | abstract only/not full paper |
| 770 | Walford,G.A., Ma,Y., Christophi,C.A., Goldberg,R.B., Jarolim,P., Horton,E., et al. Circulating natriuretic peptide concentrations reflect changes in insulin sensitivity over time in the Diabetes Prevention Program. Diabetologia 2014;57(5):935-39 | outcomes not of interest |
| 771 | Wallace,J.P. Comparing Dosing of Basal Insulin Analogues Detemir and Glargine: Is It Really Unit-Per-Unit and Dose-Per-Dose? Annals of Pharmacotherapy.48 (pp 361-368), 2014.Date of Publication: March 2014. 2014;(3):361-68. | Systematic review/meta-analysis/pooled analysis/review |
| 772 | Wang,J.S., Huang,C.N., Hung,Y.J., Kwok,C.F., Sun,J.H., Pei,D., et al. Acarbose plus metformin fixed-dose combination outperforms acarbose monotherapy for type 2 diabetes. Diabetes Research and Clinical Practice 2013;102(1):16-24. | Drug comparison not of interest - 2 OADs vs 1 OAD |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 773 | Wang,L., Sun,X., Du,L., Yuan,Q., Li,H., Tian,H. Effects and patient compliance of sustained-release versus immediate-release glipizides in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. Journal of Evidence-Based Medici | Systematic review/meta-analysis/pooled analysis/review |
| 774 | Wang,X.L., Lu,J.M., Pan,C.Y., Mu,Y.M., Dou,J.T., Ba,J.M. Evaluation of the superiority of insulin glargine as basal insulin replacement by continuous glucose monitoring system. Diabetes Research & Clinical Practice 2007;76(1):30-36. | comparison with unlicensed drug or drug indication |
| 775 | Wang,Y., Li,L., Yang,M., Liu,H., Boden,G. Glucagon-like peptide-1 receptor agonists versus insulin in inadequately controlled patients with type 2 diabetes mellitus: a meta-analysis of clinical trials. [Review]. Diabetes, Obesity & Metabolism 2011;13( | Systematic review/meta-analysis/pooled analysis/review |
| 776 | Wang,Y., Ye,S., Hu,Y. The effect of hydrochloride pioglitazone on urinary 8-hydroxy -deoxyguanosine excretion in type 2 diabetics. Journal of Diabetes & its Complications 2013;27(1):75-77. | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 777 | Webb,D.R., Davies,M.J., Gray,L.J., Abrams,K.R., Srinivasan,B., Das,S., et al. Searching for the right outcome? A systematic review and meta-analysis of controlled trials using carotid intima-media thickness or pulse wave velocity to infer antiatherog | Systematic review/meta-analysis/pooled analysis/review |
| 778 | White,J.L. & Buchanan,P. A randomized controlled trial of the efficacy and safety of twice-daily saxagliptin plus metformin combination therapy in patients with type 2 diabetes and inadequate glycemic control on metformin monotherapy. BMC Endocrine Diso | Drug comparison not of interest - 2 OADs vs 1 OAD |
| 779 | Wilcox,R. & Kupfer,S. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: Results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10). American Heart Journal.155 (4) | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 780 | Wilding,J.P. & Leonsson-Zachrisson,M. Dose-ranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin. Diabetes, Obesity and Metabolism 2013;15(8):750-59. | Drug comparison not of interest - 2 OADs vs 1 OAD |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 781 | Williams-Herman,D., Engel,S.S., Round,E., Johnson,J., Golm,G.T., Guo,H., et al. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocrine Disorders 2010;10():7. | Systematic review/meta-analysis/pooled analysis/review |
| 782 | Williams-Herman,D., Round,E., Swern,A.S., Musser,B., Davies,M.J., Stein,P.P., Kaufman,K.D. Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocrine Disorders 2008;8():14. | Systematic review/meta-analysis/pooled analysis/review |
| 783 | Williams-Herman,D., Xu,L., Teng,R., Golm,G.T., Johnson,J., Davies,M.J., Kaufman,K.D. Effect of initial combination therapy with sitagliptin and metformin on beta-cell function in patients with type 2 diabetes. Diabetes, Obesity & Metabolism 2012;14( | no Hba1c measures |
| 784 | Wolever,Thomas MS, Assiff,Lila, Basu,Tapan, Chiasson,Jean Louis, Boctor,M., Gerstein,Hertzel C., et al. Miglitol, an +Ý-glucosidase inhibitor, prevents the metformin-induced fall in serum folate and vitamin B12 in subjects with type 2 diabetes. | duplicate or same study results |
| 785 | Wolffenbuttel,B.H. A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group. Diabetes Care 1999;22(3):463-67. | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 786 | Wolffenbuttel,B.H., Klaff,L.J., Bhushan,R., Fahrbach,J.L., Jiang,H. Initiating insulin therapy in elderly patients with Type 2 diabetes: efficacy and safety of lispro mix 25 vs. basal insulin combined with oral glucose-lowering agents. Diabetic Medici | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 787 | Wolffenbuttel,B.H.R., Weber,R.F.A., van Koetsveld,P.M., Weeks,L. A Randomized Crossover Study of Sulphonylurea and Insulin Treatment in Patients with Type 2 Diabetes Poorly Controlled on Dietary Therapy. Diabetic Medicine 1989;6(6):520-25. | Drug comparison not of interest-insulin vs. 1 OAD |
| 788 | Wolffenbuttel,Bruce HR, Sels,Jean Pierre JE, Rondas-Colbers,Gabrielle JWM, Menheere,Paul PCA. Comparison of different insulin regimens in elderly patients with NIDDM. Diabetes Care 1996;19(12):1326-32. | unclear if previous blood glucose lowering therapies were washed out/discontinued |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 789 | Wong,M.C.S., Wang,H.H.X., Kwan,M.W.M., Zhang,D.D.X., Liu,K.Q.L., Chan,S.W.M., et al. Comparative effectiveness of dipeptidyl peptidase-4 (DPP-4) inhibitors and human glucagon-like peptide-1 (GLP-1) analogue as add-on therapies to sulphonylurea a | Systematic review/meta-analysis/pooled analysis/review |
| 790 | Wu,C.-Z., Pei,D., Hsieh,A.-T., Wang,K., Lin,J.-D., Lee,L.-H., et al. Comparison of insulin sensitivity, glucose sensitivity, and first phase insulin secretion in patients treated with repaglinide or gliclazide. Archives of Pharmacal Research.33 (3) ( | unclear if previous blood glucose lowering therapies were washed out/discontinued |
| 791 | Wu,T., Bound,M.J., Zhao,B.R., Standfield,S.D., Bellon,M., Jones,K.L. Effects of a D-xylose preload with or without sitagliptin on gastric emptying, glucagon-like peptide-1, and postprandial glycemia in type 2 diabetes. Diabetes Care.36 (pp 1913- | <12 week treatment duration |
| 792 | Wysham,C., Bergenstal,R., Malloy,J., Yan,P., Walsh,B., Malone,J. DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide. Diabetic Medicine 2011;28(6):705-14. | Parent paper included and data extracted |
| 793 | Xing,Y. & Ye,S. Podocyte as a potential target of inflammation: role of pioglitazone hydrochloride in patients with type 2 diabetes. Endocrine Practice 2012;18(4):493-98. | unclear if previous blood glucose lowering therapies were washed out/discontinued |
| 794 | Xu,L., Man,C.D., Charbonnel,B., Meninger,G., Davies,M.J., Williams-Herman,D., Cobelli,C. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach. Diabetes, Obesity & M | Systematic review/meta-analysis/pooled analysis/review |
| 795 | Yajima,K., Shimada,A., Hirose,H., Kasuga,A. 'Low dose' metformin improves hyperglycemia better than acarbose in type 2 diabetics. The Review of Diabetic Studies 2004;1(2):89-94. | no inclusion/exclusion criteria or patients drug naive and not representative |
| 796 | Yamada,S., Watanabe,M., Kitaoka,A., Shiono,K., Atsuda,K., Tsukamoto,Y., Kawana,Y. Switching from premixed human insulin to premixed insulin lispro: a prospective study comparing the effects on glucose control and quality of life. Internal Medicine 2 | Drug comparison not of interest-insulin vs. insulin |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 797 | Yang,G., Li,C., Gong,Y., Li,J. A prospective, randomized, open-label study comparing the efficacy and safety of preprandial and prandial insulin in combination with acarbose in elderly, insulin-requiring patients with type 2 diabetes mellitus. Diabetes | unclear if previous blood glucose lowering therapies were washed out/discontinued |
| 798 | Yang,W., Ji,Q., Zhu,D., Yang,J., Chen,L., Liu,Z., Yu,D. Biphasic insulin aspart 30 three times daily is more effective than a twice-daily regimen, without increasing hypoglycemia, in Chinese subjects with type 2 diabetes inadequately controlled on o | dose comparison of same drug |
| 799 | Yasunari,E., Takeno,K., Funayama,H., Tomioka,S., Tamaki,M., Fujitani,Y., et al. Efficacy of pioglitazone on glycemic control and carotid intima-media thickness in type 2 diabetes patients with inadequate insulin therapy. Journal of Diabetes Investiga | Drug comparison not of interest-unclear pre-existing therapy which is continued throughout the study |
| 800 | Yilmaz,H., Gursoy,A., Sahin,M. Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and rosiglitazone or insulin and acarbose in type 2 diabetes. Acta Diabetologica 2007;44(4):187-92. | not an RCT (no randomisation) |
| 801 | Yki-Jarvinen,H. Is there evidence to support use of premixed or prandial insulin regimens in insulin-naive or previously insulin-treated type 2 diabetic patients?. [Review]. Diabetes Care 2013;36():Suppl-11. | Systematic review/meta-analysis/pooled analysis/review |
| 802 | Yki-Jarvinen,H., Rosenstock,J., Duran-GARCIA,S., Pinnetti,S., Bhattacharya,S., Thiemann,S. Effects of Adding Linagliptin to Basal Insulin Regimen for Inadequately Controlled Type 2 Diabetes: A >=52-week randomized, double-blind study. Diabetes Care 2 | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 803 | Yokoyama,H., Sone,H., Yamada,D., Honjo,J. Contribution of glimepiride to basal-prandial insulin therapy in patients with type 2 diabetes. Diabetes Research & Clinical Practice 2011;91(2):148-53. | unclear treatment groups or intervention |
| 804 | Yudkin,J.S., Panahloo,A., Stehouwer,C., Emeis,J.J., Bulmer,K., Mohamed-Ali,V. The influence of improved glycaemic control with insulin and sulphonylureas on acute phase and endothelial markers in Type II diabetic subjects. Diabetologia.43 (9) (pp 109 | Drug comparison not of interest-insulin vs. 1 OAD |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 805 | Zdarska,D.J., Kvapil,M., Rusavy,Z., Krcma,M., Broz,J. Comparison of glucose variability assessed by a continuous glucose-monitoring system in patients with type 2 diabetes mellitus switched from NPH insulin to insulin glargine: the COBIN2 study. W | not an RCT (no randomisation) |
| 806 | Zhang,H. & Zhang,X. Exenatide reduces urinary transforming growth factor-beta1 and type IV collagen excretion in patients with type 2 diabetes and microalbuminuria. Kidney & Blood Pressure Research 2012;35(6):483-88. | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |
| 807 | Zhang,Y., Hong,J., Chi,J., Gu,W. Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - a meta-analysis from randomized clinical trials. Diabetes/Metabolism Research and Reviews.30 (pp 241-256), 2014.Date of Publication: M | Systematic review/meta-analysis/pooled analysis/review |
| 808 | Zhao,Y., Yang,L., Xiang,Y., Liu,L., Huang,G., Long,Z., et al. Dipeptidyl Peptidase 4 Inhibitor Sitagliptin Maintains beta-Cell Function in Patients with Recent-Onset Latent Autoimmune Diabetes in Adults: One Year Prospective Study. Journal of Cl | Not specifically type 2 diabetes |
| 809 | Zheng GF,Wang JP,Zhang H,Hu ZX,Liu J,Xiao JZ,et al. Clinical observation on glucobay treatment for NIDDM.. | Non-English paper |
| 810 | Zib,I., Jacob,A.N., Lingvay,I., Salinas,K., McGavock,J.M., Raskin,P. Effect of pioglitazone therapy on myocardial and hepatic steatosis in insulin-treated patients with type 2 diabetes. Journal of Investigative Medicine 2007;55(5):230-36. | Drug comparison not of interest-insulin + 1 OAD vs. insulin |
| 811 | Zinman,B., DeVries,J.H., Bode,B., Russell-Jones,D., Leiter,L.A., Moses,A. Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: Results of two phase 3, 26 week, r | not available from the British library |
| 812 | Zinman,B., Philis-Tsimikas,A., Cariou,B., Handelsman,Y., Rodbard,H.W., Johansen,T., Endahl,L. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Dia | proportion or all patients taking pre-existing OADs (contamination) or other OAD/insulin (with no subgroup analyses) |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 813 | Zinman,B., Schmidt,W.E., Moses,A., Lund,N. Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme. Diabetes, Obesity & Me | Systematic review/meta-analysis/pooled analysis/review |
| 814 | Zinman,Bernard, Hoogwerf,Byron J., DuraŸ• n GarciŸ• a,Santiago, Milton,DenaŸ• i R., Giaconia,Joseph M., Kim,Dennis D., Trautmann,Michael E. The Effect of Adding Exenatide to a Thiazolidinedione in Suboptimally Controlled Type 2 DiabetesA Randomized Tri | comparison with unlicensed drug or drug indication |

## L.2 Review Question 2: What are the serious adverse effects of long-term use of pharmacological interventions to control blood glucose in people with type 2 diabetes?

**Table 2: Excluded studies of full text papers**

| Number | Reference | Reason for exclusion |
|---|---|---|
| 1 | Anon. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes 1995;44(11):1249-58. | Longer follow-up available and included |
| 2 | Anon. UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. U.K. Prospective Diabetes Study Group. Diabetes Care 1998;21(1):87-92. | Relevant outcomes not reported |
| 3 | Anon. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United King | Relevant outcomes not reported |
| 4 | Anon. Pioglitazone ineffective in secondary prevention of macrovascular complications (PROactive). Journal of the National Medical Association.98 (1) (pp 102-103), 2006.Date of Publication: January 2006. 2006;(1):102-03. | Summary of study- insufficient data reported |
| 5 | Adler,A.I., Levy,J.C., Matthews,D.R., Stratton,I.M., Hines,G.. Insulin sensitivity at diagnosis of Type 2 diabetes is not associated with subsequent cardiovascular disease (UKPDS 67). Diabetic Medicine 2005;22(3):306-11. | Exposure to pharmacological therapy not reported |
| 6 | Andersson,C., Olesen,J.B., Hansen,P.R., Weeke,P., Norgaard,M.L., Jorgensen,C.H., et al. Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study. Diabetologia 20 | Not a prospective cohort design |
| 7 | Azoulay,L., Schneider-Lindner,V., Dell'Aniello,S., Schiffrin,A.. Combination therapy with sulfonylureas and metformin and the prevention of death in type 2 diabetes: a nested case-control study. Pharmacoepidemiology & Drug Safety 2010;19(4):335-42. | Not a prospective cohort design |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 8 | Bayraktar,S., Hernadez-Aya,L.F., Lei,X., Meric-Bernstam,F., Litton,J.K., Hsu,L., Hortobagyi,G.N.. Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer 2012;118(5):1202-11. | Insufficient sample size |
| 9 | Best,J.D., Drury,P.L., Davis,T.M.E., Taskinen,M.-R., Kesaniemi,Y.A., Scott,R., et al. Glycemic control over 5 years in 4,900 people with type 2 diabetes: Real-world diabetes therapy in a clinical trial cohort. Diabetes Care.35 (5) (pp 1165-1170), 2 | Relevant outcomes not reported |
| 10 | Blonde,L., Klein,E.J., Han,J., Zhang,B., Mac,S.M., Poon,T.H., et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes, Obes | Relevant outcomes not reported |
| 11 | Bolen,S., Feldman,L., Vassy,J., Wilson,L., Yeh,H.C., Marinopoulos,S., et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Annals of Internal Medicine 2007;147(6):386-99. | Systematic review- included studies appraised individually |
| 12 | Bowker,S.L., Majumdar,S.R., Veugelers,P.. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006;29(2):254-58. | Not a prospective cohort design |
| 13 | Br„ndle,M., Goodall,G., Erny-Albrecht,K.M., Erdmann,E.. Cost-effectiveness of pioglitazone in patients with type 2 diabetes and a history of macrovascular disease in a Swiss setting. Swiss Medical Weekly 2009;139(11-12):173-84. | Not a prospective cohort design |
| 14 | Brown,J.B., Nichols,G.A., Glauber,H.S.. Ten-year follow-up of antidiabetic drug use, nonadherence, and mortality in a defined population with type 2 diabetes mellitus. Clinical Therapeutics 1999;21(6):1045-57. | Not a prospective cohort design |
| 15 | Buse,J.B., Klonoff,D.C., Nielsen,L.L., Guan,X., Bowlus,C.L., Holcombe,J.H., Maggs,D.G.. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data | Relevant outcomes not reported |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 16 | Cardoso,C.R.L.. Predictors of development and progression of microvascular complications in a cohort of Brazilian type 2 diabetic patients. Journal of Diabetes and its Complications.22 (3) (pp 164-170), 2008.Date of Publication: May 2008/June 2008. 2008 | Exposure to pharmacological therapy not reported |
| 17 | Carney,G.A., Bassett,K., Wright,J.M.. Is thiazolidinediones use a factor in delaying the need for insulin therapy in type 2 patients with diabetes? A population-based cohort study. BMJ Open 2012;2(6):2012. | Not a prospective cohort design |
| 18 | Caro,J.J., Salas,M., Ward,A.J., Raggio,G., O'Brien,J.A.. Combination therapy for type 2 diabetes: What are the potential health and cost implications in Canada? Canadian Journal of Diabetes.27 (1) (pp 33-41), 2003.Date of Publication: 2003. 2003;(1) | Not a prospective cohort design |
| 19 | Chang,C.-H., Lin,J.-W., Wu,L.-C., Lai,M.-S.. Oral insulin secretagogues, insulin, and cancer risk in type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism.97 (7) (pp E1170-E1175), 2012.Date of Publication: July 2012. 2012;(7):E11 | Not a prospective cohort design |
| 20 | Chaturvedi,N., Jarrett,J., Morrish,N., Keen,H.. Differences in mortality and morbidity in African Caribbean and European people with non-insulin dependent diabetes mellitus: Results of 20 year follow up of a London cohort of a multinational study. Br | Exposure to pharmacological therapy not reported |
| 21 | Clarke,P., Gray,A., Adler,A., Stevens,R., Raikou,M., Cull,C., et al. Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51). Diabetologia 2001;44(3):298-304. | Not a prospective cohort design |
| 22 | Cluxton,Jr, Li,Z., Heaton,P.C., Weiss,S.R., Zuckerman,I.H., Moomaw,C.J., Hsu,V.D.. Impact of regulatory labeling for troglitazone and rosiglitazone on hepatic enzyme monitoring compliance: Findings from the state of Ohio medicaid program. Pharmaco | Rosiglitazone |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 23 | Colhoun,H.M., Livingstone,S.J., Looker,H.C., Morris,A.D., Wild,S.H., Lindsay,R.S., et al. Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-Lowering drugs. Diabetologia.55 (11) (pp 2929-2937), 2012.D | Rosiglitazone |
| 24 | Colmers,I.N. & Bowker,S.L.. Thiazolidinedione use and cancer incidence in type 2 diabetes: A systematic review and meta-analysis. Diabetes and Metabolism.38 (6) (pp 475-484), 2012.Date of Publication: December 2012. 2012;(6):475-84. | Systematic review- included studies appraised individually |
| 25 | Corrao,G., Romio,S.A., Zambon,A., Merlino,L., Bosi,E.. Multiple outcomes associated with the use of metformin and sulphonylureas in type 2 diabetes: a population-based cohort study in Italy. European Journal of Clinical Pharmacology 2011;67(3):289-9 | Not a prospective cohort design |
| 26 | Duckworth,W., Abraira,C., Moritz,T., Reda,D., Emanuele,N., Reaven,P.D., et al. Glucose control and vascular complications in veterans with type 2 diabetes. New England Journal of Medicine 2009;360(2):129-39. | Rosiglitazone |
| 27 | Ekstrom,N., Schioler,L., Svensson,A.M., Eeg-Olofsson,K., Miao,Jonasson J., Zethelius,B., et al. Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish Nat | Not a prospective cohort design |
| 28 | Eliasson,B., Eeg-Olofsson,K., Cederholm,J., Nilsson,P.M., Gudbjornsdottir,S.. Antihyperglycaemic treatment of type 2 diabetes: results from a national diabetes register. Diabetes & Metabolism 2007;33(4):269-76. | Relevant outcomes not reported |
| 29 | Evans,J.M., Ogston,S.A., Emslie-Smith,A.. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 2006;49(5):930-36. | Not a prospective cohort design |
| 30 | Evans,J.M., Ogston,S.A., Reimann,F., Gribble,F.M., Morris,A.D.. No differences in mortality between users of pancreatic-specific and non-pancreatic-specific sulphonylureas: a cohort analysis. Diabetes, Obesity & Metabolism 2008;10(4):350-52. | Not a prospective cohort design |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 31 | Evans,J.M., Doney,A.S., AlZadjali,M.A., Ogston,S.A., Petrie,J.R., Morris,A.D., et al. Effect of Metformin on mortality in patients with heart failure and type 2 diabetes mellitus. American Journal of Cardiology 2010;106(7):1006-10. | Not a prospective cohort design |
| 32 | Fisman,E.Z., Tenenbaum,A., Benderly,M., Goldbourt,U., Behar,S.. Antihyperglycemic treatment in diabetics with coronary disease: increased metformin-associated mortality over a 5-year follow-up. Cardiology 1999;91(3):195-202. | Not a prospective cohort design |
| 33 | Fu,A.Z., Qiu,Y., Radican,L., Yin,D.D.. Pre-existing cardiovascular diseases and glycemic control in patients with type 2 diabetes mellitus in Europe: A matched cohort study. Cardiovascular Diabetology.9 , 2010.Article Number: 15.Date of Publication: | Relevant outcomes not reported |
| 34 | Fu,A.Z., Qiu,Y., Radican,L., Yin,D.D.. Impact of concurrent macrovascular co-morbidities on healthcare utilization in patients with type 2 diabetes in Europe: a matched study. Diabetes, Obesity & Metabolism 2010;12(7):631-37. | Not a prospective cohort design |
| 35 | Gapstur,S.M., Patel,A.V., Diver,W.R., Hildebrand,J.S., Gaudet,M.M., Jacobs,E.J.. Type II diabetes mellitus and the incidence of epithelial ovarian cancer in the cancer prevention study-II nutrition cohort. Cancer Epidemiology Biomarkers and Prevent | Insufficient sample size |
| 36 | Gerstein,H.C., Bosch,J., Dagenais,G.R., D¡az,R., Jung,H., Maggioni,A.P., et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. The New England journal of medicine 2012;367(4):319-28. | Mixed population with no subgroup analysis of the TTD cohort |
| 37 | Goldberg,R.B., Temprosa,M., Haffner,S., Orchard,T.J., Ratner,R.E., Fowler,S.E., et al. Effect of progression from impaired glucose tolerance to diabetes on cardiovascular risk factors and its amelioration by lifestyle and metformin intervention: the | Not a type two diabetes population |
| 38 | Gosmanova,E.O., Canada,R.B., Mangold,T.A., Rawls,W.N.. Effect of metformin-containing antidiabetic regimens on all-cause mortality in veterans with type 2 diabetes mellitus. American Journal of the Medical Sciences 2008;336(3):241-47. | Not a prospective cohort design |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 39 | Gu,Y., Wang,C., Zheng,Y., Hou,X., Mo,Y., Yu,W., et al. Cancer incidence and mortality in patients with type 2 diabetes treated with human insulin: a cohort study in shanghai. PLoS ONE [Electronic Resource] 2013;8(1):e53411. | Not a prospective cohort design |
| 40 | Gulliford,M.. Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study. Diabetes/Metabolism Research Reviews 2004;20(3):239-45. | Not a prospective cohort design |
| 41 | Hense,H.-W., Kajuter,H., Wellmann,J.. Cancer incidence in type 2 diabetes patients - First results from a feasibility study of the D2C cohort. Diabetology and Metabolic Syndrome.3 (1) , 2011.Article Number: 15.Date of Publication: 2011. 2011;(1):n. pa | Not a prospective cohort design |
| 42 | Holman,R.R., Cull,C.A., Fox,C.. United Kingdom prospective diabetes study (UKPDS) 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three | Relevant outcomes not reported |
| 43 | Hong,J.S.. Relationship between oral antihyperglycemic medication adherence and hospitalization, mortality, and healthcare costs in adult ambulatory care patients with type 2 diabetes in South Korea. Medical Care.49 (4) (pp 378-384), 2011.Date of Public | Not a prospective cohort design |
| 44 | Horsdal,H.T., Johnsen,S.P., Sondergaard,F.. Type of preadmission glucose-lowering treatment and prognosis among patients hospitalised with myocardial infarction: a nationwide follow-up study. Diabetologia 2008;51(4):567-74. | Insufficient follow up |
| 45 | Horsdal,H.T., Johnsen,S.P., Sondergaard,F., Jacobsen,J., Thomsen,R.W., Schmitz,O., Sorensen,H.T.. Sulfonylureas and prognosis after myocardial infarction in patients with diabetes: a population-based follow-up study. Diabetes/Metabolism Research R | Insufficient follow up |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 46 | Horsdal,H.T., Mehnert,F., Rungby,J.. Type of preadmission antidiabetic treatment and outcome among patients with ischemic stroke: a nationwide follow-up study. Journal of Stroke & Cerebrovascular Diseases 2012;21(8):717-25. | Not a prospective cohort design |
| 47 | Hsu,C.C., Wahlqvist,M.L., Lee,M.S.. Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin. Journal of Alzheimer's Disease 2011;24(3):485-93. | Not a prospective cohort design |
| 48 | Huang,E.S., Liu,J.Y., Moffet,H.H., John,P.M.. Glycemic control, complications, and death in older diabetic patients: The diabetes and aging study. Diabetes Care.34 (6) (pp 1329-1336), 2011.Date of Publication: June 2011. 2011;(6):1329-36. | Not a prospective cohort design |
| 49 | Huerta,C. & Zhao,S.Z.. Risk of acute liver injury in patients with diabetes. Pharmacotherapy.22 (9 I) (pp 1091-1096), 2002.Date of Publication: September 2002. 2002;(9 I):1091-96. | Not a prospective cohort design |
| 50 | Hung,Y.-J., Kuo,S.-W., Wang,C.-H., Chang,H.-Y., Hsieh,S.-H.. Postmarketing surveillance of acarbose treatment in Taiwanese patients with type 2 diabetes mellitus. Clinical Drug Investigation.26 (10) (pp 559-565), 2006.Date of Publication: 2006. 2006 | Insufficient follow up |
| 51 | Jain,R. & Kabadi,U.. Is beta-cell failure in type 2 diabetes mellitus reversible? International Journal Of Diabetes In Developing Countries 2008;28(1):1-5. | Relevant outcomes not reported |
| 52 | Johannes,C.B., Koro,C.E., Quinn,S.G., Cutone,J.A.. The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metforming and sulfonylurea therapy. Pharmacoepidemiology and Drug Safety.16 (5) (pp 504-512), | Not a prospective cohort design |
| 53 | Johnson,J.A., Majumdar,S.R., Simpson,S.H.. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 2002;25(12):2244-48. | Not a prospective cohort design |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 54 | Jones,C.D., Greenwood,R.H., Misra,A.. Incidence and progression of diabetic retinopathy during 17 years of a population-based screening program in England. Diabetes Care.35 (3) (pp 592-596), 2012.Date of Publication: March 2012. 2012;(3):592-96. | Exposure to pharmacological therapy not reported |
| 55 | Jorgensen,C.H., Gislason,G.H., Andersson,C., Ahlehoff,O., Charlot,M., Schramm,T.K., et al. Effects of oral glucose-lowering drugs on long term outcomes in patients with diabetes mellitus following myocardial infarction not treated with emergent perc | Not a prospective cohort design |
| 56 | Juhaeri,J. & Gao,S.. Incidence rates of heart failure, stroke, and acute myocardial infarction among Type 2 diabetic patients using insulin glargine and other insulin. Pharmacoepidemiology & Drug Safety 2009;18(6):497-503. | Not a prospective cohort design |
| 57 | Kawaguchi,T., Taniguchi,E., Morita,Y., Shirachi,M., Tateishi,I., Nagata,E.. Association of exogenous insulin or sulphonylurea treatment with an increased incidence of hepatoma in patients with hepatitis C virus infection. Liver International 2010;3 | Not a prospective cohort design |
| 58 | Kolb,H., Schneider,B., Heinemann,L., Lodwig,V., Scherbaum,W.A.. Altered disease course after initiation of self-monitoring of blood glucose in noninsulin-treated type 2 diabetes (ROSSO 3). Journal of Diabetes Science & Technology 2007;1(4):487-95. | Not a prospective cohort design |
| 59 | Koro,C. & Barrett,S.. Cancer risks in thiazolidinedione users compared to other anti-diabetic agents. Pharmacoepidemiology and Drug Safety.16 (5) (pp 485-492), 2007.Date of Publication: May 2007. 2007;(5):485-92. | Not a prospective cohort design |
| 60 | Koro,C.E. & Bowlin,S.J.. Antidiabetic therapy and the risk of heart failure in type 2 diabetic patients: an independent effect or confounding by indication. Pharmacoepidemiology & Drug Safety 2005;14(10):697-703. | Not a prospective cohort design |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 61 | Koro,C.E. & Fu,Q.. An assessment of the effect of thiazolidinedione exposure on the risk of myocardial infarction in type 2 diabetic patients. Pharmacoepidemiology and Drug Safety.17 (10) (pp 989-996), 2008.Date of Publication: 2008. 2008;(10):989-96. | Not a prospective cohort design |
| 62 | Lachin,J.M., Viberti,G., Zinman,B., Haffner,S.M., Aftring,R.P., Paul,G., et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of The American Society of Nephrology: CJASN 2011;6(5):1032 | Rosiglitazone |
| 63 | Leblond,J., Pilon,D., Beaudette,C.-P.. Predictors of nonpersistence with thiazolidinediones in patients with type 2 diabetes. Canadian Journal of Diabetes.29 (2) (pp 95-101), 2005.Date of Publication: 2005. 2005;(2):95-101. | Relevant outcomes not reported |
| 64 | Lee,M.-S., Hsu,C.-C., Wahlqvist,M.L., Tsai,H.-N., Chang,Y.-H.. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: A representative population prospective cohort study of 800,000 ind | Not a prospective cohort design |
| 65 | Liebl,A., Jones,S., Goday,A., Benroubi,M., Castell,C., Haupt,A., Nicolay,C.. Clinical Outcomes After Insulin Initiation in Patients with Type 2 Diabetes: 24-Month Results from INSTIGATE. Diabetes Therapy Research, Treatment and Education of Diabet | Relevant outcomes not reported |
| 66 | Magliano,D.J., Davis,W.A., Shaw,J.E., Bruce,D.G.. Incidence and predictors of all-cause and site-specific cancer in type 2 diabetes: The Fremantle Diabetes Study. European Journal of Endocrinology.167 (4) (pp 589-599), 2012.Date of Publication: Octob | Exposure to pharmacological therapy not reported |
| 67 | Matthews,D.R., Cull,C.A., Stratton,I.M., Holman,R.R.. UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabetic medicine : a journal of the British Diabetic Associ | Relevant outcomes not reported |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 68 | Nichols,G.A. & Koo,Y.H.. Delay of insulin addition to oral combination therapy despite inadequate glycemic control: Delay of insulin therapy. Journal of General Internal Medicine.22 (4) (pp 453-458), 2007.Date of Publication: April 2007. 2007;(4):453-5 | Relevant outcomes not reported |
| 69 | Nichols,G.A. & Vupputuri,S.. Change in high-density lipoprotein cholesterol and risk of subsequent hospitalization for coronary artery disease or stroke among patients with type 2 diabetes mellitus. American Journal of Cardiology.108 (8) (pp 1124-1128) | Not a prospective cohort design |
| 70 | Palmer,A.J. & Sendi,P.P.. Applying some UK Prospective Diabetes Study results to Switzerland: the cost-effectiveness of intensive glycaemic control with metformin versus conventional control in overweight patients with type-2 diabetes. Schweizerische M | Not a prospective cohort design |
| 71 | Pan,C.-Y.. Post-marketing surveillance of acarbose treatment in patients with type 2 diabetes mellitus and subjects with impaired glucose tolerance in China. Clinical Drug Investigation.27 (6) (pp 397-405), 2007.Date of Publication: 2007. 2007;(6):397-4 | Insufficient follow up |
| 72 | Penfornis,A., Bourdel-Marchasson,I., Quere,S.. Real-life comparison of DPP4-inhibitors with conventional oral antidiabetics as add-on therapy to metformin in elderly patients with type 2 diabetes: The HYPOCRAS study. Diabetes & Metabolism 2012;38(6):5 | Insufficient follow up |
| 73 | Redaniel,M.T., Jeffreys,M., May,M.T., Ben-Shlomo,Y.. Associations of type 2 diabetes and diabetes treatment with breast cancer risk and mortality: a population-based cohort study among British women. Cancer Causes & Control 2012;23(11):1785-95. | Exposure to pharmacological therapy not reported |
| 74 | Roumie,C.L., Hung,A.M., Greevy,R.A., Grijalva,C.G., Liu,X., Murff,H.J., Elasy,T.A.. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study.[Summary for patients in An | Not a prospective cohort design |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 75 | Scheen,A.J.. [Proactive study: secondary cardiovascular prevention with pioglitazione in type 2 diabetic patients]. Revue m,dicale de LiŠge 2005;60(11):896-901. | Not in English |
| 76 | Seck,T., Nauck,M., Sheng,D., Sunga,S., Davies,M.J., Stein,P.P., Kaufman,K.D.. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: A 2-year study. International Journ | Included as part of pharamcological therapy |
| 77 | Sejil,S., Janand-Delenne,B., Avierinos,J.-F., Habib,G., Labastie,N., Raccah,D., Vague,P.. Six-year follow-up of a cohort of 203 patients with diabetes after screening for silent myocardial ischaemia. Diabetic Medicine.23 (11) (pp 1186-1191), 2006. | Exposure to pharmacological therapy not reported |
| 78 | Shapiro,M.S. & Abrams,Z.. Clinical experience with repaglinide in patients with non-insulin-dependent diabetes mellitus. Israel Medical Association Journal.7 (2) (pp 75-77), 2005.Date of Publication: February 2005. 2005;(2):75-77. | Insufficient follow up |
| 79 | Shenolikar,R.A., Balkrishnan,R., Camacho,F.T., Whitmire,J.T.. Comparison of medication adherence and associated health care costs after introduction of pioglitazone treatment in African Americans versus all other races in patients with type 2 diabetes | Not a prospective cohort design |
| 80 | Sullivan,S.D., Alfonso-Cristancho,R., Conner,C., Hammer,M.. A simulation of the comparative long-term effectiveness of liraglutide and glimepiride monotherapies in patients with type 2 diabetes mellitus. Pharmacotherapy 2009;29(11):1280-88. | Insufficient follow up |
| 81 | Tschope,D., Bramlage,P., Binz,C., Krekler,M., Plate,T., Deeg,E.. Antidiabetic pharmacotherapy and anamnestic hypoglycemia in a large cohort of type 2 diabetic patients - an analysis of the DiaRegis registry. Cardiovascular Diabetology.10 , 2011.Art | Relevant outcomes not reported |
| 82 | . Benign prostatic hyperplasia is a significant risk factor for bladder cancer in diabetic patients: a population-based cohort study using the National Health Insurance in Taiwan. BMC Cancer 2013;13():7. | Not a prospective cohort design |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 83 | Turner,R. & Cull,C.. United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Annals of Internal Medicine 19 | Longer follow-up available and included |
| 84 | Turner,R., Murchison,L., Wright,A.D., Oakley,N., Kohner,E., Hayes,R., et al. United Kingdom prospective diabetes study 24: A 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed | Relevant outcomes not reported |
| 85 | Turner,R.C., Cull,C.A., Frighi,V.. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA | Relevant outcomes not reported |
| 86 | Ved,P.. Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over 3 months in patients with type 2 diabetes mellitus. Indian Journal of Endocrinology and Metabolism 2012;16():Suppl-3. | Relevant outcomes not reported |
| 87 | Wahlqvist,M.L., Lee,M.S., Chuang,S.Y., Hsu,C.C., Tsai,H.N., Yu,S.H.. Increased risk of affective disorders in type 2 diabetes is minimized by sulfonylurea and metformin combination: a population-based cohort study. BMC Medicine 2012;10():150. | Not a prospective cohort design |
| 88 | Wahlqvist,M.L., Lee,M.-S., Hsu,C.-C., Chuang,S.-Y., Lee,J.-T.. Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease occurring with Type 2 diabetes in a Taiwanese population cohort. Parkinsonism and Related Disorders.18 (6 | Not a prospective cohort design |
| 89 | Wenten,M., Gaebler,J.A., Hussein,M., Pelletier,E.M., Smith,D.B., Girase,P., et al. Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: A follow-up study. Diabetic Medicine.29 (11) | Not a prospective cohort design |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 90 | Wertz,D.A., Chang,C.-L., Sarawate,C.A., Willey,V.J., Cziraky,M.J.. Risk of cardiovascular events and all-cause mortality in patients treated with thiazolidinediones in a managed-care population. Circulation: Cardiovascular Quality and Outcomes.3 (5) | Not a prospective cohort design |
| 91 | Yang,X., So,W.Y., Ma,R.C.W., Yu,L.W.Y., Ko,G.T.C., Kong,A.P.S., et al. Use of sulphonylurea and cancer in type 2 diabetes-The Hong Kong Diabetes Registry. Diabetes Research and Clinical Practice.90 (3) (pp 343-351), 2010.Date of Publication: Decemb | Not a prospective cohort design |
| 92 | Alavudeen,S.S., Dhanapal,C.K., Khan,N.A., Al Akhali,K.M.. Prevalence and control of cardiovascular risk factors among type 2 diabetes mellitus patients in southern region of Saudi Arabia. Journal of Young Pharmacists.5 (4) (pp 144-147), 2013.Date of | Not a prospective cohort design |
| 93 | Althouse,A.D., Abbott,J.D., Forker,A.D., Bertolet,M., Barinas-Mitchell,E., Thurston,R.C., et al. Risk factors for incident peripheral arterial disease in type 2 diabetes: Results from the bypass angioplasty revascularization investigation in type 2 | Rosiglitazone |
| 94 | An,S.-Y., Kim,H.J., Chun,K.H., Kim,T.H., Jeon,J.Y., Kim,D.J., et al. Clinical and economic outcomes in medication-adherent and -nonadherent patients with type 2 diabetes mellitus in the republic of Korea. Clinical Therapeutics.36 (2) (pp 245-254), | Not a prospective cohort design |
| 95 | Assael,B.M., Kronfeld,K., Honer,M., Holl,R.W., Staden,U., Classen,M., et al. Open randomised prospective comparative multi-centre intervention study of patients with Cystic fibrosis and early diagnosed diabetes mellitus. BMC Pediatrics.14 (1) , 201 | Abstract/study protocol |
| 96 | Banerjee,D., Leong,W.B., Arora,T., Nolen,M., Punamiya,V., Grunstein,R.. The potential association between obstructive sleep apnea and diabetic retinopathy in severe obesity - The role of hypoxemia. PLoS ONE.8 (11) , 2013.Article Number: e79521.Date | Exposure to pharmacological therapy not reported |
| 97 | Blaslov,K., Zibar,K., Bulum,T.. Relationship of vascular complications and exenatide therapy failure in type 2 diabetic patients. Acta Clinica Croatica 2013;52(3):328-36. | Not a prospective cohort design |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 98 | Bray,G.A., Smith,S.R., Banerji,M.A., Tripathy,D., Clement,S.C., Buchanan,T.A., et al. Effect of pioglitazone on body composition and bone density in subjects with prediabetes in the ACT NOW trial. Diabetes, Obesity & Metabolism 2013;15(10):931-37. | Not a type two diabetes population |
| 99 | Cho,Y.N., Lee,K.O., Jeong,J., Park,H.J., Kim,S.-M., Shin,H.Y., et al. The role of insulin resistance in diabetic neuropathy in Koreans with type 2 diabetes mellitus: A 6-year follow-up study. Yonsei Medical Journal.55 (3) (pp 700-708), 2014.Date of | Comparison not relevant |
| 100 | Choi,S.B., Lee,J.H., Lee,J.H., Kim,S., Han,S.D., Kim,I.H.. Improvement of beta-cell function after achievement of optimal glycaemic control via long-term continuous subcutaneous insulin infusion therapy in non-newly diagnosed type 2 diabetic patient | Not a prospective cohort design |
| 101 | Faillie,J.-L., Azoulay,L., Patenaude,V., Hillaire-Buys,D.. Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: Cohort study. BMJ (Online).348 , 2014.Article Number: g2780.Date of Publication: 25 Apr 2014. 2014;(Onlin | Not a prospective cohort design |
| 102 | Garcia,De La Torre, Duran,A., Del,Valle L., Fuentes,M., Barca,I., Martin,P., et al. Early management of type 2 diabetes based on an SMBG strategy: The way to diabetes regression-the St. Carlos study: A 3-year, prospective, randomized, clinic-based, | Abstract/study protocol |
| 103 | Hancu,N., Czupryniak,L., Genestin,E.. A pan-European and Canadian prospective survey to evaluate patient satisfaction with the SoloSTAR insulin injection device in Type 1 and Type 2 diabetes. Diabetes Technology and Therapeutics.15 (SUPPL.1) (pp S51), | Abstract/study protocol |
| 104 | Hong,J.-S.. Relationship between continuity of ambulatory care and medication adherence in adult patients with type 2 diabetes in Korea: A longitudinal analysis. Medical Care.52 (5) (pp 446-453), 2014.Date of Publication: May 2014. 2014;(5):446-53. | Not a prospective cohort design |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 105 | Ioacara,S., Guja,C., Ionescu-Tirgoviste,C., Fica,S.. Cancer specific mortality in insulin-treated type 2 diabetes patients. PLoS ONE.9 (3) , 2014.Article Number: e93132.Date of Publication: 25 Mar 2014. 2014;(3):n. pag.. | Not a prospective cohort design |
| 106 | Li,J., Zhang,H., Yan,L., Xie,M.. Fracture is additionally attributed to hyperhomocysteinemia in men and premenopausal women with type 2 diabetes. Journal of Diabetes Investigation.5 (2) (pp 236-241), 2014.Date of Publication: March 2014. 2014;(2):236 | Not a prospective cohort design |
| 107 | Li,L., Shen,J., Bala,M.M., Busse,J.W., Ebrahim,S., Vandvik,P.O., et al. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: Systematic review and meta-analysis of randomised and non-randomised studies. BMJ (Online | Systematic review- included studies appraised individually |
| 108 | Lin,H.-C., Kachingwe,B.H., Lin,H.-L., Cheng,H.W., Uang,Y.-S.. Effects of metformin dose on cancer risk reduction in patients with type 2 diabetes mellitus: A 6-year follow-up study. Pharmacotherapy.34 (1) (pp 36-45), 2014.Date of Publication: Januar | Not a prospective cohort design |
| 109 | Malin,S.K., Samat,A., Wolski,K., Abood,B., Pothier,C.E., Bhatt,D.L., et al. Improved acylated ghrelin suppression at 2 years in obese patients with type 2 diabetes: Effects of bariatric surgery vs standard medical therapy. International Journal of | Exposure to pharmacological therapy not reported |
| 110 | Onitilo,A.A., Donald,M., Stankowski,R.V., Engel,J.M., Williams,G.. Breast and prostate cancer survivors in a diabetic cohort: Results from the living with diabetes study. Clinical Medicine and Research.11 (4) (pp 210-218), 2013.Date of Publication: | Not a prospective cohort design |
| 111 | Pols-Vijlbrief,R., Dekker,J.M., Stehouwer,C.D., de Boer,M.R., Nijpels,G., Snoek,F.J.. Symptom burden and its association with change in glucose metabolism status over a 7-year period: The Hoorn Study. Diabetic Medicine.31 (6) (pp 747-753), 2014.Dat | Exposure to pharmacological therapy not reported |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 112 | Roussel,R., Hadjadj,S., Pasquet,B., Wilson,P.W., Smith,S.C.,Jr., Goto,S., et al. Thiazolidinedione use is not associated with worse cardiovascular outcomes: a study in 28,332 high risk patients with diabetes in routine clinical practice: brief title | Rosiglitazone |
| 113 | Vujasinovic,M., Zaletel,J., Tepes,B., Popic,B., Makuc,J., Epsek,Lenart M., Predikaka,M.. Low prevalence of exocrine pancreatic insufficiency in patients with diabetes mellitus. Pancreatology 2013;13(4):343-46. | Not a prospective cohort design |

## L.3 Review Question 3: What are the optimal target values for HbA1c, fasting blood glucose and post prandial blood glucose in people with type 2 diabetes?

## L.4 Review Question 4: Should intensive or conventional target values be used to control blood glucose levels in people with type 2 diabetes?

**Table 3: Excluded studies of full text papers**

| Number | Reference | Reason for exclusion |
|---|---|---|
| 1 | Abraira C, Emanuele N, Colwell J et al. (1992) Glycemic control and complications in type II diabetes. Design of a feasibility trial. VA CS Group (CSDM). Diabetes Care 15: 1560-71 | trial protocol |
| 2 | Abraira C, Colwell JA, Nuttall FQ et al. (1995) Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes. Diabetes Care 18: 1113-23 | feasibility study |
| 3 | Abraira C, Colwell J, Nuttall F et al. (1997) Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes. Archives of Internal Medicine 157: 181-8 | feasibility study |
| 4 | Abraira C, Henderson WG, Colwell JA et al. (1998) Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM). Diabetes Care 21: 574-9 | feasibility study |
| 5 | Abraira C, Duckworth WC, Moritz T et al. (2009) Glycaemic separation and risk factor control in the Veterans Affairs Diabetes Trial: an interim report. Diabetes, Obesity & Metabolism 11: 150-6 | interim report |
| 6 | ACCORD Study Group, Buse JB, Bigger JT et al. (2007) Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. American Journal of Cardiology 99: 21i-33i | study protocol |
| 7 | Adler AI, Erqou S, Lima TA et al. (2010) Association between glycated haemoglobin and the risk of lower extremity amputation in patients with diabetes mellitus-review and meta-analysis. [Review] [56 refs]. Diabetologia 53: 840-9 | Review |
| 8 | Agrawal L, Emanuele NV, Abraira C et al. (1998) Ethnic differences in the glycemic response to exogenous insulin treatment in the Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus (VA CSDM). Diabetes Care 21: 510-5 | Subgroup analysis |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 9 | Aguilar D, Bozkurt B, Ramasubbu K et al. (2009) Relationship of hemoglobin A1C and mortality in heart failure patients with diabetes. Journal of the American College of Cardiology 54: 422-8 | Retrospective cohort |
| 10 | Anderson RT, Narayan KM, Feeney P et al. (2011) Effect of intensive glycemic lowering on health-related quality of life in type 2 diabetes: ACCORD trial. Diabetes Care 34: 807-12 | No relevant outcomes |
| 11 | Andersson C, Van GL, Caterson ID et al. (2012) Relationship between HbA1c levels and risk of cardiovascular adverse outcomes and all-cause mortality in overweight and obese cardiovascular high-risk women and men with type 2 diabetes. Diabetologia 55: 2348-55 | Post hoc analysis |
| 12 | Bagg W, Whalley GA, Gamble G et al. (2001) Effects of improved glycaemic control on endothelial function in patients with type 2 diabetes. Internal Medicine Journal 31: 322-8 | No relevant outcomes |
| 13 | Balkau B, Simon D (2010) Survival in people with type 2 diabetes as a function of HbA1c. The Lancet 375: 438-40 | Review |
| 14 | Bonds DE, Kurashige EM, Bergenstal R et al. (2007) Severe hypoglycemia monitoring and risk management procedures in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology 99: 80i-9i | study protocol |
| 15 | Bonds DE, Miller ME, Bergenstal RM et al. (2010) The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 340: b4909 | Retrospective cohort |
| 16 | Brinchmann-Hansen O, Dahl-Jørgensen K, Sandvik L et al. (1992) Blood glucose concentrations and progression of diabetic retinopathy: the seven year results of the Oslo study. BMJ (Clinical research ed.) 304: 19-22 | Wrong population - type 1 diabetes |
| 17 | Brito JP, Montori VM (2012) Intensive BP control and/or glucose control did not reduce microvascular events in hypertensive type 2 diabetes. Annals of Internal Medicine 157: JC4-JC7 | Review |
| 18 | Brocco E, Velussi M, Cernigoi AM et al. (2001) Evidence of a threshold value of glycated hemoglobin to improve the course of renal function in type 2 diabetes with typical diabetic glomerulopathy. Journal of Nephrology 14: 461-71 | No relevant outcomes |
| 19 | Brown A, Reynolds LR, Bruemmer D (2010) Intensive glycemic control and cardiovascular disease: an update. [Review]. Nature Reviews Cardiology 7: 369-75 | Review |
| 20 | Brown SH, Abdelhafiz AH (2009) Trials review: cardiovascular outcome with intensive glycemic control and implications for patients with type 2 diabetes (Structured abstract). Postgraduate Medicine 121: 31-41 | Review |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 21 | Cavalot F, Petrelli A, Traversa M et al. (2006) Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. Journal of Clinical Endocrinology & Metabolism 91: 813-9 | Not prospective cohort design |
| 22 | Chalmers J (2003) [ADVANCE study: objectives, design and current status]. Drugs 63 Spec No 1: 39-44 | Not in English |
| 23 | Chalmers J, Perkovic V, Joshi R et al. (2006) ADVANCE: breaking new ground in type 2 diabetes. Journal of Hypertension - Supplement 24: S22-S28 | Review |
| 24 | Chalmers J, Kengne AP, Joshi R et al. (2007) New insights from ADVANCE. [Review] [44 refs]. Journal of Hypertension - Supplement 25: S23-S30 | Review |
| 25 | Charles M, Ejskjaer N, Witte DR et al. (2009) Neuropathy in a population with screen-detected type 2 diabetes. Journal of the Peripheral Nervous System 14: 254-5 | Abstract |
| 26 | Chen J, Alemao E, Yin D et al. (2008) Development of a diabetes treatment simulation model: with application to assessing alternative treatment intensification strategies on survival and diabetes-related complications. Diabetes, Obesity & Metabolism 10: Suppl-42 | Health economics |
| 27 | Chew EY, Ambrosius WT, Howard LT et al. (2007) Rationale, design, and methods of the Action to Control Cardiovascular Risk in Diabetes Eye Study (ACCORD-EYE). American Journal of Cardiology 99: 103i-11i | study protocol |

## L.5 Review Question 5: Should self-monitoring be used to manage blood glucose levels in people with type 2 diabetes?

**Table 4: Excluded studies of full text papers**

| Number | Reference | Reason for exclusion |
|---|---|---|
| 1 | Allemann,S., Houriet,C., Diem,P., Stettler,C.. Self-monitoring of blood glucose in non-insulin treated patients with type 2 diabetes: a systematic review and meta-analysis. Current Medical Research & Opinion 2009;25(12):2903-13. | Systematic review |
| 2 | Balk,E., Teplinsky,E., Trikalinos,T., Chew,P., Chung,M., Lau,J., Pittas,A.. Applicability of the evidence regarding intensive glycemic control and self-monitored blood glucose to Medicare patients with Type 2 diabetes (Structured abstract). Health | Not full paper or insufficient data to extract |
| 3 | Bennion,N., Christensen,N.K., McGarraugh,G.. Alternate site glucose testing: a crossover design. Diabetes Technology & Therapeutics 2002;4(1):25-33. | Focus on correlation between different blood glucose measures |
| 4 | Bergenstal,R.M., Anderson,R.L., Bina,D.M., Johnson,M.L., Davidson,J.L., Solarz-Johnson,B., Kendall,D.M.. Impact of modem-transferred blood glucose data on clinician work efficiency and patient glycemic control. Diabetes Technology & Therapeutics 2 | Mixed population of type 1 and type 2 diabetes |
| 5 | Biermann,E., Dietrich,W., Standl,E.. Telecare of diabetic patients with intensified insulin therapy. A randomized clinical trial. Studies in health technology and informatics 2000;77:327-32. | Mixed population of type 1 and type 2 diabetes |
| 6 | Bujnowska-Fedak,M.M., Puchala,E., Steciwko,A.. The impact of telehome care on health status and quality of life among patients with diabetes in a primary care setting in Poland. Telemedicine Journal & E-Health 2011;17(3):153-63. | Mixed population of type 1 and type 2 diabetes |
| 7 | Chidum,E., Agbai,D., Fidelis,O., Teppany,S., Martina,R., Rian,E., et al. Self-monitoring of blood glucose improved glycaemic control and 10-year coronary heart disease risk profile of type 2 diabetic patients. Chinese Medical Journal 2011;124(2):16 | Control group stopped follow up after 3 months |
| 8 | Cho,J.H., Kwon,H.S., Kim,H.S., Oh,J.A., Yoon,K.H.. Effects on diabetes management of a health-care provider mediated, remote coaching system via a PDA-type glucometer and the Internet. Journal of Telemedicine & Telecare 2011;17(7):365-70. | Not self-monitoring (i.e. testing not carried out by patient) |
| 9 | Clar,C., Barnard,K., Cummins,E., Royle,P., Waugh,N., Aberdeen Health Technology Assessment Group. Self-monitoring of blood glucose in type 2 diabetes: systematic review. Health Technology Assessment (Winchester, England) 2010;14(12):1-40. | Systematic review |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 10 | Cosson,E., Hamo-Tchatchouang,E., Dufaitre-Patouraux,L., Attali,J.R., Paries,J., Schaepelynck-Belicar,P.. Multicentre, randomised, controlled study of the impact of continuous sub-cutaneous glucose monitoring (GlucoDay) on glycaemic control in type 1 | Not focused on SMBG |
| 11 | Coster,S., Gulliford,M.C., Seed,P.T., Powrie,J.K., Swaminathan,R.. Monitoring blood glucose control in diabetes mellitus: a systematic review (Structured abstract). Health Technology Assessment 2000;4(12):1-93. | Systematic review |
| 12 | Dallosso,H.M., Eborall,H.C., Daly,H., Martin-Stacey,L., Speight,J., Realf,K., et al. Does self monitoring of blood glucose as opposed to urinalysis provide additional benefit in patients newly diagnosed with type 2 diabetes receiving structured educ | Protocol only |
| 13 | Davidson,M.B.. Evaluation of self monitoring of blood glucose in non-insulin-treated diabetic patients by randomized controlled trials: little bang for the buck. [Review]. Reviews on Recent Clinical Trials 2010;5(3):138-42. | Systematic review |
| 14 | Duran,A., Martin,P., Runkle,I., Perez,N., Abad,R., Fernandez,M., et al. Benefits of self-monitoring blood glucose in the management of new-onset Type 2 diabetes mellitus: the St Carlos Study, a prospective randomized clinic-based interventional stud | Not full paper or insufficient data to extract |
| 15 | Edelman,S.V., Bell,J.M., Serrano,R.B., Kelemen,D.. Home testing of fructosamine improves glycemic control in patients with diabetes. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinic | testing of fructosamine |
| 16 | Ehrhardt,N.M., Chellappa,M., Walker,M.S., Fonda,S.J., Vigersky,R.A.. The effect of real-time continuous glucose monitoring on glycemic control in patients with type 2 diabetes mellitus. Journal of Diabetes Science & Technology 2011;5(3):668-75. | Parent paper included and data extracted |
| 17 | Farmer,A., Wade,A., French,D.P., Goyder,E., Kinmonth,A.L., Neil,A.. The DiGEM trial protocol - A randomised controlled trial to determine the effect on glycaemic control of different strategies of blood glucose self-monitoring in people with type 2 | Protocol only |
| 18 | Farmer,A.. Meta-analysis: Self-monitoring in non-insulin-treated type 2 diabetes improved HbA1c by 0.25%. Annals of Internal Medicine.156 (12) (pp e486), 2012.Date of Publication: 19 Jun 2012. 2012;(12):e486. | Systematic review |
| 19 | Farmer,A.J., Heneghan,C., Barnett,A.H., Davidson,M.B., Guerci,B., O'Kane,M., et al. Individual patient data meta-analysis of trials of self-monitoring of blood glucose in non-insulin treated type 2 diabetes: protocol for a systematic review. Primar | Systematic review |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 20 | Farmer,A.J., Perera,R., Ward,A., Heneghan,C., Oke,J., Barnett,A.H., et al. Meta-analysis of individual patient data in randomised trials of self monitoring of blood glucose in people with non-insulin treated type 2 diabetes. BMJ 2012;344:e486. | Systematic review |
| 21 | Farmer,A.J., Wade,A.N., French,D.P., Simon,J., Yudkin,P., Gray,A., et al. Blood glucose self-monitoring in type 2 diabetes: a randomised controlled trial. Health Technology Assessment (Winchester, England) 2009;13(15):iii-iv. | Systematic review |
| 22 | Fisher,L., Polonsky,W., Parkin,C.G., Jelsovsky,Z., Amstutz,L., Wagner,R.S.. The impact of blood glucose monitoring on depression and distress in insulin-naive patients with type 2 diabetes. Current Medical Research & Opinion 2011;27:Suppl-46. | Parent paper included and data extracted |
| 23 | Fisher,L., Polonsky,W.H., Parkin,C.G., Jelsovsky,Z., Petersen,B., Wagner,R.S.. The impact of structured blood glucose testing on attitudes toward self-management among poorly controlled, insulin-naive patients with type 2 diabetes. Diabetes Researc | Parent paper included and data extracted |
| 24 | French,D.P., Wade,A.N., Yudkin,P., Neil,H.A., Kinmonth,A.L., Farmer,A.J.. Self-monitoring of blood glucose changed non-insulin-treated Type 2 diabetes patients' beliefs about diabetes and self-monitoring in a randomized trial. Diabetic Medicine 200 | Parent paper included and data extracted |
| 25 | Gallichan,M.J.. Self-monitoring by patients receiving oral hypoglycaemic agents: A survey and a comparative trial. PRACT DIABETES 1994;11(1):28-30. | testing of fructosamine |
| 26 | Gandhi,G.Y., Kovalaske,M., Kudva,Y., Walsh,K., Elamin,M.B., Beers,M., et al. Efficacy of continuous glucose monitoring in improving glycemic control and reducing hypoglycemia: a systematic review and meta-analysis of randomized trials. [Review]. Jo | Systematic review |
| 27 | Gerrald,K.R., Malone,R.M., Shilliday,B.B.. Clinical benefit of self-monitoring of blood glucose is uncertain for non-insulin-treated patients with type 2 diabetes. Clinical Diabetes.28 (3) (pp 121-123), 2010.Date of Publication: 2010. 2010;(3):121-23. | Systematic review |
| 28 | Goyder,E.. Should we stop patients with non-insulin treated diabetes using self monitoring of blood glucose? The implications of the Diabetes Glycaemic Education and Monitoring (DiGEM) trial. Primary care diabetes 2008;2(2):91-93. | Systematic review |
| 29 | Graziano,J.A. & Gross,C.R.. A randomized controlled trial of an automated telephone intervention to improve glycemic control in type 2 diabetes. Advances in Nursing Science 2009;32(3):E42-57. | Systematic review |
| 30 | Haupt,A., Berg,B., Paschen,P., Dreyer,M., H„ring,H.U., Smedegaard,J., et al. InDuo, a novel combined insulin injection and blood glucose monitoring device - effective and save as other devices, and patient preference. Experimental and clinical endo | Mixed population of type 1 and type 2 diabetes |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 31 | Hoskins,P.L., Alford,J.B., Handelsman,D.J., Yue,D.K., Turtle,J.R.. Comparison of different models of diabetes care on compliance with self-monitoring of blood glucose by memory glucometer. Diabetes Care 1988;11(9):719-24. | Mixed population of type 1 and type 2 diabetes |
| 32 | IQWiG. Urine and blood glucose self-measurement in diabetes mellitus type 2 (Structured abstract). Health Technology Assessment Database 2009;(3):n. pag.. | Systematic review |
| 33 | Istepanian,R.S., Zitouni,K., Harry,D., Moutosammy,N., Sungoor,A., Tang,B., Earle,K.A.. Evaluation of a mobile phone telemonitoring system for glycaemic control in patients with diabetes. Journal of Telemedicine & Telecare 2009;15(3):125-28. | Not full paper or insufficient data to extract |
| 34 | Ito,T., Kamoi,K., Minagawa,S., Kimura,K., Kobayashi,A.. Patient perceptions of different lancing sites for self-monitoring of blood glucose: a comparison of fingertip site with palm site using the OneTouch Ultra Blood Glucose Monitoring System. Jour | Mixed population of type 1 and type 2 diabetes |
| 35 | Jansen,J.P.. Self-monitoring of glucose in type 2 diabetes mellitus: a Bayesian meta-analysis of direct and indirect comparisons (Structured abstract). Current medical research and opinion 2006;22(4):671-81. | Not full paper or insufficient data to extract |
| 36 | John,A., Davis,W.A., Price,C.P., Davis,T.M.. The value of self-monitoring of blood glucose: a review of recent evidence (Structured abstract). Journal of diabetes and its complications 2010;24(2):129-41. | Not full paper or insufficient data to extract |
| 37 | Johnson,J.A., Majumdar,S.R., Bowker,S.L., Toth,E.L., Edwards,A.. Self-monitoring in Type 2 diabetes: a randomized trial of reimbursement policy. Diabetic Medicine 2006;23(11):1247-51. | Focus on availability/cost of SMBG |
| 38 | Jones,H., Edwards,L., Vallis,T.M., Ruggiero,L., Rossi,S.R., Rossi,J.S., et al. Changes in diabetes self-care behaviors make a difference in glycemic control: the Diabetes Stages of Change (DiSC) study. Diabetes Care 2003;26(3):732-37. | Not focused on SMBG |
| 39 | Kempe,K.C., Budd,D., Stern,M., Ellison,J.M., Saari,L.A., Adiletto,C.A., et al. Palm glucose readings compared with fingertip readings under steady and dynamic glycemic conditions, using the OneTouch Ultra Blood Glucose Monitoring System. Diabetes T | Mixed population of type 1 and type 2 diabetes |
| 40 | Kibriya,M.G., Ali,L., Banik,N.G., Azad Khan,A.K.. Home monitoring of blood glucose (HMBG) in Type-2 Diabetes mellitus in a developing country. Diabetes Research & Clinical Practice 1999;46(3):253-57. | Focus on availability/cost of SMBG |
| 41 | Kleefstra,N., Hortensius,J., van Hateren,K.J., Logtenberg,S.J., Houweling,S.T., Gans,R.O., Bilo,H.J.. Self-monitoring of blood glucose in noninsulin-treated type 2 diabetes: an overview. Diabetes, Metabolic Syndrome and Obesity Targets and Therapy | Systematic review |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 42 | Li,X., Zhou,Q., Zou,F., Wu,L., Chen,H., Liu,Z.. Effectiveness of systematic self-management education on blood sugar level of patients in the community with type 2 diabetes. [Chinese]. Journal of Central South University (Medical Sciences) 2012;37( | Not in English |
| 43 | Liang,X., Wang,Q., Yang,X., Cao,J., Chen,J., Mo,X., et al. Effect of mobile phone intervention for diabetes on glycaemic control: a meta-analysis. Diabetic Medicine 2011;28(4):455-63. | Systematic review |
| 44 | Lock,J.P., Szuts,E.Z., Malomo,K.J., Anagnostopoulos,A.. Whole-blood glucose testing at alternate sites: glucose values and hematocrit of capillary blood drawn from fingertip and forearm. Diabetes Care 2002;25(2):337-41. | Mixed population of type 1 and type 2 diabetes |
| 45 | Malanda,U.L., Bot,S.D., French,D.P., Kostense,P.J., Wade,A.N., Dekker,J.M., et al. Experience of hypoglycaemia is associated with changes in beliefs about diabetes in patients with type 2 diabetes. Diabetic Medicine 2011;28(11):1395-4000. | Prospective cohort analysis of DIGEM trial but data not analysed by randomised treatment group |
| 46 | Malanda,U.L., Bot,S.D., Kostense,P.J., Snoek,F.J., Dekker,J.M., Nijpels,G.. Effects of self-monitoring of glucose in non-insulin treated patients with type 2 diabetes: design of the IN CONTROL-trial. BMC Family Practice 2009;10:26. | Protocol only |
| 47 | Malanda,U.L., Welschen,L.M., Riphagen,I.I., Dekker,J.M., Nijpels,G., Bot,S.D.. Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin. [Review][Update of Cochrane Database Syst Rev. 2005;(2):CD005060; PM | Systematic review |
| 48 | McAndrew,L., Schneider,S.H., Burns,E., Leventhal,H.. Does patient blood glucose monitoring improve diabetes control? A systematic review of the literature. Diabetes Educator 1012;33(6):991-1011. | Systematic review |
| 49 | McIntosh,B., Yu,C., Lal,A., Chelak,K., Cameron,C., Singh,S.R., Dahl,M.. Efficacy of self-monitoring of blood glucose in patients with type 2 diabetes mellitus managed without insulin: a systematic review and meta-analysis. Open Medicine : A Peer-r | Systematic review |
| 50 | Miller,C.K., Gutschall,M.D., Holloman,C.. Self-monitoring predicts change in fiber intake and weight loss in adults with diabetes following an intervention regarding the glycemic index. Patient Education & Counseling 2009;76(2):213-19. | Not focused on SMBG |
| 51 | Mohan,V., Ravikumar,R., Poongothai,S., Amutha,A., Sowmya,S., Karkhuzali,K., Parkin,C.G.. A single-center, open, comparative study of the effect of using self-monitoring of blood glucose to guide therapy on preclinical atherosclerotic markers in typ | Not focused on self monitoring for blood glucose control |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 52 | Moreland,E.C., Volkening,L.K., Lawlor,M.T., Chalmers,K.A., Anderson,B.J., Laffel,L.M.B.. Use of a blood glucose monitoring manual to enhance monitoring adherence in adults with diabetes: A randomized controlled trial. Archives of Internal Medicine. | Mixed population of type 1 and type 2 diabetes |
| 53 | Nicolucci,A., Del,Prato S., Vespasiani,G., ELEONOR Study Group. Optimizing insulin glargine plus one injection of insulin glulisine in type 2 diabetes in the ELEONOR study: similar effects of telecare and conventional self-monitoring of blood glucose | Parent paper included and data extracted |
| 54 | Oh,J.A., Kim,H.S., Yoon,K.H., Choi,E.S.. A telephone-delivered intervention to improve glycemic control in type 2 diabetic patients. Yonsei medical journal 2003;44(1):1-8. | Unclear intervention in control group |
| 55 | Oria-Pino,A., Montero-P,rez,F.J., Luna-Morales,S., Campo-V zquez,P., S nchez-Guijo,P.. [Effectiveness and efficacy of self-measurement of capillary blood glucose in patients with type 2 diabetes mellitus]. Medicina cl¡nica 2006;126(19):728-35. | Not in English |
| 56 | Petitti,D.B., Contreras,R., Dudl,J.. Randomized trial of fructosamine home monitoring in patients with diabetes. Effective clinical practice : ECP 2001;4(1):18-23. | testing of fructosamine |
| 57 | Pignone,M.. Value of self-monitoring of blood glucose in non-insulin-using patients with type 2 diabetes. Clinical Diabetes.27 (1) (pp 17-18), 2009.Date of Publication: January 2009. 2009;(1):17-18. | Not full paper or insufficient data to extract |
| 58 | Polonsky,W., Fisher,L., Schikman,C., Hinnen,D., Parkin,C., Jelsovsky,Z., et al. The value of episodic, intensive blood glucose monitoring in non-insulin treated persons with Type 2 Diabetes: design of the Structured Testing Program (STeP) study, a c | Protocol only |
| 59 | Polonsky,W.H., Fisher,L., Schikman,C.H., Hinnen,D.A., Parkin,C.G., Jelsovsky,Z., et al. Structured self-monitoring of blood glucose significantly reduces A1C levels in poorly controlled, noninsulin-treated type 2 diabetes: results from the Structure | Parent paper included and data extracted |
| 60 | Poolsup,N., Suksomboon,N., Jiamsathit,W.. Systematic review of the benefits of self-monitoring of blood glucose on glycemic control in type 2 diabetes patients. Diabetes Technology and Therapeutics.10 (SUPPL.1) (pp S51-S66), 2008.Date of Publication: | Systematic review |
| 61 | Poolsup,N., Suksomboon,N., Rattanasookchit,S.. Meta-analysis of the benefits of self-monitoring of blood glucose on glycemic control in type 2 diabetes patients: an update. Diabetes Technology & Therapeutics 2009;11(12):775-84. | Systematic review |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 62 | Quinn,C.C., Clough,S.S., Minor,J.M., Lender,D., Okafor,M.C., Gruber-Baldini,A.. WellDoc mobile diabetes management randomized controlled trial: Change in clinical and behavioral outcomes and patient and physician satisfaction. Diabetes Technology a | Pilot study using WellDoc-full cluster RCT results available |
| 63 | Quinn,C.C., Gruber-Baldini,A.L., Shardell,M., Weed,K., Clough,S.S., Peeples,M., et al. Mobile diabetes intervention study: Testing a personalized treatment/behavioral communication intervention for blood glucose control. Contemporary Clinical Trial | Protocol only |
| 64 | Russell-Minda,E., Jutai,J., Speechley,M., Bradley,K., Chudyk,A., Petrella,R.. Health technologies for monitoring and managing diabetes: a systematic review. Journal of Diabetes Science & Technology 2009;3(6):1460-71. | Systematic review |
| 65 | Sarol,J.N., Nicodemus,N.A., Tan,K.M., Grava,M.B.. Self-monitoring of blood glucose as part of a multi-component therapy among non-insulin requiring type 2 diabetes patients: a meta-analysis (1966 - 2004) (Structured abstract). Current medical researc | Systematic review |
| 66 | Sarwat,S., Ilag,L.L., Carey,M.A., Shrom,D.S., Heine,R.J.. The relationship between self-monitored blood glucose values and glycated haemoglobin in insulin-treated patients with Type 2 diabetes. Diabetic Medicine 2010;27(5):589-92. | Focus on correlation between different blood glucose measures |
| 67 | Sevick,M.A., Korytkowski,M., Stone,R.A., Piraino,B., Ren,D., Sereika,S., et al. Biophysiologic outcomes of the Enhancing Adherence in Type 2 Diabetes (ENHANCE) trial. Journal of the Academy of Nutrition & Dietetics 2012;112(8):1147-57. | Head to head comparison of SMBG but focus on behavioural intervention |
| 68 | Shiraiwa,T., Takahara,M., Kaneto,H., Miyatsuka,T., Yamamoto,K., Yoshiuchi,K., et al. Efficacy of occasional self-monitoring of postprandial blood glucose levels in type 2 diabetic patients without insulin therapy. Diabetes Research & Clinical Pract | Not full paper or insufficient data to extract |
| 69 | Siebolds,M., Gaedeke,O., Schwedes,U.. Self-monitoring of blood glucose--psychological aspects relevant to changes in HbA1c in type 2 diabetic patients treated with diet or diet plus oral antidiabetic medication. Patient education and counseling 2006;6 | Parent paper included and data extracted |
| 70 | St,John A., Davis,W.A., Price,C.P., Davis,T.M.. The value of self-monitoring of blood glucose: a review of recent evidence. Journal of Diabetes & its Complications 2010;24(2):129-41. | Systematic review |
| 71 | Thielen,V., Scheen,A., Bringer,J., Renard,E.. Attempt to improve glucose control in type 2 diabetic patients by education about real-time glucose monitoring. Diabetes & Metabolism 2010;36(3):240-43. | Not full paper or insufficient data to extract |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 72 | Towfigh,A., Romanova,M., Weinreb,J.E., Munjas,B., Suttorp,M.J., Zhou,A., Shekelle,P.G.. Self-monitoring of blood glucose levels in patients with type 2 diabetes mellitus not taking insulin: a meta-analysis. American Journal of Managed Care 2008;14 | Systematic review |
| 73 | Ward,A.M., Heneghan,C., Perera,R., Lasserson,D., Nunan,D., Mant,D., Glasziou,P.. What are the basic self-monitoring components for cardiovascular risk management? BMC Medical Research Methodology 2010;10:105. | Systematic review |
| 74 | Welschen,L.M., Bloemendal,E., Nijpels,G., Dekker,J.M., Heine,R.J., Stalman,W.A., Bouter,L.M.. Self-monitoring of blood glucose in patients with type 2 diabetes who are not using insulin: a systematic review (Brief record). Diabetes Care 2005;28(6) | Not full paper or insufficient data to extract |
| 75 | Willett,L.R.. ACP Journal Club. Meta-analysis: self-monitoring in non-insulin-treated type 2 diabetes improved HbA1c by 0.25%. Annals of Internal Medicine 2012;156(12):JC6-12. | Systematic review |
| 76 | Yeh,H.-C., Brown,T.T., Maruthur,N., Ranasinghe,P., Berger,Z., Suh,Y.D., et al. Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: A systematic review and meta-analysis. Annals of Intern | Mixed population of type 1 and type 2 diabetes |
| 77 | Yoo,H.J., Park,M.S., Kim,T.N., Yang,S.J., Cho,G.J., Hwang,T.G., et al. A Ubiquitous Chronic Disease Care system using cellular phones and the internet. Diabetic Medicine 2009;26(6):628-35. | Not focused on SMBG |
| 78 | Zhang,D.A., Katznelson,L., Li,M.. Postprandial glucose monitoring further improved glycemia, lipids, and weight in persons with type 2 diabetes mellitus who had already reached hemoglobin A1c goal. Journal of Diabetes Science & Technology 2012;6(2):28 | Not available from the British Library |

| | |
|---|---|
| | |
| | |

*(a) <Insert Note here>*

## L.6 Review Question 6: Should aspirin and/ or clopidogrel be used for primary prevention of cardiovascular disease in people with type 2 diabetes?

**Table 5: Excluded studies of full text papers**

| Number | Reference | Reason for exclusion |
|---|---|---|
| 1 | Angiolillo,D.J., Capranzano,P., Desai,B., Shoemaker,S.B., Charlton,R., Zenni,M.M., et al. Impact of P2Y(12) inhibitory effects induced by clopidogrel on platelet procoagulant activity in type 2 diabetes mellitus patients. Thrombosis Research 2009;1 | Secondary prevention of CVD (some or all patients with CVD or unclear CVD status) |
| 2 | Anon. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: A randomized controlled trial (JAMA - Journal of the American Medical Association (2008) 300 18, (2134-2141)). JAMA - Journal of the American Medic | Parent paper included and data extracted |
| 3 | Azcona,L., L¢pez Farr,,A.J., Jim,nez Mateos-C ceres,P., Segura,A., Rodr¡guez,P., Modrego,J., et al. Impact of clopidogrel and aspirin treatment on the expression of proteins in platelets from type-2 diabetic patients with stable coronary ischemia. | No relevant outcomes reported |
| 4 | Belch,J., MacCuish,A., Campbell,I., Cobbe,S., Taylor,R., Prescott,R., et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: Factorial randomised placebo controlled trial of aspirin and antioxidants in patients with d | mixed population of type 1 and type 2 diabetes (no subgroup analysis) |
| 5 | Berardis,G., Sacco,M., Evangelista,V., Filippi,A., Giorda,C.B., Tognoni,G., et al. Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): Design of a randomized study of the efficacy of low-dose aspiri | Comparison with pharmacological intervention other than cloidogrel/aspirin/placebo |
| 6 | Berardis,G., Sacco,M., Strippoli,G.F., Pellegrini,F., Graziano,G., Tognoni,G., Nicolucci,A.. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials (Structured abstract). BMJ | review |
| 7 | Camargo,E.G., Pedrini,R.O., Gross,J.L., Camargo,J.L., Silveiro,S.P.. Lack of interference of aspirin in HbA1c measured by ion-exchange HPLC in type 2 diabetic patients: a randomized, double-blind, placebo-controlled study. Clinica Chimica Acta 2008; | Not full text paper |
| 8 | Camargo,E.G., Weinert,L.S., Lavinsky,J., Gross,J.L., Silveiro,S.P.. The effect of aspirin on the antiproteinuric properties of enalapril in microalbuminuric type 2 diabetic patients: a randomized, double-blind, placebo-controlled study. Diabetes Car | Not full text paper |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 9 | Dash,A., Maiti,R., Bandakkanavar,T.K., Bhaskar,A., Prakash,J., Pandey,B.L.. Prophylactic Add-on Antiplatelet Therapy in Chronic Kidney Disease With Type 2 Diabetes Mellitus: Comparison Between Clopidogrel and Low-dose Aspirin. International Journal | No relevant outcomes reported |
| 10 | de,Berardis G., Sacco,M., Evangelista,V., Filippi,A., Giorda,C.B., Tognoni,G., et al. Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose asp | Not full text paper |
| 11 | de,Berardis G., Sacco,M., Strippoli,G.F.M., Pellegrini,F., Graziano,G., Tognoni,G., Nicolucci,A.. Aspirin for primary prevention of cardiovascular events in people with diabetes: Meta-analysis of randomised controlled trials. BMJ.339 (7732) (pp 12 | review |
| 12 | Ferguson,A.D., Dokainish,H., Lakkis,N.. Aspirin and clopidogrel response variability: review of the published literature. Texas Heart Institute Journal 2008;35(3):313-20. | review |
| 13 | Ferreiro,J.L., Ueno,M., Desai,B., Capranzano,P., Capodanno,D., Angiolillo,D.J.. Impact of adjunctive cilostazol therapy versus high maintenance dose of clopidogrel in suboptimal responders with diabetes mellitus. Revista Espanola de Cardiologia 201 | Comparison with pharmacological intervention other than cloidogrel/aspirin/placebo |
| 14 | Goldfine,A.B., Fonseca,V., Jablonski,K.A., Pyle,L., Staten,M.A., Shoelson,S.E.. The effects of salsalate on glycemic control in patients with type 2 diabetes: A randomized trial. Annals of Internal Medicine.152 (6) (pp 346-357), 2010.Date of Public | Comparison with pharmacological intervention other than cloidogrel/aspirin/placebo |
| 15 | Gresele,P., Marzotti,S., Guglielmini,G., Momi,S., Giannini,S., Minuz,P., et al. Hyperglycemia-induced platelet activation in type 2 diabetes is resistant to aspirin but not to a nitric oxide-donating agent. Diabetes Care 2010;33(6):1262-68. | Secondary prevention of CVD (some or all patients with CVD or unclear CVD status) |
| 16 | Hovens,M.M., Snoep,J.D., Groeneveld,Y., Frolich,M., Tamsma,J.T., Huisman,M.V.. Effects of aspirin on serum C-reactive protein and interleukin-6 levels in patients with type 2 diabetes without cardiovascular disease: a randomized placebo-controlled c | No relevant outcomes reported |
| 17 | Kappagoda,C.T. & Amsterdam,E.A.. Trials of primary prevention of cardiovascular events using aspirin. American Journal of Cardiology.108 (8) (pp 1198), 2011.Date of Publication: 15 Oct 2011. 2011;(8):1198. | Non-randomised |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 18 | Katakami,N., Kim,Y.S., Kawamori,R., Yamasaki,Y.. The phosphodiesterase inhibitor cilostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus: principal results of the Diabetic Atherosclerosis Prevention by Cilost | Secondary prevention of CVD (some or all patients with CVD or unclear CVD status) |
| 19 | Konstantinopoulos,P.A., Karamouzis,M.V., Papavassiliou,A.G.. Effect of aspirin use on thiazolidinediones and cardiovascular events. JAMA - Journal of the American Medical Association.299 (13) (pp 1539), 2008.Date of Publication: 02 Apr 2008. 2008;(13) | Non-randomised |
| 20 | Macchia,A., Laffaye,N., Comignani,P.D., Cornejo,Pucci E., Igarzabal,C., Scazziota,A.S., et al. Statins but not aspirin reduce thrombotic risk assessed by thrombin generation in diabetic patients without cardiovascular events: the RATIONAL trial. PL | No relevant outcomes reported |
| 21 | Ogawa,H.. [Series, clinical study from Japan and its reflections; Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes (JPAD) Trial]. Nihon Naika Gakkai zasshi.The Journal of the Japanese Society of Internal Medicine 2011;100(1):218- | Not english |
| 22 | Ogawa,S., Mori,T., Nako,K., Ishizuka,T., Ito,S.. Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in type 2 diabetes. Clinical Journal of The American Society of Nephrology: CJASN 2008;3 | Secondary prevention of CVD (some or all patients with CVD or unclear CVD status) |
| 23 | Okada,S., Morimoto,T., Ogawa,H., Kanauchi,M., Nakayama,M., Uemura,S., et al. Differential effect of low-dose aspirin for primary prevention of atherosclerotic events in diabetes management: a subanalysis of the JPAD trial. Diabetes Care 2011;34(6): | Parent paper included and data extracted |
| 24 | Okada,S., Morimoto,T., Ogawa,H., Sakuma,M., Soejima,H., Nakayama,M., et al. Effect of low-dose aspirin on primary prevention of cardiovascular events in Japanese diabetic patients at high risk. Circulation journal 2014;77(12):3023-28. | Parent paper included and data extracted |
| 25 | Pignone,M., Alberts,M.J., Colwell,J.A., Cushman,M., Inzucchi,S.E., Mukherjee,D., et al. Aspirin for primary prevention of cardiovascular events in people with diabetes. Journal of the American College of Cardiology 2010;55(25):2878-86. | review |
| 26 | Raghavan,R.P., Laight,D.W., Cummings,M.H.. Aspirin in type 2 diabetes, a randomised controlled study: Effect of different doses on inflammation, oxidative stress, insulin resistance and endothelial function. International Journal of Clinical Practice. | No relevant outcomes reported |
| 27 | Rosiak,M., Postula,M., Kaplon-Cieslicka,A., Trzepla,E., Filipiak,K.J., Czlonkowski,A., Opolski,G.. The effect of doubling the dose of acetylsalicylic acid (ASA) on platelet function parameters in patients with type 2 diabetes and platelet hyperreac | No relevant outcomes reported |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 28 | Rumore,M.M. & Kim,K.S.. Potential role of salicylates in type 2 diabetes. Annals of Pharmacotherapy 2010;44(7-8):1207-21. | review |
| 29 | Saito,Y., Morimoto,T., Ogawa,H., Nakayama,M., Uemura,S., Doi,N., et al. Low-dose aspirin therapy in patients with type 2 diabetes and reduced glomerular filtration rate: subanalysis from the JPAD trial. Diabetes Care 2011;34(2):280-85. | Parent paper included and data extracted |
| 30 | Simpson,S.H., Gamble,J.-M., Mereu,L., Chambers,T.. Effect of aspirin dose on mortality and cardiovascular events in people with diabetes: A meta-analysis. Journal of General Internal Medicine.26 (11) (pp 1336-1344), 2011.Date of Publication: November | review |
| 31 | Soejima,H. & Ogawa,H.. [Investigation of the effects of low dose aspirin therapy on primary and secondary prevention of cardiovascular disease]. Nihon rinsho.Japanese journal of clinical medicine 2010;68(5):882-86. | Not english |
| 32 | Soejima,H., Ogawa,H., Morimoto,T., Nakayama,M., Okada,S., Uemura,S., et al. Aspirin reduces cerebrovascular events in type 2 diabetic patients with poorly controlled blood pressure. Subanalysis from the JPAD trial. Circulation Journal 2012;76(6):15 | Parent paper included and data extracted |
| 33 | Spectre,G., Arnetz,L., Ostenson,C.G., Brismar,K., Li,N., Hjemdahl,P.. Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications. Thrombosis & Haemos | Secondary prevention of CVD (some or all patients with CVD or unclear CVD status) |
| 34 | Stulman,J., McGinn,T., Korenstein,D.. Clopidogrel for preventing cardiovascular events. Mount Sinai Journal of Medicine.76 (2) (pp 194-197), 2009.Date of Publication: 2009. 2009;(2):194-97. | review |
| 35 | Taher,M.A. & Nassir,E.S.. Beneficial effects of clopidogrel on glycemic indices and oxidative stress in patients with type 2 diabetes. Saudi Pharmaceutical Journal.19 (2) (pp 107-113), 2011.Date of Publication: April 2011. 2011;(2):107-13. | No relevant outcomes reported |
| 36 | Udell,J.A., Scirica,B.M., Braunwald,E., Raz,I., Steg,P.G., Davidson,J., et al. Statin and aspirin therapy for the prevention of cardiovascular events in patients with type 2 diabetes mellitus. [Review]. Clinical Cardiology 2012;35(12):722-29. | review |
| 37 | Wittmann,I., Molnar,G.A., Wagner,L., Koszegi,T., Wagner,Z., Laczy,B., et al. Single dose of acetylsalicylic acid in patients with Type 2 diabetes mellitus and/or chronic renal failure ameliorates anaemia by decreasing the rate of neocytolysis. Acta | Non-randomised |

| Number | Reference | Reason for exclusion |
|---|---|---|
| 38 | Younis,N., Williams,S., Ammori,B., Soran,H.. Role of aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: a meta-analysis. Expert Opinion on Pharmacotherapy 2010;11(9):1459-66. | review |
| 39 | Zhang,C., Sun,A., Zhang,P., Wu,C., Zhang,S., Fu,M., et al. Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis. Diabetes Research & Clinical Practice 2010;87(2):211-18. | review |

## L.7 Review Question 7: What pharmacological treatment should be used to manage erectile dysfunction in men with type 2 diabetes?

**Table 6: Excluded studies of full text papers**

| Number | Reference | Reason for exclusion |
|---|---|---|
| 1 | Corona,G., Monami,M., Rastrelli,G., Aversa,A., Sforza,A., Lenzi,A., et al. Type 2 diabetes mellitus and testosterone: a meta-analysis study. International Journal of Andrology 2011;34(6:Pt 1):t-40. | Systematic review |
| 2 | Donatucci,C.F., Wong,D.G., Giuliano,F., Glina,S., Dowsett,S.A., Watts,S., Sorsaburu,S.. Efficacy and safety of tadalafil once daily: Considerations for the practical application of a daily dosing option. Current Medical Research and Opinion.24 (12 | Systematic review |
| 3 | Hatzimouratidis,K. & Hatzichristou,D.. Erectile dysfunction and diabetes mellitus. Insulin.4 (2) (pp 114-122), 2009.Date of Publication: April 2009. 2009;(2):114-22. | Not RCT |
| 4 | Lepore,G. & Nosari,I.. Efficacy of oral sildenafil in the treatment of erectile dysfunction in diabetic men with positive response to intracavernosal injection of alprostadil. Diabetes Care 2001;24(2):409-11. | Not RCT |
| 5 | Segal,R. & Burnett,A.L.. Avanafil for the treatment of erectile dysfunction. Drugs of Today.48 (1) (pp 7-15), 2012.Date of Publication: January 2012. 2012;(1):7-15. | Not available |
| 6 | Vardi,Moshe & Nini,Asaph. Phosphodiesterase inhibitors for erectile dysfunction in patients with diabetes mellitus. Cochrane Database of Systematic Reviews 2007;:n. pag.. | Systematic review |